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ABSTRACT
Functional interactions of tau, Pin1, p53 and mRNA 3’ processing factors in non-neuronal cells
by Jorge E. Baquero
Advisor: Dr. Frida E. Kleiman
mRNA 3’ end processing, an essential step in eukaryotic RNA metabolism, regulates the
steady-state levels of different mRNAs and contributes to the cells rapid response to stress.
Studies have described potential contributions of mRNA 3’ end processing to numerous human
diseases, including cancer and Alzheimer’s disease (AD). Therefore, the main purpose of this
dissertation is to further elucidate some of the roles of disease-related factors Pin1, p53 and tau
in the regulation mRNA 3’ end processing in non-neuronal cells under different cellular
conditions, including during the DNA damage response (DDR).
The results from Chapter II show that the prolyl isomerase Pin1, a mitotic regulator
overexpressed in most human cancers and depleted in the brains of AD patients, enhances
nuclear deadenylase activity during DDR. Interestingly, p53 expression, a Pin1 substrate, is
necessary to detect this Pin1-mediated activation in non-neuronal cells. Chapter III confirms
that tau, a microtubule-associated protein involved in a number of neurodegenerative disorders
including AD and a Pin1 substrate, is present in the nucleus of non-neuronal cells where it
associates with Pin1, p53 and PARN to regulate mRNA 3’ end processing under non-stress and
DDR conditions. More specifically, I demonstrate that tau expression induces PARN
deadenylase activity, and that this p53-dependent increase is lost with phosphorylation at certain
tau residues implicated in neurological diseases. Additionally, Chapter IV shows evidence that
Pin1 and tau also inhibit the mRNA 3’ cleavage step of the polyadenylation reaction during
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DDR. Extending from results collected in previous microarray analysis, I show in Chapter V
that the expression of a group of mRNAs deregulated in AD and/or cancer are targeted by Pin1,
tau and PARN, supporting overlapping functions for these factors in the nucleus of non-neuronal
cells. Finally, Chapter VI confirms potential roles of tau and p53 in the regulation of the protein
and mRNA expression levels of each other, and extends the functional connections between
these two disease-related factors in non-neuronal cells.
These findings identify novel biological roles of Pin1 and tau and highlight other possible
toxicity effects of hyperphosphorylated-tau forms in the nucleus of non-neuronal cells. They also
suggest that factors involved in cancer and AD might play a role in regulating gene expression
by a functional interaction with the mRNA 3’ processing machinery in different conditions,
resulting in specific gene expression patterns. In that scenario it is possible that tau
phosphorylation and localization in neurons might play a key role in controlling gene expression,
affecting the cellular transcriptome before the appearance of traditional markers of disease.
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SIGNIFICANCE

The DNA damage response (DDR) involves rapid functional and structural changes in a
number of nuclear proteins, resulting in a coordinated control of gene expression and DNA
repair. This cellular response to DNA damage is important because it is a protective mechanism
against disease. Additionally, DNA damage and repair responses are not limited to pathological
conditions but are also important for neuronal activity and gene expression regulation under
different physiological conditions (Madabhushi et al., 2015; Su et al., 2015). Failure to repair
DNA damage and control of gene expression during the response also has the potential to lead to
cancer (Taneja et al., 2010). The studies presented in this dissertation reveal new potential roles
for Pin1 and tau in the regulation of mRNA 3’ processing in non-neuronal cells, similar to those
previously described for p53 (Devany et al., 2013). The idea that Pin1 is involved in the
regulation of mRNA processing was suggested long ago (Hani et al., 1999). Other studies have
linked Pin1 to gene expression modifications in other ways, including affecting transcription or
mRNA stability (Hanes, 2015; Thapar, 2015). However, my data is the first indication of a direct
role of Pin1 in the regulation of nuclear deadenylation and the cleavage step of the
polyadenylation reaction. I also present additional results that support functional connections
between tau and tumor suppressor p53. Together, my studies are consistent with the idea that
common factors are involved in cancer and Alzheimer’s disease (AD).
The results presented here indicate that Pin1 activity as well as tau phosphorylation and
nuclear localization might play key roles in controlling cellular functions in non-neuronal cells.
This is important because both factors have been linked to the development of cancer and AD.
The results obtained in these non-neuronal models could be extended to neurons, and more
specifically to study the effect of mRNA regulation on cognitive functions, memory,
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apoptosis/neurogenesis, etc. Deregulation of the functions of these factors in controlling mRNA
3’ processing, and hence gene expression, might affect the neuronal and non-neuronal
transcriptomes before the appearance of traditional markers such as estrogen receptor
upregulation, neurofibrillary tangles, and amyloid plaques.
Previous studies have shown that tau not only localizes to the nucleus of neuronal and
non-neuronal cells but also binds and protects DNA (Bukar Maina et al., 2016; Multhaup et al.,
2015). This dissertation confirms that tau is involved in DDR in roles other than DNA protection
after stress by regulating of mRNA 3’ end processing as part of the response. My results also
show that changes in tau phosphorylation at pathological sites affect this nuclear role of tau,
which could prove important in the further characterization of tauopathies such as AD.
Considering that tau has been linked to low sensitivity to anti-cancer drugs in some tissues
(Ikeda et al., 2010), identification of more common PARN/Pin1/tau mRNA targets might reveal
factors that are deregulated in both diseases, and that could become potential drug candidates.
The findings presented in this dissertation highlight a common link between mRNA 3’ end
processing and diseases, such as cancer and AD, and provide leads from basic biological
functions of PARN/Pin1/tau/p53 to novel therapeutic interventions targets for cancer, AD and
others tau-related neurodegenerative diseases. Although more studies are needed, knowledge
gained may also help to manipulate, for therapeutic purposes, the way in which cells respond to
DNA damage affecting cell death or survival, mutation rates and/or the development of these
diseases.
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CHAPTER I

BACKGROUND

1

Regulation of mRNA 3’ end processing during the DNA damage response (DDR).
All organisms are constantly exposed to environmental agents that cause diverse damages
in their DNA material and cellular machineries. These damaging agents, including ultraviolet
(UV)-light, lead to replication and transcription blockages, mutations, and cellular cytotoxicity
(Friedberg, 1995; Rastogi et al., 2010). Therefore, it is fundamental that DNA repair mechanisms
exist to recognize and repair DNA lesions as part of a larger, coordinated control of gene
expression response that maintains the genome integrity and prevents the production of
erroneous proteins (Jackson and Bartek, 2009; Sancar, 1994). Part of this coordinated control
includes rapid changes in the functional properties of a number of nuclear proteins involved in
the DNA damage response (DDR), such as tumor suppressors breast cancer 1 (BRCA1)/BRCA1associated RING domain protein 1 (BARD1) and p53 (Baer and Ludwig, 2002; Ljungman et al.,
1999; Nazeer et al., 2011). Additionally, this response involves a general, transient decrease of
cellular poly(A)+ mRNA levels following UV irradiation (Cevher and Kleiman, 2010; Hanawalt,
1994; Ljungman et al., 1999) (Figure 1). All eukaryotic mRNAs are polyadenylated at the 3’end,
with the exception of histone mRNAs (Zhang et al., 2010). These poly(A) tails are crucial for the
regulation of stability, translation and subcellular localization, such as nuclear export (Colgan
and Manley, 1997; Mandel et al., 2008; Zhao et al., 1999); and their removal from mRNA
transcripts is the earliest and rate-limiting step in mRNA decay (Chen and Shyu, 1995; Wilusz et
al., 2001). It has been proposed that this reported decrease in poly(A) mRNA levels occurs
because of a general UV-induced transcription inhibition (Donahue et al., 1994). Indeed, mRNA
transcription has been shown to be transiently inhibited following DNA damage as part of the
transcription-coupled repair (TCR) response (Mullenders, 1998). In TCR, DNA damage is
repaired more rapidly in transcriptionally active genes than in the rest of the genome as a whole
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(Spivak, 2016). The largest subunit of RNA polymerase II (RNAP II) is phosphorylated,
ubiquitinated, and degraded by the proteasome after UV irradiation as part of this response
(Muratani and Tansey, 2003; van den Boom et al., 2002). However, those studies did not
consider the possibility that mRNA processing might influence poly(A) mRNA levels during
DDR. Studies from Dr. Kleiman’s lab have addressed the role of mRNA processing, and most
importantly of mRNA 3’ end processing, on poly(A) mRNA levels as part of DDR.

Figure 1. General and gene-specific effects of DNA-damaging conditions on
mRNA levels. The level of poly(A)+ mRNAs of genes not involved in DDR
decreases after DNA damage. The levels of poly(A)+ mRNAs of genes involved
in DDR are down- or up-regulated at different time points after DNA damage.
Taken from (Cevher and Kleiman, 2010).
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Nuclear polyadenylation/deadenylation machineries and DDR.
In order to study how mRNA 3’ end processing contributes to the cells rapid response to
DNA damage, it is important to understand first how 3’ end poly(A) tails are formed and
regulated. The 3’end formation in mRNA precursors (pre-mRNAs) includes a two-step reaction
(Figure 2) (Russell, 2009), an initial cleavage step followed by the synthesis of a 200-adenosine
residue tail to the 3’end of the cleaved product (Shatkin and Manley, 2000; Zhao et al., 1999).
One of the first steps of the polyadenylation reaction is the recognition of the highly conserved
hexamer AAUAAA located at 10 to 30 nucleotides upstream of the cleavage site by the cleavage
and polyadenylation specific factor (CPSF) and of the G/U- and U-rich region located further
downstream by cleavage stimulation factor (CstF) (Takagaki and Manley, 1997; Zhang et al.,
2010). While a relatively simple signal sequence in the mRNA precursor is required for the
reaction, many diverse and specific interactions among a large number of protein factors are
involved in the formation of polyadenylation complex and regulation of 3’ end processing in
different tissues and under different cellular conditions. In general, CPSF, CstF, cleavage factors
1 (CF I) and 2 (CF II), RNAP II and poly(A) polymerase (PAP) play a role in the cleavage
reaction. CPSF, PAP, symplekin and poly(A) binding protein (PABP) are involved in the
subsequent poly(A)-tail synthesis (Zhang et al., 2010). Almost all eukaryotic pre-mRNAs
undergo this co-transcriptional modification and addition of the poly(A) tail at the 3' end. As
mentioned, histone mRNAs are the exception, as they are cleaved but not polyadenylated (Zhang
et al., 2010). Nonetheless, polyadenylation plays a fundamental role in regulating mRNA
stability, translation and nuclear export, and thus is essential for the proper control of mRNA
levels and of gene expression in eukaryotes (Mandel et al., 2008; Zhao et al., 1999). It has been
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Figure 2. Schematic representation of the mammalian mRNA 3’ end formation.
A) The cleavage step of the 3’ end processing takes place after the assembly of
cleavage complex through a cooperative binding of CstF at the G/U- and U-rich
region and CPSF at the AAUAAA signal. CPSF directly interacts with CstF and
PAP (not shown in the scheme). CF I, CF II and RNAP II also play a role in the
cleavage reaction. B) After the cleavage step, CPSF and PAP remain bound to the
cleaved RNA and elongate a 200-adenosine residue poly(A) tail to the 3’end of the
cleaved product in the presence of PABP. Taken from (Russell, 2009).
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shown that regulation of 3’ end formation, and more precisely polyadenylation, is important and
highly regulated in cell growth control; and that it is used to direct tissue- or developmentspecific gene expression (Chuvpilo et al., 1999; Takagaki and Manley, 1998; Takagaki et al.,
1996). In addition, deficiencies in the polyadenylation machinery have been linked to disease
development, including tumor formation (Scorilas, 2002).
Interestingly, it has been shown that pre-mRNA polyadenylation is strongly but
transiently inhibited following DNA damage (Kleiman and Manley, 2001). CstF-50, one of the
CstF subunits that is essential for the endonucleolytic cleavage step, is involved in the regulation
of mRNA processing during DDR (Kleiman and Manley, 1999, 2001; Mirkin et al., 2008). CstF50 interacts with BRCA1-associated protein BARD1 (Kleiman and Manley, 1999), and this
interaction decreases mRNA polyadenylation after DNA damage, providing a link between
mRNA processing and DNA repair/tumor suppression (Kleiman and Manley, 2001). Following
studies showed that CstF-50 plays a more direct role in DDR by associating to RNAP II and
BARD1 at sites of DNA repair (Mirkin et al., 2008). In fact, CstF-50 specifically interacts with
the C-terminal domain (CTD) of the largest subunit of RNAP II, likely facilitating RNAP IImediated activation of 3’ end processing (Hirose and Manley, 1998; McCracken et al., 1997). As
discussed later, CstF-50-associated BARD1 also activates deadenylation and participates in the
regulation of steady-state levels of endogenous transcripts under DNA-damaging conditions after
binding to nuclear poly(A)-specific ribonuclease (PARN) (Cevher et al., 2010).
Another protein factor that regulates the mRNA 3’ cleavage reaction is the tumor
suppressor p53. The TP53 gene is the most commonly mutated target in human tumors (Rivlin et
al., 2011). Activation of p53 pathway affects the expression levels of a large set of genes
involved in cellular responses such as DNA repair, cell cycle and apoptosis (Levine et al., 2006;
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Vogelstein et al., 2000). The expression of these genes is regulated by transactivating properties
of p53, where it binds to p53-response elements found in promoters or introns of these target
genes (Tokino and Nakamura, 2000). Although p53 was previously established as a
transcriptional regulator, other transactivation-independent functions of p53 have been reported
(Takwi and Li, 2009). For example, certain microRNAs (miRNAs) are also regulated by p53,
causing major changes in gene expression (Chang et al., 2007). Besides, the induction of p53
expression upon DNA damage is associated with a general decrease in total poly(A) mRNA
levels (Ljungman et al., 1999). It was later shown that p53 associates with BARD1 and CstF-50
to inhibit mRNA 3’ cleavage after UV irradiation, providing a link between mRNA processing
and the p53 pathway (Nazeer et al., 2011). As p53 expression levels change during DDR, this
regulatory mechanism represents a transactivation-independent function of p53. p53 is also
involved in a feedback loop with PARN deadenylase. While PARN keeps p53 levels low by
destabilizing p53 mRNA in non-stress conditions, the increase in p53 levels after UV treatment
results in PARN deadenylase activation in a transcription-independent manner (Devany et al.,
2013).
Although the cleavage/polyadenylation reaction is relatively well understood, the
mechanisms underlying poly(A) tail shortening or removal have not been completely elucidated
(Zhang et al., 2010). Once the poly(A) tail has been synthesized, changes in the poly(A) length
are determined by what appears to be a highly regulated event, depending on different cellular
conditions (Zhang et al., 2010). In general, the turnover rates of mRNAs vary in response to
changes in the cellular environment, and one of the fundamental cis-acting elements required for
proper mRNA degradation is the mRNA poly(A) tail itself (Mandel et al., 2008; Zhao et al.,
1999). This means that mechanisms involving control of poly(A) tail length and degradation

7

represent an extra checkpoint to regulate gene expression (Beilharz and Preiss, 2007).
Deadenylation, or the removal of adenosine residues from the 3’ end tail, is one of the
mechanisms regulating poly(A) tail length. This mechanism might regulate gene expression,
especially during DDR, by affecting mRNA stability, mRNA transport, or translation initiation
(Zhang et al., 2010). Most of the mRNA decay pathways that have been studied in eukaryotes
are deadenylation-dependent (Parker and Song, 2004). In general, the steady-state levels of
cellular mRNAs are determined by the balance between their biosynthesis and turnover. The
mRNA lifetimes of different mRNAs range from several minutes to days, depending on various
genes and the cellular conditions (Khodursky and Bernstein, 2003).
In most cases, the poly(A) tail is removed or shortened by either nuclear or cytoplasmic
deadenylases. In eukaryotes, there are 3 characterized deadenylases, including the CCR4-POP2NOT complex, which is a predominant deadenylase in all eukaryotes, the poly(A) nuclease
(PAN), which is involved in the early steps of poly(A) tail metabolism, and the previously
mentioned PARN deadenylase (Goldstrohm and Wickens, 2008; Parker and Song, 2004). PARN
is the major poly(A) specific 3’ exoribonucleases identified in the nucleus of mammalian cells
(Figure 3) (Chen and Shyu, 1995; Mitchell and Tollervey, 2000; Wu et al., 2005). These
deadenylases are involved in different cellular processes such as DDR, cell cycle regulation,
inflammatory response, cell differentiation, etc. (Cevher and Kleiman, 2010). PARN is expressed
ubiquitously in all tissues of most eukaryotic organisms (Copeland and Wormington, 2001). In
calf thymus cell free extracts and in Xenopus oocytes, two isoforms of PARN have been
described with molecular sizes of approximately 74 kDa and 62 kDa, both of which have shown
enzymatic activity and different nuclear-cytoplasmic distribution. While the 74 kDa isoform of
PARN is exclusively nuclear, the 62 kDa isoform is cytoplasmic (Korner et al., 1998; Martinez
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et al., 2000). While the cytoplasmic activity of PARN has been extensively studied, the nuclear
functions are not completely understood. PARN has been identified as an oligomeric, highly
processive, metal-ion dependent and cap-interacting poly(A) specific 3’ exonuclease (Wu et al.,
2009). Sequence analysis shows that PARN consists of the nuclease domain, the R3H domain,
and the RNA recognition motif (RRM) (Figure 3) (He et al., 2013). R3H domain, a singlestranded nucleic-acid-binding domain, is responsible for PARN’s specificity for single-stranded
poly(A) (Martinez et al., 2001) and the RRM harbors the cap binding properties (Nilsson et al.,
2007). PARN deadenylation activity and processivity are enhanced by the mRNA 5’ end-located
cap structure (Astrom et al., 1991; Dehlin et al., 2000; Korner et al., 1998; Martinez et al., 2001).
On the other hand, PARN activity is inhibited by cap binding protein (CBP80) or nuclear
poly(A) binding protein-1 (PABPN-1) (Balatsos et al., 2006). Interestingly, a functional
connection exist between PARN deadenylase and factors involved in polyadenylation, such as
CstF-50, BARD1, and p53 (Cevher et al., 2010; Devany et al., 2013; Nazeer et al., 2011). In
addition, PARN has been shown to regulate the expression of genes involved in mRNA
metabolism, transcription and cell motility in mouse fibroblasts (Lee et al., 2012).
Gene expression and mRNA levels are regulated under different cellular conditions.
Following UV-irradiation, the 3’ cleavage step of the polyadenylation reaction is repressed as a
result of the proteasome-mediated degradation of RNAP II (Kleiman et al., 2005), an activator of
the reaction, and of the direct interaction between the polyadenylation factor CstF-50 and tumor
suppressor BARD1 (Kleiman and Manley, 1999). It has been shown that the DNA-damage
induced

inhibition

of

polyadenylation

correlates

with

increasing

amount

of

a

BRCA1/BARD1/CstF-50 complex formation (Kleiman and Manley, 2001), providing a link
between transcription-coupled RNA processing and DNA repair. Interestingly, the mechanism
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Figure 3. PARN consists of a nuclease domain, a R3H domain, and a RRM
motif. The nuclease domain goes from residues 1-134 and 269-446. The R3H
domain (residues 135-268) is a single-stranded nucleic-acid-binding domain
responsible for PARN’s specificity for single-stranded poly(A), while the RRM
(residues 446-520) harbors the cap binding properties. The nuclear localization
signal (NLS) goes from residues 520-540 and tags the protein for entry into the
nucleus. PARN forms a homodimer, with the R3H domain of one subunit
partially enclosing the active site of the other subunit and poly(A) bound in a deep
cavity of the nuclease domain. Modified from (He et al., 2013).
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underlying the regulation of 3’ end cleavage in response to DNA damage also involves the
functional interaction of the deadenylation/polyadenylation machineries. As mentioned,
following UV-induced DNA damage, CstF-50 directly interacts with the C-terminal domain of
PARN, and this is accompanied with an increase in PARN expression levels (Cevher et al.,
2010). The formation of CstF-50/PARN complex has both a role in the activation of PARNmediated deadenylation and in the inhibition of 3’ cleavage as a result of repressed CstF-50
activity (Figure 4) (Cevher et al., 2010). Under DNA-damaging conditions, the formation of
BARD1/CstF-50/PARN complex plays a role in downregulating the mRNA levels of some
housekeeping genes, such as GAPDH and β-actin. Interestingly, the BARD1/CstF-50/PARN
complex also has a role in decreasing the levels of short-lived mRNAs involved in the control of
cell growth and differentiation, keeping their expression levels low under non-stress conditions
(Figure 1) (Cevher and Kleiman, 2010). These studies described a mechanism of gene expression
regulation in response to DNA damage involving both the deadenylation and polyadenylation
machineries. Finally, these studies confirm that not only transcription regulation but also 3’end
mRNA processing are responsible for the transient decrease of total, cellular poly(A) mRNA
levels following UV-irradiation (Figure 1).
Further studies showed that under non-stress conditions PARN expression significantly
affects the cellular expression of genes that are part of the p53-signaling pathway. In fact, PARN
regulates p53 expression through indirect association to AU-rich elements (ARE) present in the
3’ untranslated region (3’UTR) of the TP53 mRNA, destabilizing this mRNA, and therefore
keeping p53 protein levels low in non-stress conditions (Figure 5) (Devany et al., 2013). This is
consistent with previous studies showing that PARN decreases the steady-state levels of shortlived mRNAs involved in cell growth and differentiation under non-stress conditions (Cevher et

11

P

P

AAAAAAAAAA

2

P
3

P
P

UV

3

P
1

Untreated cells
Long poly(A) tail

A
AAA

2

P

P

A

A

A
A

1

UV-treated cells
Shorter poly(A) tail

Figure 4. A model of poly(A) tail dynamics after DNA damage. In the absence
of DNA damage treatment, CBP80 binds to nuclear PARN, inhibiting its
deadenylase activity. After exposure to UV treatment, the CBP80 protein
dissociates from PARN, allowing binding of PARN to the CstF-50/BARD1
complex. As a result of these functional interactions, polyadenylation is inhibited
and a 5’ cap-dependent deadenylation decay pathway is activated, generating a
decrease in the levels of total mRNA. Taken from (Cevher et al., 2010).
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Figure 5. A model for the regulation of expression of genes in the p53
pathway by PARN-associated p53 in different cellular conditions. A) PARN
decreases the stability of TP53 mRNA under non-stress conditions. ARE in the
3’UTR of TP53 plays an important role. B) Under DNA damage condition, p53
protein accumulates and activates PARN, resulting in a decrease in levels of
target mRNAs. Taken from (Devany et al., 2013).
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al.,(Cevher et al., 2010). The levels of p53 increase after UV treatment resulting in the p53PARN complex formation and the activation of deadenylation (Devany et al., 2013). This is
consistent with the following observations: increase in PARN deadenylase activity during DDR
(Cevher et al., 2010); and the general decrease in total poly(A) mRNA levels of genes not
involved in DDR by p53 induction upon UV (Ljungman et al., 1999) (Figure 1).
Deadenylation of mRNAs is regulated by ARE-binding proteins (ARE-BP),
polyadenylation factors, and RNA binding factors that recognize cis-acting sequences in the
mRNA targets. The identity of most of the ARE-BP and RNA binding factors involved in PARNmediated deadenylation are not known. About 12% of mammalian mRNAs contain functional
ARE signals in their 3’UTRs, including genes involved in DDR such as the TP53 mRNA (Zhang
et al., 2010). ARE typically contains one or several AUUUA pentamer repeats within a U-rich
region of the 3’UTR (Chen and Shyu, 1995; Lagnado et al., 1994; Zubiaga et al., 1995). ARE
sequences are frequently present in genes that encode tightly regulated proteins involved in cell
growth regulation, differentiation and responses to external stimuli. The destabilizing functions
of AREs are important because in their absence proto-oncogenes, such as c-fos, c-myc, c-jun,
could become oncogenes (Schiavi et al., 1992). A number of trans-acting factors, known as AREBPs, regulate ARE-mediated decay of mRNAs by either inhibiting or activating deadenylation,
and subsequently change the stability of ARE-containing mRNAs. PARN has been shown to be
involved in ARE-mediated deadenylation and to promote exosome-mediated degradation by
being recruited, as part of the same complex, to different AREs in 3’UTRs of target mRNAs (Lin
et al., 2007).

14

Prolyl isomerase Pin1 and mRNA 3’ end processing factors
Studies from Dr. Kleiman’s lab have shown that mRNA 3’ end processing is involved in
a coordinated control of gene expression under different cellular conditions, and that it regulates
the steady-state levels of diverse mRNAs. Therefore, it is important that we identify and
characterize other factors involved in this process. One of those potential protein factors is
peptidyl-prolyl cis/trans isomerase (PPIase) Pin1 (Figure 6) (Lee et al., 2011; Yeh and Means,
2007). Like other PPIases in the cell, Pin1 catalyzes the cis/trans isomerization of peptidyl-prolyl
peptide bonds. However, Pin1 is the only PPIase in humans that binds exclusively to
phosphorylated

serine/threonine-proline

motifs

to

regulate

the

post-phosphorylation

conformation of its substrates (Lu et al., 1996). pSer/Thr-Pro motifs exist in two distinct
conformations, and their conversion is markedly slowed by phosphorylation, but catalyzed by
Pin1 (Figure 6) (Lee et al., 2011; Lu et al., 2007; Lu et al., 1996; Lu and Zhou, 2007; Yeh and
Means, 2007). Pin1 accelerates this conversion rate by more than 1000-fold compared to the
uncatalyzed reaction (Pastorino et al., 2006; Yeh and Means, 2007). It is a nuclear, 163-amino
acid long protein that consists of two domains that provide it with great substrate specificity. The
31-residue N-terminal (WW-protein interacting domain) binds specifically to pSer/Thr-Pro
motifs, while the PPIase domain modifies the motifs in target proteins, thus forming a ‘double
check’ mechanism (Figure 6) (Lee et al., 2011; Lu et al., 1996; Maleszka et al., 1996; Yeh and
Means, 2007).
Prolyl isomerization can result in substantial conformational changes of the target
proteins leading to alterations in their function, stability and/or intracellular localization (Yeh
and Means, 2007). In fact, Pin1-conformational regulation has profound effects on proteins
involved in the regulation of cell growth, germ cell development, neuronal differentiation and
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survival, the immune response, and DDR (Lu and Zhou, 2007). Pin1 plays a role in mitosis
regulation; its overexpression in HeLa cells causes arrest in the G2 phase and its depletion
induces mitotic arrest (Lu et al., 1996). Pin1 also regulates cell cycle progression and DNA
replication checkpoints in frogs (Winkler et al., 2000), and cyclin D1 functions at the
transcriptional and post-translational level in mouse (Liou et al., 2002). c-Jun, c-Fos, c-Myc, p53,
p73, the carboxyl-terminal domain of RNAP II, and β-catenin are among the protein targets that
are regulated by conformational changes upon Pin1 binding (Shaw, 2007). Interestignly, Pin1
deregulation has been linked to an increasing number of pathological conditions, including
premature ageing, Parkinson disease, cancer, and Alzheimer’s disease (AD) (Lee et al., 2011).
The first indication that Pin1 might be involved in mRNA 3’ end processing in humans
was the observation that mutations in a peptidylprolyl-cis/trans-isomerase gene lead to defects in
the 3’ end formation of a pre-mRNA in Saccharomyces cerevisiae (Hani et al., 1999). The
expression of ESS1/PTF1, a homologue of human Pin1, was able to rescue these defects in the
mRNA 3’ end formation. Further reports described an interaction between the hyperphosphorylated carboxy-terminal domain (CTD) of RNAP II and the WW domain of Ess1 in
yeast, representing a potential mechanism in which Ess1 binds to the elongating RNAP II and
reconfigures the CTD affecting a variety of RNAP II-coupled pre-mRNA maturation events such
as splicing, transcription, and polyadenylation (Morris et al., 1999). In fact, RNAP II functions in
pre-mRNA splicing, where the phosphorylated status of CTD dramatically affects this process
(Hirose et al., 1999), as well as in polyadenylation, where RNAP II CTD activates mRNA 3’ end
processing upon binding to cleavage factors CPSF and CstF (Hirose and Manley, 1998;
McCracken et al., 1997). Pin1 was shown to influence the phosphorylation state of RNAP II
CTD at Ser 2 and Ser 5 by either stimulating phosphorylation by cdc2/cyclin B kinase or
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Figure 6. Pin1 consists of a WW and a PPIase domain, and facilitates
isomerization of pSer/Thr-Pro motifs. Pin1 is an 18 kDa protein consisting of a
WW domain and a catalytic PPIase domain. Each domain can bind to proteins
that are phosphorylated on Ser or Thr residues and followed by a Pro. The
isomerase domain of Pin1 facilitates the rapid cis or trans isomerization of the
prolyl bond, increasing the rate of this reaction by over 1,000-fold. Taken from
(Yeh and Means, 2007).
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inhibiting dephosphorylation by FCP1 phosphatase (Kops et al., 2002; Xu et al., 2003). The CTD
is phosphorylated on Ser 5 during transcription initiation and on Ser 2 during elongation by
different cyclin-dependent kinases, and then dephosphorylated during transcription termination
by FCP1 phosphatase (Xu and Manley, 2004). The RNAP II CTD contains 52 repeats of the
heptapeptide YSPTSPS that are extensively phosphorylated and can bind many Pin1 molecules
at once. Pin1-/- cells showed an accumulation of hypophosphorylated RNAP II, while hyperhyperphosphorylated forms were seen in cells overexpressing Pin1 (Xu et al., 2003). Hyperhyperphosphorylated RNAP II associates to Pin1 inhibiting ongoing transcription (Figure 7) (Xu
and Manley, 2004).
Interestingly, Pin1 overexpression causes the release of RNAP II from active genes,
which then accumulates in nuclear speckle-associated structures (Xu and Manley, 2007b).
Furthermore, Pin1 inhibits RNAP II transcription during the transition from initiation to
elongation but not during elongation (Xu and Manley, 2007b), suggesting that Pin1 is a regulator
of RNAP II activity during the transcription cycle. Additional studies in yeast indicate that Ess1
prevents the binding of RNAP II to the ubiquitin ligase Rsp5 inhibiting RNAP II’s ubiquitination
and subsequent degradation (Wu et al., 2001). Considering that RNAP II participates in mRNA
3’ processing (Hirose and Manley, 1998; McCracken et al., 1997; Mirkin et al., 2008), and that
UV-induced proteasomal degradation of RNAP-II inhibits mRNA 3’ processing (Kleiman et al.,
2005), further studies are necessary to characterize the potential role of Pin1 in mRNA 3’ end
processing during DDR.
The tumor suppressor p53, which regulates several steps in mRNA 3’ processing
(Devany et al., 2013; Nazeer et al., 2011), is also a Pin1 substrate. Pin1 interacts with
phosphorylated p53 after DNA damage (Zacchi et al., 2002; Zheng et al., 2002). This interaction

18

Figure 7. A model for the role of Pin1 in RNAP II phosphorylation during
transcription and cell cycle. RNAP II CTD is phosphorylated during initiation
(Ser 5) and elongation (Ser 2) and then dephosphorylated in termination. Pin1
facilitates these changes and influences CTD interactions with other factors. As
cells enter mitosis, Pin1 promotes hyperphosphorylation of elongating RNAP II,
resulting in premature transcriptional termination and formation of the inactive
hyper-hyperphosphorylated RNAP II. Taken from (Xu and Manley, 2004).
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is strictly dependent on p53 phosphorylation at Ser 33, Thr 81, and Ser 315. It has been
demonstrated that when DNA damage is encountered, p53 is stabilized and activated upon
phosphorylation by p38, JNK and cdc2 kinases (Woods and Vousden, 2001; Zheng et al., 2002).
After binding, Pin1 generates conformational changes in p53 that enhance its transactivation
activity and the removal of Mdm2 (or HDM2) from p53 (Figure 8, Top) (Ryan and Vousden,
2002). The Pin1-mediated p53 activation requires the WW and the isomerase activity domains of
Pin1 (Zheng et al., 2002). p53 is not stabilized in Pin1 -/- cells after UV treatment because it is
unable to dissociate from Mdm2, resulting in a decrease in the transcriptional activation of some
p53-regulated genes (Zacchi et al., 2002). HDM2 is an ubiquitin ligase that catalyzes the
mono/oligoubiquitination of p53, keeping p53 levels low in unstressed cells (Yu et al., 2000).
Inhibition of Pin1 in mammalian cells changes the ubiquitination status of p53 from
monoubiquitination/oligoubiquitination, which triggers nuclear export, to polyubiquitination,
which causes nuclear p53 degradation by the proteasome (Jentsch and Siepe, 2009). These
results indicate that Pin1 and Mdm2 act synergistically to determine the degree and type of
ubiquitination p53 undergoes. Mdm2 and Pin1 are both necessary to balance p53 levels, each one
acting in opposite directions (Figure 8, Bottom). Since wild type- and mutant- p53 stimulation
are very similar, Pin1 can also lead to the full activation of mutant p53 (Napoli et al., 2011),
resulting in downstream events that promote pro-oncogenic properties
The consequences of the Pin1-p53 complex formation upon DNA damage involve the
transcriptional activation of target genes in the p53 pathway. p21 levels, which are usually
induced by p53 upon stress, barely increased after DNA damage in Pin1 -/- embryonic
fibroblasts (Wulf et al., 2002). In addition, Pin1 -/- cells also displayed an impaired checkpoint
control in response to DNA damage (Wulf et al., 2002; Zheng et al., 2002). Furthermore, studies
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Figure 8. Regulation of p53 conformation and ubiquitination by Pin1 and
HDM2 (MDM2). Top: Under non-damaging conditions, p53 is degraded by
HDM2-mediated ubiquitination. Upon cell stress, p53 is phosphorylated and
binds to Pin1, causing conformational changes in p53 and displacing HDM2. p53
is stabilized and functions as a transcription factor. Taken from (Ryan and
Vousden, 2002). Bottom: A) Low Mdm2 levels induce monoubiquitination of
p53, while increasing amounts promote its polyubiquitination. B) Pin1 reduces
p53 ubiquitination, but lower amounts stimulate its polyubiquitination. Taken
from (Jentsch and Siepe, 2009).
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have shown that Pin1 inactivation facilitates apoptotic cell death in response to etoposide, an
antitumor drug that causes DNA synthesis errors and induces apoptosis in cancer cells
(Shimazaki et al., 2012). Pin1-p53 interaction also controls mitochondrial permeability and
caspase activation in response to etoposide treatment, suppressing etoposide-induced apoptosis
(Shimazaki et al., 2012). Together these results show that p53 needs to form a complex with Pin1
to undergo the conformational changes necessary to fulfill its biological roles during DDR,
including regulation of the expression of genes involved in cell cycle arrest, apoptosis, and/or
tumor suppression (Figure 8).
Pin1 deregulation has been linked to a number of diseases, including Parkinson disease
and cancer. Pin1 is upregulated at the mRNA and protein levels in Parkinson Disease (Ghosh et
al., 2013). In addition, Pin1 is overexpressed in most human cancers, and this overexpression has
become a potential prognostic marker in human cancers (Wulf et al., 2001). Pin1 has been
described as a catalyst for tumorigenesis that acts by switching on and off many oncogenes and
tumor suppressors (Lee et al., 2011). Pin1 deregulation has also been linked to Alzheimer’s
disease (AD) (Lee et al., 2011). In fact, like p53, tau, which is hyperphosphorylated and forms
intracellular aggregates as one of the hallmarks in AD, is also a substrate of Pin1 (Figure 9).
Interestingly, studies have shown that there is an inverse correlation between cancer and AD, and
that Pin1 is a potential candidate that explains this correlation (Behrens et al., 2009). Data
suggests that patients with less active Pin1 would be at greater risk of developing AD and not
cancer, and those with an active Pin1 would be more prone to develop cancer and not AD. While
Pin1 expression is induced during neuronal differentiation and it is highly expressed in most
neurons in the brain, it is downregulated in the hippocampus of AD patients (Behrens et al.,
2009). Pin1 expression pattern in patients with late-onset AD is modified, supporting its role in
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Figure 9. Pin1 regulates p53 and tau conformations in different cellular
conditions. After phosphorylation, p53 and tau bind to Pin1, causing
conformational changes in both proteins. Upon stabilization, p53 functions as a
transcription factor and tau can bind to microtubules.
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the pathogenesis of the disease (Arosio et al., 2012). These studies suggest that there is an
inverse correlation between Pin1 expression and neurofibrillary degeneration in AD, and that
areas in the brain with lower Pin1 expression are more vulnerable to neuronal degeneration (Liou
et al., 2003).

Microtubule-associated protein tau
AD is a progressive neurodegenerative disease characterized by intracellular and
extracellular lesions (Lee et al., 2011). Extracellular lesions are caused by the formation of
insoluble deposits on the matrix of the brain, which are called beta-amyloid plaques, derived
from the pathological processing of the amyloid precursor protein (APP). On the other hand,
intracellular lesions are made up of insoluble hyperphosphorylated tau protein aggregates, which
accumulate in neurofibrillary tangles known as paired helical filaments (PHF), causing neuronal
death (Lee et al., 2011; Lu et al., 1999).
In normal individuals, tau is highly soluble and stabilizes microtubules in the cytoplasm
of neurons by promoting assembly of tubulin into the microtubule structure (Buee et al., 2000).
Microtubules are responsible for maintaining the cell shape, and serve as tracks for axonal
transport. It belongs to the microtubule-associated proteins (MAP) family, and is mainly
expressed in neurons, although non-neuronal cells also express it (Buee et al., 2000). Tau is a
phosphoprotein and its biological activity is significantly regulated by its degree of
phosphorylation (reviewed in (Alonso et al., 2001b). For example, it is phosphorylated on
multiple pS/T-P motifs during mitosis (reviewed in (Lu et al., 1999). Tau is abnormally
hyperphosphorylated in AD brain and, in this altered form, is the major protein subunit of PHFs
(reviewed in (Alonso et al., 2001a). Additionally, tau hyperphosphorylation and accumulation
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have been linked to other neurodegenerative diseases besides AD, such as Down syndrome,
frontotemporal dementia with Pakinsonism linked to chromosome 17 (FTDP-17), dementia
pugilistica, Pick disease, among others (reviewed in (Alonso et al., 2010). Many efforts have
been made to identify factors that might regulate tau phosphorylation under different conditions.
Different tau isoforms are present in human neurons, as well as in several peripheral
tissues such as heart, kidney, lung, muscle, pancreas and testis; and their expression patterns are
regulated by alternative splicing mechanisms and posttranslational modifications (Buee et al.,
2000; Wang and Liu, 2008). There is a single human MAPT gene, which is located on
chromosome 17 and contains 16 exons (Figure 10). Three of these exons (4A, 6 and 8) are never
present in any human brain mRNA, although 4A might be present in mRNAs from peripheral
tissues. Exon -1 is part of the promoter, and it is transcribed but not translated. Exon 14 is also
found in mRNAs but it is not translated either. Exons 1, 4, 5, 7, 9, 11, 12, and 13 are always
translated into proteins, while 2, 3, and 10 are alternatively spliced and are adult-brain specific.
In total, and after alternative splicing, there are six possible tau mRNAs in the human brain.
These six primary transcripts give rise to at least six tau protein isoforms with molecular weights
between 45 and 65 kDa and containing between 352 and 441 amino acids (Buee et al., 2000).
The tau variants differ from one another by the presence of three or four repeat-regions in the
carboxyl-terminal part of the molecule, and the absence or presence of one or two inserts in the
amino-terminal part. These isoforms are likely to have different physiological roles and are
differentially expressed during development (Buee et al., 2000).
Interestingly, tau was found to bind to Pin1 after tau is phosphorylated (Lu et al., 1999).
Initially, it was found that its WW domain binds specifically to pThr 231-Pro 232 in tau. In fact,
Pin1 specifically recognizes this motif, catalyzes its isomerization, and promotes its
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Figure 10. Human tau gene, tau primary transcript, and six tau isoforms in
the central nervous system. The human MAPT gene is located on chromosome
17. It contains 16 exons. The tau primary transcript contains 13 exons, since
exons 4A, 6 and 8 are not transcribed. Exons -1 and 14 are transcribed but not
translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 are constitutive, and exons 2, 3, 10 are
alternatively spliced, giving rise to 6 different mRNAs, translated into at least 6
different tau isoforms. The carboxyl –terminal part of these isoforms might have
either three or four repeat regions, with the fourth microtubule-binding domain
being encoded by exon 10. Taken from (Buee et al., 2000).
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dephosphorylation by PP2A phosphatase (Lonati et al., 2011; Rudrabhatla and Pant, 2011).
Other reports have shown that Pin1 binds and stimulates dephosphorylation of tau at all Cdk5p25-phosphorylation-mediated Ser or Thr residues (Kimura et al., 2013). In vitro assays showed
that Pin1 restores the function of tau even after it is phosphorylated (Lu et al., 1999). In addition,
Pin1 copurifies with and is sequestered in PHFs, meaning that the cellular environment, is
depleted of soluble Pin1 in AD (Lu et al., 1999). It is not known what might be the consequences
of this Pin1 depletion on mRNA 3’ end processing, considering that Pin1 might be involved in
this pathway as well. Reports studying the regulation of tau phosphorylation have shown that
Pin1 deficiency causes tau hyperphosphorylation in AD (Kimura et al., 2013). Using
conformation-specific antibodies, it was found that cis, but not trans, pThr 231-Tau appears first
and accumulates in degenerating neurons in AD (Nakamura et al., 2013b). Pin1 accelerates cis to
trans isomerization to prevent the accumulation of pathogenic cis p-tau in AD, providing
evidence on how Pin1 protects against AD (Nakamura et al., 2013a). While Pin1 binds
specifically to pThr 231 in tau, phosphorylation at other sites is also necessary to influence the
biological activity of tau and cause neurodegeneration (Alonso et al., 2010). Pin1 has been
identified as a key player in regulating phosphorylation of not only tau but several other proteins
in neurons during development and neurodegeneration such as neurofilaments (Binukumar et al.,
2013).
Various studies have linked tau to another Pin substrate, p53; and with some of its
isoforms. As mentioned, continuous efforts have been made to identify factors that might
regulate tau phosphorylation under different conditions. For example, it has been shown that p73,
a member of the p53 family, regulates the accumulation of phosphorylated-tau during AD.
p73+/- mice show dramatic increase of phosphorylated tau, indicating that this p53-related
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protein might be essential for the prevention of neurodegeneration (Wetzel et al., 2008). p44, a
shorter isoform of p53 that is preferentially nuclear and which levels are increased with age in
the mouse brain, promotes the phosphorylation of tau and activates the transcription of different
tau kinases (Pehar et al., 2013). Finally, p53 itself was found to be upregulated in AD, and to
induce tau phosphorylation in human embryonic kidney 293a cells (HEK293a) (Hooper et al.,
2007). Upon tau overexpression, the levels of phosphorylated p53, the form that binds to Pin1
and is involved in DDR, decrease connecting overexpression and hyperphosphorylation of tau to
anti-apoptotic mechanisms (Wang et al., 2010). Interestingly, dephosphorylated tau has been
observed in the nuclei of neurons where it binds to neuronal DNA after oxidative and mild heat
stresses (Sultan et al., 2011). In fact, dephosphorylated tau can protect neuronal genomic DNA
against heat stress-induced damage, indicating that tau is possibly a key player in the early stress
response (Sultan et al., 2011). As p53 and its isoforms are involved in nuclear functions during
the cellular response to DDR, new possible connections between tau and other nuclear processes,
such as DDR, mRNA 3’ processing and gene expression, could be considered.
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CHAPTER II

EFFECTS OF PROLYL ISOMERASE Pin1 ON THE REGULATION OF NUCLEAR
mRNA DEADENYLATION
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INTRODUCTION
Following UV-induced DNA damage, cellular levels of polyadenylated transcripts are
transiently decreased and normal recovery depends on transcription-coupled repair (TCR)
(Ljungman et al., 1999). This reported decrease in poly(A) mRNA levels occurs because of a
general UV-induced transcription inhibition (Donahue et al., 1994). In addition, it has been
shown that regulation of mRNA 3’ end processing has a general effect on the levels of poly(A)+
mRNA as part of the DNA damage response (DDR)(Cevher and Kleiman, 2010). The mRNA 3’
cleavage step of the polyadenylation reaction is inhibited as a result of the association of the
tumor suppressors BARD1/BRCA1 with the cleavage stimulation factor subunit CstF-50, as well
as the proteasome-mediated degradation of RNA polymerase II (RNAP II)(Kleiman and Manley,
2001; Kleiman et al., 2005). p53 also associates with BARD1 and CstF-50 to inhibit 3’ cleavage
after UV irradiation (Nazeer et al., 2011).
Likewise, deadenylation also has an effect on the reported decrease in cellular poly(A)
mRNA levels after UV exposure. Deadenylation, or the removal of adenosine residues from the
mRNA 3’ end tail, is one of the mechanisms regulating poly(A) tail length, and hence gene
expression (Zhang et al., 2010). Poly(A) tails are crucial for the regulation of stability, translation
and subcellular localization of mRNAs (Colgan and Manley, 1997; Mandel et al., 2008; Zhao et
al., 1999); and their removal from mRNA transcripts is the earliest and rate-limiting step in
mRNA decay (Chen and Shyu, 1995; Wilusz et al., 2001). PARN is the main deadenylase
identified in the nucleus of mammalian cells (Chen and Shyu, 1995; Mitchell and Tollervey,
2000; Wu et al., 2005), and it is involved in gene expression regulation under different cellular
conditions (Huang and Carmichael, 1996; Preiss et al., 1998). Previous studies from our lab have
functionally connected PARN deadenylase to other mRNA processing factors. For instance,
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CstF-50-associated BARD1 interacts with PARN resulting in the activation of its activity after
UV treatment (Cevher et al., 2010). p53 can also activate PARN after UV-exposure, resulting in
the regulation of mRNA 3’ end processing and gene expression during the DDR in a
transactivation-independent manner (Devany et al., 2013). The formation of these complexes
plays a role in the downregulation of the mRNA transcripts of housekeeping genes that are not
needed in the response. Furthermore, PARN is also involved in keeping low the levels of shortlived, AU-rich elements (ARE)-containing, DDR-involved mRNAs, including p53 mRNA itself,
under non-stress conditions (Cevher et al., 2010; Devany et al., 2013). Considering that the
regulation of nuclear deadenylation is an important step controlling the steady-state levels of
mRNAs and contributing to the cells rapid response to DNA damage, I extended these results by
exploring other potential factors involved in this regulation.
Although it has been suggested that prolyl isomerase Pin1 might be involved in the
regulation of mRNA 3’ end processing, the mechanism(s) involved in such a regulatory process
are unknown (Hani et al., 1999). First identified as an important factor involved in the regulation
of mitosis by binding to the Never-In-Mitosis-Gene-A (NIMA) kinase (Lu et al., 1996), Pin1 was
later shown to bind and to regulate the conformational structure of RNA processing regulators,
such as p53 and RNAP II (Siepe and Jentsch, 2009; Xu and Manley, 2004, 2007b; Zacchi et al.,
2002; Zheng et al., 2002). In fact, Pin1-p53 complex formation after DNA damage stabilizes p53
(Zheng et al., 2002), activates the transcription of target genes in the p53 pathway, such as p21
(Wulf et al., 2002), and potentiates p53 biological roles after DNA damage (Shimazaki et al.,
2012). Additionally, Pin1 inhibits the polyubiquitination of p53, which causes nuclear p53
degradation, by preventing p53 binding to MDM2 ubiquitin ligase (Jentsch and Siepe, 2009;
Siepe and Jentsch, 2009). Taken together, these studies suggest a possible involvement of Pin1 in
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mRNA 3’ end processing by binding and regulating the conformational structures of some
mRNA processing regulators, especially p53, under DNA damaging conditions. Knowing that
p53 can regulate PARN-mediated deadenylation during DDR (Devany et al., 2013), I decided to
study the potential role of Pin1 in this functional interaction and mRNA 3’ processing during the
progression of DDR.
The studies presented here indicate that Pin1 can interact with PARN and p53 to form (a)
complex(es), and that Pin1 is an activator of nuclear deadenylation, especially during DDR. It is
important to highlight that the effect of Pin1 on deadenylation is stronger under stress conditions,
most likely due to the presence of p53 in the complex(es). The results presented depict Pin1 as an
additional factor regulating nuclear deadenylase activity as part of DDR.

RESULTS
To investigate the role Pin1 on the regulation of deadenylation as part of DDR, I carried
out deadenylation assays using a radiolabeled L3(A30) RNA substrate as described (Cevher et al.,
2010; Devany et al., 2013), and nuclear extracts (NEs) from either colon cancer HCT116 cells or
colon carcinoma RKO cells treated with juglone and/or UV exposure (Figures 11A and B). 5hydroxy-1,4 naphthoquinone (juglone) has been extensively used as an inhibitor of Pin1 activity
(Chao et al., 2001; Hennig et al., 1998). It is important to highlight that since PARN is primarily
localized to the nucleus (Chen and Shyu, 1995; Mitchell and Tollervey, 2000; Wu et al., 2005)
and our previous work has focused only in nuclear functions of PARN (Cevher et al., 2010;
Devany et al., 2013; Nazeer et al., 2011), here I have continued studying PARN functions in
nuclear fractions. Importantly, Pin1 translocation and function in the nucleus in non-neuronal
cells such as HeLa (human cervical cancer), MEFs (mouse embryonic fibroblasts), and HepG2
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(human liver carcinoma) have been reported. For example, Pin1 is translocated into the nucleus
by Importin alpha5, using putative nuclear localization signals (NLS) found in Pin1’s PPIase
domain (Lufei and Cao, 2009). Pin1 also binds to chromatin and promotes histone H1
dephosphorylation (Raghuram et al., 2013). In fact, depletion of Pin1 destabilizes H1 binding to
chromatin. Additionally, Pin1 has been shown to bind to transcription factors that regulate the
expression of the c-Myc gene (Farrell et al., 2013). As described before, Pin1 binds to RNAP II
and regulates the phosphorylation of its CTD, controlling transcription initiation and elongation
(Xu et al., 2003; Xu and Manley, 2007b). It also has a critical role in the mitotic chromosome
condensation process by regulating the phosphorylation on key components and their binding to
different DNA elements (Xu and Manley, 2007a, c).
To test the role of Pin1 in deadenylation I used 5-hydroxy-1,4 naphthoquinone (juglone),
to inhibit Pin1 activity (Chao et al., 2001; Hennig et al., 1998). Juglone has been used to study
the role of Pin1 in several cellular processes (Shen et al., 2005; Siepe and Jentsch, 2009). I
treated HCT116 and RKO cells with UV irradiation (40 Jm-2) in the presence of juglone (5 µM
for the 2 h recovery time after UV treatment), a concentration reported as optimal for Pin1
inhibition. Consistent with previous studies (Cevher et al., 2010). My results showed increase in
deadenylation activity in NEs from cells treated with UV irradiation and allowed to recover for 2
h (Figures 11A and B). Importantly, these assays revealed that the reported UV-induced
activation of deadenylation was not observed with Pin1 inactivation (Figure 11A and B). While a
modest decrease in deadenylation was observed in non-UV treated RKO cells under Pin1
inactivation conditions, this was not observed in HCT116 cells. Western blot analyses of the NE
samples used in these deadenylation assays showed that juglone treatment only affects Pin1
activity and not its expression, and that p53 expression is downregulated with Pin1 inactivation
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(Chao et al., 2001; Siepe and Jentsch, 2009). I also observed the expected p53 and PARN
upregulations in UV-damaging conditions (Cevher et al., 2010; Nazeer et al., 2011), and showed
that UV treatment does not cause a detectable change in Pin1 expression. These assays revealed
that Pin1 inactivation by juglone inhibits nuclear deadenylation in samples from untreated cells
in both cell lines analyzed (Figure 11A and B). This effect is also seen under UV-damaging
conditions, where the reported UV-induced activation of deadenylation was not observed with
Pin1 inactivation. Together these results suggest that Pin1 activity plays a role mainly in the UVinduced activation of nuclear deadenylation.
To confirm Pin1 effect on nuclear deadenylation I extended these studies by treating
HCT116 cells with Pin1 small interfering RNAs (siRNAs) to knockdown Pin1 expression. NEs
were prepared 48 h after transfection with either control or Pin1 siRNAs. UV treatments were
done as described above (Figure 11C). Western blot analysis confirmed siRNA-mediated
knockdown of Pin1 expression. Like juglone-mediated inactivation of Pin1 in RKO cells,
siRNA-mediated knockdown of Pin1 in HCT116 cells slightly decreased nuclear deadenylation
activity under non-damaging conditions. Interestingly, the UV-induced activation of
deadenylation was not detected in cells depleted in Pin1 (Figure 11C). Taken together, these
results indicate that Pin1 expression and activity play a role in the regulation of nuclear mRNA
deadenylation as an activator of this reaction during DDR.
Considering that PARN is the main nuclear deadenylase in mammalian cells, that p53
binds and activates PARN after UV treatment (Devany et al., 2013), that Pin1 regulates p53
activity (Woods and Vousden, 2001; Zheng et al., 2002), and data in Figure 11 shows that Pin1
activates nuclear deadenylation, I decided to examine the physical association of these proteins
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Figure 11. Levels of nuclear deadenylation correlate with Pin1 activity and
expression. NEs from A) HCT116 and B) RKO cells incubated with 5 µM juglone
for 2 h, and C) HCT116 cells incubated with Pin1/control siRNAs for 48h were used
in deadenylation assays. Indicated samples were also treated with UV (40 Jm−2) and
allowed to recover for 2 h. The deadenylation reactions were incubated for 90
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deadenylation reactions from three independent assays are shown. Positions of the
polyadenylated RNA L3(A30) and the L3 deadenylated product are indicated.
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in NEs from HCT116 cells. I performed co-immunoprecipitation (co-IP) (Figure 12A) and pulldown assays (Figure 12B) using anti-Pin1 specific antibodies and GST-tagged Pin1
protein,respectively. NEs from cells treated under stress conditions described in Figure 11 were
used. Western blots were carried out to analyze complex(es) formation. Other Pin1 binding
proteins, tau and RNAP II (Lee et al., 2011; Lu et al., 1999; Xu et al., 2003; Xu and Manley,
2007b) were included in this analysis. Furthermore, the binding of tau and RNAP II to Pin1, as
well as some other implications, will be further discussed in Chapters III and IV. Both assays
showed that PARN and Pin1 can interact to form complex(es) in both non-stress and UV-treated
conditions. These complex(es) include(s) p53 mainly after its induction under DNA damaging
conditions (Figure 12A and B). As NE samples were treated with RNase A, the complex(es)
formed are not due to an RNA tethering effect. These results are consistent with previous reports
showing that the Pin1-p53 and the p53-PARN interactions are increased in DNA damaging
conditions (Devany et al., 2013; Siepe and Jentsch, 2009; Zacchi et al., 2002; Zheng et al., 2002).
Since that p53 might be part of the same complex as Pin1 and PARN deadenylase, and it
regulates PARN deadenylase activity, I analyzed whether p53 expression is necessary for the
Pin1-mediated regulation of nuclear deadenylation. To test this I used NEs from HCT116 and the
isogenic HCT116 p53 -/- cell lines in deadenylation assays. Since the deadenylation levels after
UV treatment are very high (see Figure 11A), I used this condition as a control of the reaction
(see Figure 11A). Deadenylation levels in NEs from HCT116 p53 -/- cell are low due to the lack
of p53 expression, an activator of the reaction (Devany et al., 2013). Inactivation of Pin1 in the
isogenic HCT116 p53 -/- cell line did not have any detectable effect on deadenylation, indicating
that the Pin1-mediated activation of deadenylation is dependent on p53 expression (Figure 13).
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Figure 12. Pin1, p53 and PARN can form (a) complex(es) in NEs of HCT116
cells, and formation is optimal under DNA damaging conditions. A) Co-IP
from NEs of HCT116 cells using anti-Pin1 antibodies. Cells were treated with 5
µM juglone for 2 h, and/or exposed to UV irradiation and allowed to recover for 2
h. NEs were treated with RNase A. B) Pull-down from NEs of HCT116 cells
using GST-Pin1 protein immobilized on glutathione-Sepharose beads. Cells were
exposed to UV irradiation and allowed to recover for 2 h, and NEs were treated
with RNase A. Equivalent amounts of the pellets (IP or PD) were resolved by
SDS-PAGE, and proteins were detected by Western blotting using the indicated
antibodies. NEs used in the co-IP (10%) and pull-down (5%) reactions are shown
as Input.
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DISCUSSION
Here I show evidence that Pin1 is involved in the regulation of deadenylation as part of
the DDR. First, I showed that Pin1 expression and activity can regulate nuclear deadenylation
levels, especially after UV exposure in different cell lines. Second, I provided evidence that Pin1,
PARN and p53 can form (a) complex(es) in NEs. Additionally, I showed that p53 expression is
necessary to the Pin1-mediated activation of nuclear deadenylation. Previous work from Dr.
Kleiman’s lab has shown that p53 is an activator of PARN deadenylase activity after UV
treatment (Devany et al., 2013). The results presented here depict Pin1 as an additional factor
regulating nuclear deadenylase activity as part of DDR. My results also show that p53 expression
is not sufficient to activate nuclear deadenylase activity, as Pin1 needs to be expressed and active
for the UV-induced activation of deadenylation. This suggests that the formation of these
complex(es) containing all these active nuclear factors is necessary for the rapid control of
deadenylation during DDR, allowing the regulation of gene expression during DDR. Although
my data indicate that Pin1 and PARN are part of the same complex(es) and that this is not due to
an RNA tethering effect, further studies are necessary to verify whether these two factors interact
directly or other nuclear factors are involved in the complex.

Additional studies are also

necessary to test whether Pin1-mediated activation of nuclear deadenylation plays a role in the
regulation of gene expression.
The concept that Pin1 is involved in the regulation of mRNA processing has been
suggested in other studies. Initially, Pin1 was linked to mRNA 3’ end processing when mutations
in a peptidylprolyl-cis/trans-isomerase gene led to defects in the 3’ end formation of a premRNA in Saccharomyces cerevisiae (Hani et al., 1999). Besides Pin1 has been functionally
connected to p53 and RNAP II, which are involved in the regulation of the cleavage step of
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polyadenylation. Although other studies have linked Pin1 to gene expression modifications in
other ways, including affecting transcription or mRNA stability (Hanes, 2015; Thapar, 2015), my
data is the first indication of a direct role of Pin1 on the regulation of nuclear deadenylation.
Pin1 has been shown to regulate mRNA steady state levels of different genes, such as
histones (Krishnan et al., 2012), collagen (Shen et al., 2008), and parathyroid hormone (Kumar,
2009; Nechama et al., 2009). Other transcripts include mRNAs of cytokines involved in
inflammatory responses, asthma, and in the activation of eosinophils in the lungs (Esnault et al.,
2006; Shen et al., 2005; Takahashi et al., 2008), as well as genes involved in the p53 pathway
(Huang et al., 2013a; Krishnan et al., 2014). In most cases, Pin1 regulates the decay of these
mRNAs by interacting with well-known ARE-binding proteins (ARE-BPs) that stabilize or
destabilize these ARE-containing mRNAs (Krishnan et al., 2014; Shen and Malter, 2015). These
binding sites are found in the 3’ untranslated regions (3’UTR) of mRNA transcripts. In that
scenario, Pin1 might be in close proximity to ARE-BPs functionally associated with either
PARN and/or other mRNA processing factors at 3’UTRs. Among these ARE-BPs are AUF1 and
KH-type splicing regulatory protein (KSRP), which enhance mRNA degradation, and HuR and
hnRNP C, which stabilize ARE-containing mRNAs (Kumar, 2009; Shen et al., 2005).
Interestingly, KSRP and PARN are part of the same complex involved in ARE-mediated
regulation of deadenylation (Zhang et al., 2010). The fact that Pin1 binds to KSRP and regulates
its phosphorylation (Nechama et al., 2009) supports the idea that Pin1 also functionally
associates to PARN, and that it localizes to mRNA 3’ ends in the nucleus, where PARN
deadenylation occurs. Interestingly, in the case of histones mRNAs, which are cleaved but do not
have poly(A) tails, Pin1 regulates the polyubiquitination of stem-loop binding protein (SLBP) by
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recruiting components of the RNA degradation machinery to the histone mRNA 3’ end
(Krishnan et al., 2012).
Pin1 has been connected to the progression of DDR and the deregulation of this response
in cancer. Pin1 is essential for the proper activation of wild-type p53 function upon genotoxic
stress, and more specifically controlling its role in stress-induced cell cycle arrest and apoptosis
(Mantovani et al., 2015; Napoli et al., 2011). On the other hand, cancer survival rates in patients
with combined germline p53 mutations and Pin1 overexpression appear to be drastically lower
because Pin1 is also able to trigger the activation of mutant p53 (Hu and Wulf, 2011; PolonioVallon et al., 2014). Pin1 is an essential co-factor of mutant p53, participating in its aberrant
functions (Mantovani et al., 2015). Importantly, Pin1 has also been shown to interact
with/regulate key DNA double-strand break (DSB) repair factors, and to contribute to the
maintenance of genome stability in non-neuronal cell models (Steger et al., 2013). In fact, Pin1
plays a critical role in coordinating DNA repair by promoting the non-homologous end-joining
pathway during DSB repair (Polonio-Vallon et al., 2014; Steger et al., 2013). Additionally, Pin1
regulates the functions of DDR factors such as ATR (Hilton et al., 2015), Che-1 (De Nicola et
al., 2007), and HIPK2 (Bitomsky et al., 2013). The roles of Pin1 in DDR are very intricate and
partially understood. My studies indicate the functional connection of Pin1 with protein factors
involved in DDR, such as PARN deadenylase and p53, resulting in the UV-induced inhibition of
nuclear deadenylation.
To identify the genes affected by Pin1 regulation microarray analyses have been
performed using RNA nuclear samples from HeLa cells treated with control and Pin1 siRNAs
(Krishnan et al., 2014) and RNA samples from Pin1 +/+ and Pin1 -/- mouse embryonic
fibroblasts (Huang et al., 2013a). Similar results were obtained in both studies. Interestingly, the
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p53 signaling pathway, the most affected pathway by PARN knockdown (Devany et al., 2013),
is also one of the most affected pathways by Pin1 knockdown (Krishnan et al., 2014). Other
pathways affected by downregulation of both PARN and Pin1 include the MAPK signaling
pathway and pathways in cancer. Short-lived ARE-containing mRNAs are significantly altered
by Pin1 silencing (Huang et al., 2013a; Kirsh et al., 2011; Krishnan et al., 2014). Together these
studies suggest a functional overlapping of Pin1, PARN and p53 in the regulation of mRNA 3’
processing and gene expression under different cellular conditions. These studies further validate
my data showing that Pin1 and PARN are part of the same complex, and that Pin1 regulates
nuclear deadenylation.
The further characterization of the PARN/Pin1 mRNA targets and the factors involved in
this PARN-dependent regulatory pathway may allow us to have a better understanding of the
role of Pin1 in mRNA 3’ end processing as part of DDR. Considering that Pin1 is overexpressed
in most human cancers and inactivated in Alzheimer disease (Driver et al., 2014; Lee et al.,
2011; Lu and Hunter, 2014), common Pin1-regulated mechanisms, such as mRNA processing,
might reveal potential mechanistic explanations for the onset and/or development of these
diseases, and could offer new opportunities for treatment and/or prevention of both.
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CHAPTER III

EFFECTS OF MICROTUBULE-ASSOCIATED PROTEIN tau ON THE REGULATION
OF NUCLEAR mRNA DEADENYLATION IN NON-NEURONAL CELLS
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INTRODUCTION
The results presented in Chapter II show that Pin1 functionally interacts with factors
involved in mRNA 3’ end processing and regulates this step under different cellular conditions.
These results are important because Pin1 deregulation has been linked to diseases such as
Alzheimer’s disease (AD) and cancer (Lee et al., 2011), suggesting a functional overlapping of
Pin1 in these two conditions. Interestingly, one of Pin1’s binding partner in neurons, tau, is
hyperphosphorylated and becomes the main component of Paired Helical Filaments (PHFs) in
the cytoplasm of neurons of patients with AD. In fact, neurons from AD patients show a
decrease in soluble Pin1 because this protein is sequestered into PHFs (Lu et al., 1999).
Additionally, some studies showed that there is an inverse correlation between Pin1 expression
and neurofibrillary degeneration in AD, and that areas in the brain with lower Pin1 expression
are more vulnerable to neuronal degeneration (Liou et al., 2003). As part of my research, I plan
to extend the studies obtained in Chapter II, and explore other factors, in addition to Pin1
(Chapter II) and p53 (Devany et al., 2013), that might be involved in the regulation of nuclear
deadenylation, especially during the DNA damaging response (DDR). As discussed in the next
paragraphs, many functional connections among tau, Pin1, and p53 have been described,
suggesting that tau might also be involved in the regulation of mRNA 3’ processing during DDR.
First, Pin1 can regulate tau phosphorylation and stability, suggesting a role for this
protein in different tau pathogenesis (Blair et al., 2015; Lu and Zhou, 2007). While tau typically
functions to stabilize and bundle microtubules in the cytoplasm, its hyperphosphorylated forms
have been found as part of filamentous tangles in over 15 neurodegenerative diseases (Buee et
al., 2000; Koren et al., 2011). Tau contains 80 Ser or Thr phosphorylation sites, and most of
them can be phosphorylated under physiological or pathological conditions by kinases such as
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Tau-tubulin kinases 1 and 2, PKA, PKB, PKC, GSK-3β, Cdk5, CK1, MARK, among others
(Beharry et al., 2014; Kimura et al., 2013; Xiong et al., 2013). Phosphatases that counterbalance
the action of these kinases include PTEN, PP1, PP2B, and particularly PP2A, which is
considered the major tau phosphatase that binds to tau to regulate its phosphorylation by GSK-3,
and accounts for 70% of the tau phosphatase activity in the normal brain (Beharry et al., 2014;
Liu et al., 2004; Rudrabhatla and Pant, 2011). Pin1 deficiency causes tau hyperphosphorylation,
since it promotes PP2A phosphatase activity (Lonati et al., 2011); and abnormal tau
hyperphosphorylation causes its aggregation in AD (Alonso et al., 2001a; Kimura et al., 2013;
Lee et al., 2011). Specific residues have been studied as pathological phosphorylation sites,
including Ser199, Thr 212, Thr 231 and Ser 262 (Alonso et al., 2010; Driver et al., 2014; Eichner
et al., 2016; Lu et al., 1999). These residues have been of special interest since they are highly
phosphorylated in AD, are found before Pro residues, and therefore can be targets of Pin1binding regulation. Particularly, Thr 231 seems to be key in the pathogenesis of the disease. Pin1
recognizes the pThr231-Pro232 motif of tau, catalyzing its isomerization, and inhibiting the
accumulation of cis-tau, which occurs at early stages of AD (Driver et al., 2014; Lonati et al.,
2011; Nakamura et al., 2013a; Nakamura et al., 2013b).
Additionally, tau hyperphosphorylation is regulated by p53 and some p53 isoforms.
p73+/- mice show dramatic accumulation of phosphorylated tau, showing that this p53-family
protein might be essential for the prevention of neurodegeneration (Wetzel et al., 2008). p44,
found preferentially in neuronal nuclei and whose levels are increased with age in the mouse
brain, promotes the phosphorylation of tau and activates the transcription of different tau kinases
(Pehar et al., 2013). p53 itself was found to be upregulated in AD, and to induce tau
phosphorylation in human embryonic kidney 293a cells (HEK293a) (Hooper et al., 2007).
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Knowing that p53 is involved in the regulation of mRNA 3’ end processing during DDR
(Devany et al., 2013; Nazeer et al., 2011), these results suggest that tau might have nuclear roles
in non-neuronal cell lines in the regulation of mRNA processing and gene expression. The
functional connections of tau and p53 in non-neuronal cells, as well as their implications on
DDR, will be further discussed in Chapter VI.
Regulation of mRNA 3’ end processing as part of DDR occurs mainly in the nucleus.
Previous studies have shown the localization of tau to the nucleus. Neuronal tau has been
traditionally studied as a cytosolic protein. Other reports have shown its nuclear localization
(Bukar Maina et al., 2016; Multhaup et al., 2015). Different nuclear tau isoforms associate with
the nuclear organizing region of chromosomes (Loomis et al., 1990). Nuclear tau has been
detected in nuclei isolated from fresh, frozen human frontal cortex (Brady et al., 1995).
Additionally, 16 % of the total Tau protein content in neuroblastoma LA-N-5 cells localizes in
the nucleus, more specifically in the DNA-containing chromatin fraction (Greenwood and
Johnson, 1995). Finally, protein factors such as TRIM28, a factor involved in DDR that binds to
p53 ubiquitin ligase HDM2, regulate the nuclear accumulation of tau (Rousseaux et al., 2016).
Several in vitro studies confirmed that tau can bind to DNA, induces its conformational
change, and protects it under stress conditions, suggesting that tau might be involve in DDR
(Hua and He, 2003; Padmaraju et al., 2010; Sultan et al., 2011; Wei et al., 2008). Interestingly,
tau phosphorylation might be an important regulatory step of its nuclear functions. Tau does not
get phosphorylated in cell nuclei, indicating that it has to be phosphorylated prior to transport
from the cytosol (Greenwood and Johnson, 1995; Qi et al., 2015). Besides tau phosphorylation
status affects its DNA binding capacity (Bukar Maina et al., 2016; Greenwood and Johnson,
1995; Qi et al., 2015; Violet et al., 2014). Nuclear tau promotes global chromatin relaxation in
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neurodegeneration as a result of oxidative stress and subsequent DNA damage (Frost et al.,
2014). Considering that Pin1 regulates tau phosphorylation and it is also present in the nucleus
where it binds to other nuclear DDR factors resulting in the regulation of deadenylation activity,
it is easy to hypothesize that tau might overlap in those Pin1-associated nuclear functions.
The cellular models used in this Chapter are non-neuronal cells lines. It is important to
highlight that tau has been also found in the cytoplasm and nucleus of non-neuronal cells,
suggesting that its roles are not only related to neurons or to neuronal diseases. For example,
multiple tau isoforms have been described in the nucleolus and nuclear organizing regions of
HeLa cells, lymphoblasts, fibroblasts and lymphocytes (Thurston et al., 1996). Human
fibroblasts and Huh-7 hepatoma cell lines contain at least three cytoplasmic tau isoforms, as well
as at least two nuclear tau isoforms (Cross et al., 2000). In endothelial cells, tau is a critical
cAMP-responsive, PKA-phosphorylated protein that controls cell barrier function and
microtubule architecture (Zhu et al., 2010). Tau levels have been found to correlate with the
response of certain cancer cells, including prostate and breast, to chemotherapy drugs (Ikeda et
al., 2010; Souter and Lee, 2010; Zhou et al., 2015). In fact, tau expression is dependent on
estrogen receptor status in MCF7 breast cancer cells (Zhou et al., 2015), and these receptors are
key drivers of cell proliferation in most breast cancers (Rajbhandari et al., 2012). Although these
tau isoforms have been described in non-neuronal cells for over 2 decades, their characteristics
and potential roles, especially in the nucleus, remain mostly unknown.
In this chapter I describe a novel function of tau in the regulation of PARN-mediated
deadenylation in the nucleus of non-neuronal cells. I show the presence of tau forms in the
nucleus and how these nuclear form patterns are affected in different cellular conditions. My
results indicate that tau forms can interact with nuclear mRNA 3’ end processing regulators such
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as p53, Pin1 and PARN; and that the complex(es) formation is regulated during DDR. Moreover,
I showed that tau and PARN interaction decreases by tau phosphorylation at pathological sites.
Furthermore, tau expression activates nuclear deadenylase activity in non-neuronal cells. Finally
I showed that tau-mediated activation of PARN deadenylase is p53 dependent, and that tau
phosphorylation at pathological sites affects PARN activity. Together, the results presented here
indicate that tau can be an additional factor that works in cooperation with Pin1 (Chapter II) and
p53 (Devany et al., 2013) to regulate nuclear PARN deadenylase activity as part of DDR.

RESULTS
Before investigating the role tau on the regulation of deadenylation as part of DDR, I
verified the presence of tau forms in the nucleus of the non-neuronal cell. I carried out a cell
fractionation assay of human colorectal carcinoma HCT116 cells using a commercial kit, and
analyzed these fractions by Western blotting. Proteins with well-characterized cellular
distribution profiles were used as controls (Figure 14A). My data is consistent with previous
reports that showed the presence of different tau forms in this cellular compartment (Bukar
Maina et al., 2016; Multhaup et al., 2015). Interestingly, while tau forms of similar molecular
weight were observed in both cytoplasmic and nuclear fractions, some tau forms were exclusive
for each compartment (Figure 14B). These differences were more evident in Western blots with
different level of exposure (Figure 14C). α-Tubulin, a protein known to be present only in the
cytoplasm, was not detected in the soluble nuclear fraction, indicating that tau forms detected in
this fraction were not contamination from the cytoplasmic fraction. To further analyze the nature
of the posttranslational modifications on these tau forms as well as other possible mechanistic
aspects, I prepared nuclear extracts (NEs) from HCT116. As discussed extensively
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Figure 14. Tau forms are present in both cytoplasmic and soluble nuclear
fractions from HCT116 cells. A) HCT116 cells were used in a subcellular
fractionation kit from Pierce to release the protein content of each cellular
compartment, as instructed by the manufacturer. Equivalent amounts of total
protein content from each fraction were analyzed by SDS-PAGE, and tau forms in
each fraction were detected using mouse monoclonal Tau-13 antibody provided
by Dr. Alonso. Antibodies against epidermal growth factor receptor (EGFR),
topoisomerase II (Topo II), α-Tubulin, and histone H2B were used as controls for
each fraction. B) Increasing amounts of cytoplasmic (5, 17.5 and 35 µg of total
protein) and soluble nuclear fractions (35, 42 and 56 µg of total protein) were
loaded again to detect tau forms. C) Cytoplasmic and soluble nuclear lanes
labeled as 3 and 6 in B) were overexposed.
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in the Introduction, many functional connections among tau, Pin1, and p53 have been described
(Hooper et al., 2007; Lee et al., 2011; Mantovani et al., 2015). To further explore these
connections I included in my studies isogenic HCT116 p53-/- cells exposed to different
treatments (Figure 15). Cells were incubated with juglone (5 µM) and/or exposed to UV
irradiation (40 Jm−2) and allowed to recover for 2 as reported before (Cevher et al., 2010;
Devany et al., 2013). As mentioned in Chapter II, juglone is an inhibitor of Pin1 activity (Chao et
al., 2001; Hennig et al., 1998), and has been used to study the role of Pin1 in other processes
(Shen et al., 2005; Siepe and Jentsch, 2009). Additionally, some samples were also treated with
calf intestinal phosphatase (CIP), which dephosphorylates all Ser, Thr and Tyr residues in
proteins. Western blot analysis revealed that the pattern of these nuclear tau forms changes
depending on p53 expression, phosphorylation, Pin1 inactivation, and/or DNA damaging
conditions (Figures 15A and B). Consistent with previous reports, (Greenwood and Johnson,
1995; Qi et al., 2015; Violet et al., 2014) some high-molecular weight forms of tau disappear
after CIP treatment, indicating that some of these nuclear forms are phosphorylated. Together
these results are consistent with the functional connections previously described for tau, p53 and
Pin1 and show that tau is dynamically regulated in the nucleus of non-neuronal cells. These
posttranslational changes might have an effect on tau’s potential nuclear roles. For example, tau
binding to DNA decreases after phosphorylation (Qi et al., 2015).
Dr. Kleiman’s lab has shown that PARN and p53 interact to form (a) complex(es), and
that p53 expression levels can activate PARN, and hence, regulate gene expression (Devany
2013). Previous studies have also characterized Pin1-p53 (Siepe and Jentsch, 2009; Zacchi et al.,
2002; Zheng et al., 2002) and Pin1-tau interactions in cytoplasmic extracts and, in the case of
tau, in neuronal cells (Kimura et al., 2013; Lee et al., 2011; Lu et al., 1999). I extended these
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Figure 15. Nuclear tau patterns are changed upon p53 expression, Pin1
inactivation, UV irradiation and calf intestinal phosphatase (CIP) treatment.
A) HCT116 cells and B) HCT116 p53 -/- cells were treated with 5 µM Juglone
for 2 h, and/or exposed to UV irradiation (40 J m−2) and allowed to recover for 2
h. NEs were prepared and treated with CIP for 1 h at 37°C. CIP treatment was
stopped with 2 mM EDTA and samples were further incubated for 20 min at
30°C. Tau form patterns were monitored by Western blotting with monoclonal
Tau-13 antibody provided by Dr. Alonso. Antibody against Topo II was used as
loading control. Whole cell extracts were prepared by sonication of cells in RIPA
buffer.
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studies by showing that PARN and Pin1 can interact to form complex(es) in both non-stress and
UV-treated conditions, and that these complex(es) include(s) p53 in DNA damaging conditions
in Chapter II (Figure 12A and B). To further analyze the formation of nuclear protein
complex(es) containing tau and these factors in non-neuronal cells, I performed coimmunoprecipitation (co-IP) assays using specific antibodies against tau, PARN and p53 and
NEs from HCT116 (Figures 16A-C) and the isogenic HCT116 p53 -/- cells (Figures 17A and B).
Juglone and/or UV treatments were also included in these studies. NEs were treated with RNase
A to verify that the observed interactions are not due to an RNA tethering effect. These co-IP
assays revealed that PARN, Pin1, and tau can co-IP from HCT116 NEs in both non-stress and
UV-treated conditions, and that the complex(es) include(s) p53 mainly after its upregulation and
stabilization in DNA damaging conditions (Figures 16A-C). Consistent with this, PARN, Pin1
and tau still associate in cells that do not express p53 (Figures 17A and B). These results indicate
that tau can interact with Pin1, PARN and p53 to form (a) complex(es) in both non-stress and
UV-treated conditions. The nature and effect of these complex(es) on PARN-mediated
deadenylation might be different in different conditions, perhaps depending on the presence of
p53 in the complex and/or the phosphorylation of both tau or p53.
To extend these studies I tested whether tau and PARN deadenylase interact directly.
Considering that tau and its phosphorylation status are highly regulated in the nucleus of these
cells (Figure 15), I also analyzed whether pseudo-phosphorylated and dementia-related tau
mutant variants might interact differently with PARN compared to the wild-type tau (WT-Tau). I
performed complementary pull-down assays using His-PARN and GST-WT-Tau, as well as
other tau variants (Figure 18A and B). pAcGFP plasmids encoding these tau mutants were kindly
provided by Dr. Alonso (College of Staten Island, CUNY). I subcloned these tau variants
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Figure 16. Tau forms (a) complex(es) with Pin1, p53 and PARN in NEs of
HCT116 cells, independently of DNA damaging conditions. Co-IP assays with
antibodies against A) Tau, B) PARN, or C) p53 were performed using NEs of
HCT116 cells treated with 5 µM Juglone for 2 h, and/or exposed to UV
irradiation (40 Jm−2) and allowed to recover for 2 h. NEs were treated with RNase
A. Equivalent amounts of the pellets (IP) were resolved by SDS-PAGE, and
proteins were detected by Western blot using the indicated antibodies. 10% of the
NEs used in the co-IP assays are shown as Input.
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Figure 17. Tau, Pin1, and PARN form (a) complex(es) in NEs of HCT116
cells that do not express p53. Co-IP assays with antibodies against A) Tau or B)
PARN antibodies were performed using NEs of HCT116 p53 -/- cells treated with
5 µM Juglone for 2 h, and/or exposed to UV irradiation (40 Jm−2) and allowed to
recover for 2 h. NEs were treated with RNase A. Equivalent amounts of the
pellets (IP) were analyzed by SDS-PAGE, and proteins were detected by Western
blot analysis using the indicated antibodies. 10% of the NEs used in the co-IP
assays are shown as Input.

54

sequences into pGEX-2TK bacterial expression vectors using DNA recombinant techniques.
Phosphomutant-Tau (PH-Tau) is a variant that is mutated at four residues (Ser 199, Thr 212, Thr
231 and Ser 262 changed to glutamic acid) to mimic phosphorylation, and hence resembles a
pathological human form found in neurological diseases such as AD (Alonso et al., 2010). On
the other hand, Frontotemporal-Tau (FT-Tau) is a variant containing Arg 406 replaced by Trp
(R406W mutation) that is found in frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) (Alonso et al., 2010; Kimura et al., 2013). These disorders are part
of a family of diseases known as tauopathies, and are characterized by abnormal accumulation of
phosphorylated-tau in intracellular filamentous deposits, causing dementia (Kovacs, 2015). I also
included a tau variant combining both modifications (PH/FT-Tau) in the pull-down assays. My
results show that His-PARN and GST-WT-Tau can interact directly (Figure 18A and B). While
PARN interaction with FT-Tau variant was similar to that observed with WT-Tau, PARN
interaction with PH-Tau was weaker. Interestingly, PARN binds less to PH/FT-Tau than to FTTau, suggesting that phosphorylation at pathological sites might significantly decrease the
PARN-tau interaction. Considering that changes in tau phosphorylation affect its binding to
DNA (Bukar Maina et al., 2016; Qi et al., 2015; Sultan et al., 2011), these results indicate that
tau phosphorylation might also have effects on its binding to nuclear protein factors such as
PARN deadenylase.
The IP and pull-down assays shown in previous figures in this thesis showed what is
apparently only one tau form (a band at approximately 55 kDa) forming (a) complex(es) with
Pin1 (Figure 12), PARN deadenylase and p53 (Figures 16B-C and 17B). Those Western blots
were immunostained with monoclonal Tau-13 antibody (kindly provided by Dr. Alonso). To
verify whether other tau forms are also part of the nuclear complex(es) formed with p53, Pin1
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Figure 18. WT-Tau interacts with PARN, and the interaction is reduced by
tau phosphorylation at pathological sites. A) Immobilized GST-WT-Tau or
phospho-variants on glutathione-Sepharose beads were incubated with HisPARN. B) Alternatively, immobilized His-PARN on nickel beads was incubated
with GST-WT-Tau or tau phospho-variants. PH-Tau is a phosphomimic mutant
with Ser199, Thr212, Thr231 and Ser262 residues changed to glutamic acid to
mimic phosphorylation as found in dementia-causing tauopathies (Alonso et al.
2010). FT-Tau has R406W mutation as in Frontotemporal dementia. In A) and B)
equivalent amounts of the pellets (pull-down) were resolved by SDS-PAGE, and
proteins were detected by immunoblotting using the indicated antibodies. 5% of
the proteins used in the PD assays are shown as Input. Representative pull-down
reactions from three independent assays are shown. Numbers beneath gel lanes
are relative binding (RB) (compared to WT-Tau/His-PARN binding), and
calculated as [(PD-ed protein/bait protein) / (Control PD-ed protein/ control bait
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Figure 19. More than one tau form can constitute (a) complex(es) with Pin1,
p53 and PARN in NEs of HCT116 cells. Co-IP assay with a monoclonal antip53 antibody was performed using NEs of HCT116 cells treated with 5 µM
Juglone for 2 h, and/or exposed to UV irradiation (40 Jm−2) and allowed to
recover for 2 h. NEs were treated with RNase A. Equivalent amounts of the
pellets (IP) were resolved by SDS-PAGE, and proteins were detected by Western
blotting using a polyclonal tau antibody (H-150, Santa Cruz Biotechnology) and
the indicated antibodies. 10% of the NEs used in the co-IP assay are shown as
Input.
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and PARN I repeated co-IPs using a monoclonal antibody against p53 for the IP and a polyclonal
antibody against tau in the Western blot analysis (Figure 19). This set of co-IPs confirmed that
Pin1, PARN, p53 and tau can interact to form (a) complex(es) in NEs from HCT116 cells. At
least two bands of approximately 55 and 72 kDa were detected with the tau polyclonal antibody
(H-150, Santa Cruz Biotechnology) in these co-IP assays. Although more studies with other tau
antibodies are necessary, these results indicate that at least two different forms of tau could
interact with these nuclear mRNA processing factors in HCT116 cells.
As the proteins analyzed in this Chapter undergo several post-translational modifications
that might affect the interaction with the other factors of the complex, I performed
complementary pull-down assays using recombinant proteins incubated with HCT116 NEs. This
strategy allowed me to analyze how modifications induced in different cellular conditions might
affect the interaction of these cellular factors. I bound His-PARN, His-p53, GST-WT-Tau, or
GST-PH-Tau to beads, and incubated them with NEs from non-treated or UV-irradiated HCT116
cells (Figure 20A-C). His-PARN pulled-down Pin1 and tau mainly from NEs of UV-treated
cells, when p53 levels are increased (Figure 20A). Interestingly, His-PARN can pull-down at
least three tau forms of approximately 55 kDa, 72 kDa, and 95kDa when polyclonal antibodies
were used for Western blot detection (Tau Polyclonal, H-150). Likewise, His-p53 pulled-down
PARN, Pin1 and three tau forms with similar molecular weight than the ones pulled-down by
His-PARN (Figure 20B). Furthermore, WT-Tau pulled-down p53 and Pin1 from NEs of non
treated-HCT116 cells (Figure 20C). These interactions were stronger, and PARN was included in
this complex when NEs of UV-treated cells were used. Interestingly, this UV-induced complex
formation with PARN was not seen with PH-Tau, suggesting again that tau phosphorylation at
pathological sites might affect its binding to PARN. These results indicate that in non-neuronal
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cells, more than one tau form might be part of nuclear complex(es) that include the mRNA
processing factors PARN, Pin1 and p53. Furthermore, the presence of all these factors in the
complex(es) is favored in UV-stress conditions, when p53 is overexpressed.
My studies indicate that tau interacts with PARN, and that their interaction in the nuclear
complex(es) is influenced by p53 expression, DNA damage induction, and tau phosphorylation
at disease associated sites. To investigate whether tau plays a role in the regulation of
deadenylation under different conditions in non-neuronal cells, first, I carried out deadenylation
assays using NEs from Chinese hamster ovary (CHO) cells transfected with pAcGFP expression
constructs containing either WT- or PH-Tau sequences. Radiolabeled L3(A30) RNA was used as
substrate as described in Chapter II (Cevher et al., 2010, Devany et al., 2013). Transfected CHO
cells were generously provided by Dr. Alonso’s lab. My results indicate that overexpression of
WT-, but not PH-Tau, induced nuclear deadenylase activity in this cell line (Figure 21A, top
panel). As shown by Western blot analysis, the expression levels of PARN and Pin1 were not
affected by the overexpression of these tau forms in CHO cells (Figure 21A, lower panel). As
previously reported (Boom et al., 2009; Hu et al., 1999; Matsumura et al., 1999; Moro et al.,
1995; Vogelsberg-Ragaglia et al., 2000), tau and p53 were not detected in samples from CHO
cells. These results indicate that tau can activate deadenylation and this is lost by tau
phosphorylation at pathological sites.
I extended these studies to test the effect of tau on deadenylation in human non-neuronal
cells. I transfected HCT116 cells with the pAcGFP vectors (WT- and PH-Tau constructs) for 24
h. Then cells were exposed to UV irradiation (40 Jm−2) and allowed to recover for 2 h, and NEs
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Figure 20. Complex(es) formation of PARN, Pin1 and tau in NEs of HCT116
cells is affected by p53 expression and tau phosphorylation at pathological
sites. Immobilized A) His-PARN or B) His-p53 on nickel beads, and C) GSTWT-Tau or GST-PH-Tau on glutathione-Sepharose beads were incubated with
NEs from HCT116 cells. Cells were exposed to UV irradiation (40 Jm−2) and
allowed to recover for 2 h. NEs were treated with RNase A. Equivalent amounts
of the pellets (PD) were resolved by SDS-PAGE, and proteins were detected by
Western blotting using indicated antibodies. 5% of the NEs used in the pull-down
reactions are shown as Input.

60

were prepared. As described in previous reports (Cevher and Kleiman, 2010; Devany et al.,
2013), deadenylation activity in NEs of HCT116 cells increased significantly after UV treatment
(Figure 21B). My data also shows that WT-Tau expression activated nuclear deadenylation
before and after UV exposure, and this strong activation was not observed in NEs of cells
expressing PH-Tau. Interestingly, WT-Tau overexpression increased p53 level before and after
UV, and this effect was lost when PH-Tau is expressed (Figure 21B, lower panel). The
functional connections between tau and p53 will be further discussed in Chapter VI. These
results suggest that tau might activate deadenylation by induction of the expression of an
activator of the reaction, the tumor suppressor p53, and all this is lost by tau phosphorylation at
pathological sites.
To further prove the tau-mediated activation of nuclear deadenylation I depleted tau
expression in HCT116 cells using MAPT siRNA. NEs were prepared after a 48 hr incubation.
Cells were UV irradiated (40 Jm−2) and allowed to recover for 2 h. As expected, nuclear
deadenylation activity increased significantly after UV treatment (Figure 22). Interestingly, tau
knockdown abolished this UV-induced activation of deadenylation, indicating that tau is an
activator of this reaction. p53 expression levels decreased in samples of cells depleted in tau
expression both in non-stress and stress conditions (Figure 22, right panel), suggesting a
potential regulatory connection between these two factors (discussed in Chapter VI).
To test whether p53 has an effect on the tau-mediated regulation of nuclear deadenylation
I performed transfections of HCT116 and isogenic HCT116 p53 -/- cell lines with WT-Tau
construct for 24 h. Then cells were exposed to UV irradiation (40 Jm−2) and allowed to recover
for 2 h, and NEs were prepared. WT-Tau-mediated activation of deadenylation in HCT116 p53 /- cells was not as strong as in the isogenic HCT116 cell line (Figure 23). Western blot analysis

61

A

B
CHO
cont

RD: 6 0.9

WT PH-Tau

54 5

Cont
UV: +

HCT116
WT
+

PH-Tau
+

-L3(A30)

-L3(A30)

-L3

-L3

RD: 2 0.7

13 1

18 2

14 1

29 3

3 0.9 16 3

HCT116
cont

CHO
WT PH-Tau

UV:

Cont
+

WT
-

+

PH-Tau
+

-PARN

-PARN

-Topo II

-p53

-actin
95-

-actin
95-

72-

-Tau

72-

-Tau
55-

55-

-Pin1
1

2

3

-Pin1
1

2

3

4

5

6

Figure 21. Expression of tau but not of its phospho-derivative PH-Tau induces nuclear
deadenylase activity in CHO and HCT116 cells before and after UV irradiation. NEs
from A) CHO and B) HCT116 cells transfected with pAc-GFP expression vectors
containing WT-Tau or PH-Tau (described in Figure 18, Alonso et al. 2010), were used in
deadenylation assays. Additionally, HCT116 cells were treated with UV (40 Jm−2) and
allowed to recover for 2 h. The deadenylation reactions were incubated for 90 min. RNAs
were purified and analyzed by denaturing PAGE. Representative deadenylation reactions
from three independent assays are shown. Positions of the polyadenylated RNA L3(A30) and
the L3 deadenylated product are indicated. Numbers beneath gel lanes indicate relative
deadenylation (RD), calculated as [L3 fragment/(L3 fragment + L3 (A30)] ×100. The means
± standard deviation of RD values are indicated. Quantifications were done using ImageJ
software (http://rsb.info.nih.gov/ij/). Lower panels show expression levels of indicated
proteins from NEs tested in deadenylation assays.
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Figure 22. Tau knockdown inhibits nuclear deadenylation under non-stress
and UV-induced conditions in HCT116 cells. NEs from HCT116 cells treated
with either MAPT or control siRNAs for 48 h, and/or treated with UV (40 Jm−2)
and allowed to recover for 2 h. NEs from those cells were used in deadenylation
assays as described in Figure 21. Deadenylation reactions were incubated for 90
min. RNAs were purified and analyzed by denaturing PAGE. Representative
deadenylation reactions from three independent assays are shown. Positions of the
polyadenylated RNA L3(A30) and the L3 deadenylated product are indicated.
Numbers beneath gel lanes indicate relative deadenylation (RD), calculated as [L3
fragment/(L3 fragment + L3 (A30)] ×100. The means ± standard deviation of RD
values are indicated. Quantifications were done using ImageJ software
(http://rsb.info.nih.gov/ij/). Panels on the left show expression levels of indicated
proteins from NEs tested in deadenylation assays.
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showed again that tau expression had an effect on p53 expression in HCT116 cells (Figure 23,
right panel). This indicates that p53 expression, which is an activator of PARN deadenylase in
the nucleus under DNA damaging conditions (Devany et al. 2013), is necessary for the taumediated activation of deadenylation. These results are consistent with the tau-p53 interaction
described in Figures 16-20, and support the functional overlapping of both proteins in the
regulation of mRNA 3’ processing.
My results indicate that tau, like p53 (Devany et al., 2013) can interact directly with
PARN deadenylase (Figure 18), and that tau, PARN and p53 are part of the same nuclear
complex(es) (Figures 12, 16 and 17). To test whether tau directly influences PARN deadenylase
activity I performed in vitro reconstituted deadenylation assays using a limited amount of HisPARN in a cell-free assay (Cevher et al., 2010) and increasing amounts of GST-tagged
recombinant tau variants. Consistent with previous studies, increasing amounts of His-p53
activated His-PARN deadenylase activity (Devany et al., 2013). Increasing amounts of WT-Tau
can also induce His-PARN deadenylation activity (Figure 24A). Interestingly, WT-Tau-mediated
activation of His-PARN activity was greater when a limited amount of His-p53 were also
included in the reaction. These results are consistent with the results in Figure 23, indicating that
p53 is required in the tau-mediated activation of PARN. Additionally, PH-Tau did not activate
PARN deadenylation as strongly as WT-Tau (Figure 24B), even when a limited amount of p53
was included in the reactions. These results together with the ones shown in Figure 21B indicate
that tau phosphorylation at pathological sites plays an important role in tau-mediated regulation
of PARN functions.
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Figure 23. Tau-mediated activation of deadenylation depends on p53
expression. NEs were prepared from HCT116 and HCT116 p53 -/- cells
transfected with WT-Tau expressing vector (as in Figure 21, Alonso et al. 2010),
and/or treated with UV (40 Jm−2) and allowed to recover for 2 h. NEs were used
in deadenylation assays as described in Figure 21. Right panels show expression
levels of indicated protein in NEs tested in deadenylation assays. Representative
deadenylation reactions from three independent assays are shown. Positions of the
polyadenylated RNA L3(A30) and the L3 deadenylated product are indicated.
Numbers beneath gel lanes indicate relative deadenylation (RD), calculated as [L3
fragment/(L3 fragment + L3 (A30)] ×100. The means ± standard deviation of RD
values are indicated. Quantifications were done using ImageJ software
(http://rsb.info.nih.gov/ij/).
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Figure 24. WT-Tau but not PH-Tau phospho-variant can activate PARNdependent deadenylation in vitro, and this activation is stronger in the presence
of p53. In vitro deadenylation assays were performed using different concentrations
of His-PARN and His-p53, and increasing amounts of A) GST-WT-Tau or B) either
GST-WT-Tau or GST-PH-Tau. Deadenylations assays were performed in the
presence of radiolabeled capped L3(A30) RNA substrates. RNAs from reactions
were analyzed as in Figure 21. Deadenylation reactions were incubated for 90 min.
Representative deadenylation reactions from three independent assays are shown.
Positions of the polyadenylated RNA L3(A30) and the L3 deadenylated product are
indicated. Numbers beneath gel lanes indicate relative deadenylation (RD),
calculated as [L3 fragment/(L3 fragment + L3 (A30)] ×100. The means ± standard
deviation of RD values are indicated. Quantifications were done using ImageJ
software (http://rsb.info.nih.gov/ij/).
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DISCUSSION
The studies presented in this Chapter indicate a novel function of tau in the regulation of
PARN-mediated deadenylation in the nucleus of non-neuronal cells. First, I confirmed the
presence of tau forms in the nucleus of HCT116 cells (Figure 14). The appearance of these tau
nuclear forms is regulated by DNA damage, Pin1 activation, p53 expression and phosphorylation
(Figure 15). Second, I presented data that indicate that more than one tau form can functionally
interact with nuclear mRNA 3’ end processing regulators, including p53, Pin1 and PARN
deadenylase; and that the complex(es) formation is regulated during DDR (Figures 16-20).
Interestingly, tau, Pin1 and PARN can interact independently of p53 expression. Moreover, I
showed that tau and PARN can interact directly, and this interaction is inhibited by tau
phosphorylation at 4 specific sites (Ser199, Thr 212, Thr 231 and Ser 262), as found in some
neurological diseases (Figures 18 and 20). Furthermore, tau can activate nuclear deadenylase
activity in non-neuronal cells (Figures 21-22). Tau-mediated regulation of nuclear deadenylation
is dependent on p53 expression, and is lost when PH-Tau is overexpressed (Figure 23). Finally I
showed that tau can activate PARN deadenylase, the main deadenylase in the nucleus, in a p53dependent manner (Figure 24). I also showed that tau phosphorylation at pathological sites
affects PARN activity. Together, the results presented in this Chapter depict tau as an additional
factor which works jointly with Pin1 (Chapter II) and p53 (Devany et al., 2013) to regulate
nuclear PARN deadenylase activity as part of DDR. My results also suggest that the accurate
formation of nuclear complex(es) containing tau, Pin1, p53 and PARN is necessary for the
control of deadenylation, as part of the rapid and efficient response to UV-induced DNA damage
in non-neuronal cells. Although my data indicates that tau activates nuclear deadenylation in
general (Figures 21 and 22) and PARN deadenylase (Figure 24), I cannot discard the possibility
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that tau might regulate the activity of other deadenylases. Further studies are necessary to verify
if tau can also activate other nuclear deadenylases in addition to PARN. Further studies are also
necessary to prove whether this tau-mediated regulation of PARN deadenylase occurs in
neurons. Together, the results in this Chapter indicate a functional overlapping of tau and these
nuclear factors in the regulation of mRNA 3’ deadenylation. Therefore, tau expression and
phosphorylation might play an important role in the regulation of gene expression. The nuclear
functions of tau in mRNA 3’ processing and its functional connections to the tumor suppressor
p53 might play important roles in the onset and/or development of diseases such as cancer and
AD (discussed in Chapter V).
Previous studies have shown that tau is localized to the nucleus of neuronal and nonneuronal cells where it binds the DNA to protect it, suggesting that tau might play some function
during DDR (Bukar Maina et al., 2016; Multhaup et al., 2015). In fact, nuclear tau protects
neuronal genomic DNA against oxidative and heat stress by binding to the DNA (Sultan et al.,
2011). Recent studies suggest that DNA damage and repair responses are not limited to
pathological conditions but are also important for normal neuronal activity and gene expression
regulation under different physiological conditions (Madabhushi et al., 2015; Su et al., 2015). In
that scenario, the characterization of the potential roles of tau in these responses is essential.
Moreover, DNA damage is highly toxic in neurons and may trigger the deregulation in gene
expression, either transcriptionally or post-transcriptionally, as it has been seen in AD brains
(Cooper-Knock et al., 2012; Zekanowski and Wojda, 2009). My studies in non-neuronal cells
indicate that nuclear tau is involved in DDR in roles other than DNA protection after stress. My
data show that tau is involved in the regulation of mRNA 3’ end processing as part of the
response to UV-induced stress. Tau can form (a) complex(es) with Pin1 and PARN, which also
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includes p53 after DNA damage, and this results in the activation of PARN deadenylase and the
regulation of gene expression in cellular stress. These results are important considering that Pin1
and p53 have been involved in both cancer and AD (Hooper et al., 2007; Lee et al., 2011;
Mantovani et al., 2015), and that tau has an effect on the response of cancer cells to
chemotherapy drugs (Ikeda et al., 2010; Souter and Lee, 2010).
Furthermore, my data supports studies showing that changes in tau phosphorylation
might have an effect on its nuclear roles. Different tau isoforms are present in human neurons,
and their expression patterns are regulated by alternative splicing mechanisms (Buee et al.,
2000). However, additional tau variability comes from post-translational modifications,
including phosphorylation by different kinases, and isomerization of certain motifs by Pin1
(Bukar Maina et al., 2016; Lee et al., 2011). Interestingly, tau is not phosphorylated in the
nucleus but before it is transported from the cytoplasm (Greenwood and Johnson, 1995; Qi et al.,
2015; Violet et al., 2014), and it is predominantly non-phosphorylated in the nucleus (Brady et
al., 1995; Loomis et al., 1990). Besides tau binds to DNA preferentially when it is
dephosphorylated (Bukar Maina et al., 2016; Qi et al., 2015; Sultan et al., 2011), supporting the
idea that in pathological conditions, such as AD, phosphorylation might alter tau functions and
enhance genome vulnerability. In fact, tau hyperphosphorylation in nuclei correlated with
accumulation of DNA strand breaks, showing that tau phosphorylation alters its DNA protective
function (Cleary et al., 2005). My data shows that the numerous nuclear tau forms are constantly
regulated under different conditions in non-neuronal cells, and that some of these nuclear forms
are phosphorylated (Figure 15). Additionally, my results demonstrate that tau phosphorylation at
specific disease-related residues (Alonso et al., 2010) has an effect on its binding to PARN and
other nuclear factors (Figures 18 and 20C), and on tau-mediated activation of PARN
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deadenylation before and after UV treatment (Figures 21 and 24). Therefore, these results further
extend the body of literature focused on the characterization of the effects of tau phosphorylation
on its nuclear roles; and could prove of great importance in the further understanding of
tauopathies, including AD.
Recent reports have linked tau to the regulation of gene expression (Bukar Maina et al.,
2016; Multhaup et al., 2015). In neuronal cultures, lack of tau expression affects the expression
of some genes, including calbindin, a calcium-binding protein, and of Baf-57, a protein involved
in chromatin remodeling (Barreda and Avila, 2011; de Barreda et al., 2010). It has also been
shown that there is a significant rise in the mRNA levels of 13 genes in the knockout mice brain,
including Gem GTPase, a small GTP-binding protein of the ras superfamily (Oyama et al.,
2004). Tau overexpression in mouse neuroblastoma N2A cells and human neuroblastoma SK-NSH cells causes a reduction in mRNA levels of several voltage-gated K+ channels, which are
important for cell proliferation and might play a role in the development of cancer (Hu et al.,
2016; Li et al., 2015). These studies connecting tau expression to mRNA levels of K+ channels
are important because they suggest an alternative explanation for the low sensitivity to anticancer chemical drugs in some specific cancer types (Ikeda et al., 2010). Additionally, reports
suggest that tau might act as a transcriptional activator due to its ability to induce the separation
of double-stranded DNA into single-stranded (Krylova et al., 2005). However, none of these
studies show a direct mechanism of tau involvement in the expression levels of these genes,
either by transcription or posttranscriptional regulation.
Further characterization of the PARN/tau targets and of other factors involved in this
PARN-dependent regulatory pathway, such as Pin1 and p53, may allow us to have a better
understanding of the role of tau in mRNA 3’ end processing as part of DDR. Identification of
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PARN/Pin1/tau mRNA targets might reveal factors that are deregulated in both cancer and AD,
and help in the development of potential drugs for treatment. These functional connections might
further support the idea that these two diseases may share biological pathways, with common
factors deregulated in opposite directions. These ideas will be further examined in Chapter V.
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CHAPTER IV

EFFECTS OF Pin1 AND tau ON THE REGULATION OF THE mRNA 3’ CLEAVAGE
STEP OF THE POLYADENYLATION REACTION
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INTRODUCTION
After being transcribed, almost all eukaryotic mRNA precursors, with the exception of
histones mRNAs, undergo a co-transcriptional modification at the 3' end (Zhang et al., 2010).
This modification, known as polyadenylation, plays a fundamental role in regulating translation,
nuclear export, and most importantly mRNA stability; and it is essential for the proper control of
mRNA levels and gene expression in eukaryotes (Mandel et al., 2008; Zhao et al., 1999). As
shown in Figure 2 (Russell, 2009), polyadenylation of mRNA precursors (pre-mRNAs) includes
a two-step reaction, starting with an initial cleavage step followed by the synthesis of a 200adenosine residue tail to the 3’end of the cleaved product (Shatkin and Manley, 2000; Zhao et
al., 1999). The initial cleavage step, which will be the focus of this Chapter, is highly regulated
mainly by the interaction of a large number of factors under different cellular conditions,
recognizing a relatively simple set of signals in the mRNA precursor (See Figure 2, Chapter 1)
(Takagaki and Manley, 1997; Zhang et al., 2010).
Interestingly, after UV-induced DNA damage, cellular levels of polyadenylated
transcripts are transiently decreased as part of transcription-coupled repair (TCR) (Ljungman et
al., 1999). This decrease occurs, to some extend, because the largest subunit of RNA polymerase
II (RNAP II) gets phosphorylated, ubiquitinated, and degraded by the proteasome after UV
irradiation (Muratani and Tansey, 2003; van den Boom et al., 2002). Dr. Kleiman’s lab showed
that mRNA 3’ end processing is also involved in this general effect of DNA damage on poly(A)+
mRNA levels, as part of the DNA damage response (DDR) (Cevher and Kleiman, 2010;
Kleiman and Manley, 1999, 2001; Mirkin et al., 2008). More specifically, they showed that the
mRNA 3’ cleavage step of the polyadenylation reaction is strongly but transiently inhibited after
DNA damage, as a result of the association of the tumor suppressors BARD1/BRCA1 with the
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cleavage stimulation factor CstF-50 (Kleiman and Manley, 1999, 2001; Kleiman et al., 2005).
Knowing that poly (A)+ tails are essential regulators of gene expression, it is important that we
further characterize and identify other factors involved in the regulation of mRNA 3’ end
cleavage as part of DDR, and with connections to other nuclear processes. Considering that Pin1
regulates the function of some mRNA processing factors (Xu et al., 2003; Xu and Manley,
2007c; Zacchi et al., 2002) and that Pin1 (Chapter II) and tau (Chapter III) are involved in the
regulation of nuclear deadenylation as part of DDR, I will extend those studies to the potential
effects of these two factors on the regulation of mRNA 3’ end cleavage under non-stress and
UV-induced conditions.
Some of the factors that regulate mRNA 3’ cleavage include the carboxy-terminal
domain (CTD) of RNAP II and the tumor suppressor p53. The CTD of the largest subunit of
RNAP II was first shown to be required for efficient polyadenylation in the absence of on-going
transcription (Hirose and Manley, 1998; McCracken et al., 1997). Furthermore, addition of GSTCTD to nuclear extracts (NEs) of HeLa cells exposed to UV light restores the mRNA 3’ cleavage
activity, counterbalancing the reported UV-induced inhibition of this step (Kleiman et al., 2005).
Together these studies suggest that when RNAP II is degraded in UV-treated extracts, this
degradation contributes to the inhibition of mRNA 3’ end processing. Additional studies
revealed that CstF-50 interacts with the CTD of RNAP II (Hirose and Manley, 1998; McCracken
et al., 1997); likely facilitating the reported RNAP II-mediated activation of mRNA 3’ end
processing. On the other hand, p53 also associates with CstF-50 and BARD1 to inhibit 3’
cleavage after UV irradiation (Nazeer et al., 2011). There is an inverse correlation between the
levels of p53 expression and the levels of mRNA 3' cleavage under different cellular conditions.
The results from Nazeer et al. (2011) suggest that p53 is an inhibitor of the mRNA 3’ processing
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machinery during DDR. Together, all these reports indicate that 3′ end processing can be
repressed after DNA damage as a result of an interaction between CstF-50 and BRCA1-BARD1
and p53 (Kleiman and Manley, 1999) and of the proteasome-mediated degradation of RNAP II
(Kleiman et al., 2005).
As mentioned in Chapter II, Pin1 regulates different substrates by accelerating the rate of
conversion between cis and trans conformations of pSer/Thr-Pro motifs found in these proteins
(Lu et al., 1996). First evidence that Pin1 might be involved in mRNA 3’ end processing in
humans included the observation that mutations in a peptidylprolyl-cis/trans-isomerase gene lead
to defects in the 3’ end formation of a pre-mRNA in Saccharomyces cerevisiae (Hani et al.,
1999). The expression of ESS1/PTF1, a yeast homologue of human Pin1, was able to rescue
these defects in the mRNA 3’ end formation. Further Pin1 connections to mRNA 3’ processing
originated from its association to RNAP II: hyper-phosphorylated CTD of RNAP II can interact
with the WW domain of Ess1 in yeast (Morris et al., 1999). Moreover, Pin1 itself was shown to
influence the phosphorylation state of RNAP II CTD (Kops et al., 2002; Xu et al., 2003), and to
inhibit RNAP II-mediated transcription during the transition from initiation to elongation (Xu
and Manley, 2007b). Lastly, Pin1-p53 complex formation after DNA damage stabilizes the
mRNA 3’ cleavage inhibitor p53 (Zheng et al., 2002), inhibits its degradation by HDM2 (Jentsch
and Siepe, 2009; Siepe and Jentsch, 2009), activates the transcription of target genes in the p53
pathway, and potentiates the p53 biological roles after DNA damage (Shimazaki et al., 2012).
Taken together, these functional connections to mRNA 3’ cleavage factors suggest a
potential Pin1 role in the regulation of the first step of polyadenylation during the progression of
DDR. Interestingly, another Pin1 substrate is tau (Blair et al., 2015; Lee et al., 2011; Lu and
Zhou, 2007). Tau has been connected to mRNA 3’ cleavage inhibitor p53 and some of its
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isomers (Pehar et al., 2013; Pehar et al., 2010; Wetzel et al., 2008), and has been linked to the
regulation of gene expression of some mRNA targets (Bukar Maina et al., 2016; Multhaup et al.,
2015), suggesting a possible connection of tau to the regulation of mRNA 3’ cleavage reaction.
In this Chapter I show that Pin1 and tau play a role in the regulation of the mRNA 3’
cleavage step of polyadenylation during the progression of DDR. First, I showed that Pin1 is an
activator of mRNA 3’ cleavage in non-stress conditions. However, Pin1 can inhibit the cleavage
reaction in DNA damaging conditions. These results suggest opposite roles for Pin1 in the
regulation of mRNA 3’ cleavage during the progression of DDR. This change of Pin1 function in
the mRNA processing reaction might be due to Pin1 regulatory binding to factors involved in the
control of mRNA 3’ cleavage under different conditions, such as p53 (inhibitor) and RNAP II
(activator). Consistent with this, data from Chapter II shows that Pin1 interacts with RNAP II
and weakly with p53 under non-damaging conditions (Figure 12B). After UV treatment, Pin1
interacts with p53 (as well as PARN and tau) but not with RNAP II, which also gets degraded as
part of the DDR (Figure 12B). These results are the first mechanistic evidence of the role of
Pin1 in the regulation of polyadenylation. Although more studies are necessary to further
understand the mechanism involved in Pin1-mediated regulation of gene expression, these results
add another layer of complexity to the Pin1 nuclear functions.

RESULTS
To determine whether Pin1 has an effect on the regulation of the mRNA 3’ cleavage
reaction of polyadenylation, I performed cleavage assays using nuclear extracts (NEs) from
colon cancer HCT116 (Figure 25A) and cervical cancer HeLa cells (Figure 25B), and a
radiolabeled L3 pre-mRNA substrate as described (Nazeer et al., 2011). As mRNA 3’ cleavage is
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inhibited during DDR (Kleiman and Manley, 1999, 2001; Kleiman et al., 2005), HCT116 and
HeLa cells were UV-irradiated (40 Jm-2). Cells were also incubated with 5-hydroxy-1,4
naphthoquinone (5 µM, juglone) to inhibit Pin1 activity (Chao et al., 2001; Hennig et al., 1998).
NEs were prepared after 2 h recovery as described before (Devany et al., 2013) and used in in
vitro cleavage reactions. My data showed the previously described UV-induced inhibition of
mRNA 3’ cleavage (Kleiman and Manley, 1999, 2001; Nazeer et al., 2011). Interestingly,
juglone treatment reverses the UV-induced inhibition of mRNA 3’ cleavage previously seen in
NEs of both HCT116 and HeLa cells, suggesting that Pin1 acts as in inhibitor of the reaction in
damaging conditions. However, inactivation of Pin1 decreased 3’ cleavage in NEs from nonstressed cells, indicating that Pin1 is an activator of this reaction under non-damaging conditions
(Figure 25). Western blot analysis (Figure 25, lower panels) showed the previously described
increase in p53 and PARN expression levels under UV-damaging conditions (Cevher et al.,
2010; Nazeer et al., 2011), decrease in p53 expression after Pin1 inactivation (Chao et al., 2001;
Siepe and Jentsch, 2009), and the UV-induced degradation of RNAP II (Muratani and Tansey,
2003; van den Boom et al., 2002). No changes in the expression levels of Pin1 and cleavage
factor CstF-50 were observed in the analyzed NEs. Together, these results indicate that Pin1
plays different roles in the regulation of mRNA 3’ cleavage during the progression of DDR.
To confirm Pin1 effect on the 3’ cleavage reaction I extended these studies by treating
HCT116 cells with Pin1 small interfering RNAs (siRNAs) to knockdown Pin1 expression. NEs
were prepared 48 h after transfection with either control or Pin1 siRNAs. UV treatments were
done as described above (Figure 26). Western blot analysis confirmed Pin1 depletion after
siRNA treatment as well as the increase in p53 levels after UV treatment. It was also evident the

77

A

B
HCT116

UV:
Jug:

-

HeLa
+

+

RC: 25 2 13 1

-

12 2

UV:
Jug: -

+

-

-

-

+
-AdL3

-5’

-5’

RC: 21 3

29 3

4 0.8 10 1

22 4

HeLa
+

+

-

-AdL3

HCT116
UV:
Jug:

+
+

UV:
Jug: -

+

-

+
+

-

+

-Topo II

-Topo II

-RNAPII

-RNAPII

-PARN

-PARN

-p53

-p53

-CstF-50

-CstF-50

-Pin1
1

2

3

4

-Pin1
1

2

3

4

Figure 25. Inactivation of Pin1 by juglone inhibits mRNA 3’ cleavage in nonstress conditions and reverses the UV-induced inhibition of 3’ cleavage. NEs
from A) HCT116 or B) HeLa cells incubated with 5 µM juglone for 2 h, and/or
treated with UV (40 Jm−2) and allowed to recover for 2 h, were used in 3’
cleavage assays with a L3 pre-mRNA probe. The cleavage reaction was incubated
for 2 h. RNAs were purified and analyzed by denaturing PAGE. Representative
cleavage reactions from three independent assays are shown. Positions of the
AdL3 pre-mRNA and the 5’ cleavage product are indicated. Numbers beneath gel
lanes indicate relative cleavage (RC), calculated as [5’ fragment/(5’ fragment +
AdL3)] ×100. The means ± standard deviation of RC values are indicated.
Quantifications were done with ImageJ software (http://rsb.info.nih.gov/ij/).
Lower panels show expression levels of indicated protein tested by Western
blotting from NEs used in the cleavage reaction.
78

decrease in p53 levels in samples from Pin1 depleted cells (Figure 26, right panel). mRNA 3’
cleavage activity in NEs of HCT116 cells treated with Pin1 siRNA under non-stress conditions
decreased, indicating that Pin1 is an activator of the reaction under non-damaging conditions
(Figure 26). These results are consistent with the ones observed with Pin1 inhibition by juglone
(Figure 25). Interestingly, siRNA-mediated knockdown of Pin1 in HCT116 cells abolished the
UV-induced inhibition of mRNA 3’ cleavage, suggesting that Pin1 might act as an inhibitor of
the reaction in UV-induced conditions.
To further analyze the Pin1-mediated regulation of the mRNA 3’ cleavage reaction I used
limiting amounts of NEs from non-treated or UV-irradiated HeLa cells, and increasing amounts
of recombinant GST-Pin1 in cleavage assays (Figure 27). As most of the functional studies on
mRNA polyadenylation have been carried out in HeLa cells (Hirose and Manley, 1998; Kleiman
and Manley, 1999, 2001; Nazeer et al., 2011; Takagaki et al., 1989), this cell line provides a
good system to use as comparison with HCT116 cell line employed in most of the experiments in
this Chapter. The addition of recombinant Pin1 activated mRNA 3’ end cleavage reaction in NEs
from non-stressed cells (Figure 27), indicating one more time that Pin1 can activate this reaction
in non-damaging conditions. In NEs from UV-treated cells, as cleavage levels were already low,
the addition of recombinant Pin1 did not affect the expected Pin1-mediated inhibition effect
under DNA damaging conditions (Figures 25 and 26). Together, my results indicate that in nonstress conditions, when p53 expression is low (Nazeer et al., 2011) and RNAP II is not degraded
(Kleiman et al. 2005), Pin1 is necessary to keep basal levels of mRNA 3’ cleavage, functioning
as an activator of this reaction. After UV treatment, when p53 expression levels increase and
RNAP II is degraded, Pin1 plays a role in the UV-induced inhibition of 3’ cleavage, possibly in
functional association with the cleavage inhibitor p53.
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Figure 26. siRNA-mediated knockdown of Pin1 inhibits mRNA 3’ cleavage in
non-stress conditions and abolishes the UV-induced inhibition of 3’ cleavage.
NEs from HCT116 cells incubated Pin1 or control siRNAs for 48 h and/or treated
with UV (40 Jm−2) and allowed to recover for 2 h, were used in cleavage assays
as described in Figure 25. RNAs were purified and analyzed by denaturing
PAGE. Representative cleavage reactions from three independent assays are
shown. Positions of the AdL3 pre-mRNA and the 5’ cleavage product are
indicated. Numbers beneath gel lanes indicate relative cleavage (RC), calculated
as [5’ fragment/(5’ fragment + AdL3)] ×100. The means ± standard deviation of
RC values are indicated. Quantifications were done with ImageJ software
(http://rsb.info.nih.gov/ij/). Panels on the right show expression levels of indicated
protein tested by Western blotting from NEs used in the cleavage reaction.
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Figure 27. Recombinant Pin1 stimulates 3’ cleavage activity in NEs of
untreated HeLa cells. NEs from HeLa cells treated or not with UV (40 Jm−2)
were preincubated with no addition or with increasing amounts of GST-Pin1 (20,
40, 80 ng). After 15 min, L3 pre-mRNA was added and incubation continued for
2 h. RNAs were purified and analyzed by denaturing PAGE as in Figure 25.
RNAs were purified and analyzed by denaturing PAGE. Representative cleavage
reactions from three independent assays are shown. Positions of the AdL3 premRNA and the 5’ cleavage product are indicated. Numbers beneath gel lanes
indicate relative cleavage (RC), calculated as [5’ fragment/(5’ fragment + AdL3)]
×100. The means ± standard deviation of RC values are indicated.
Quantifications were done with ImageJ software (http://rsb.info.nih.gov/ij/).
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As tau regulates nuclear mRNA deadenylation activity (Chapter III), can form (a)
complex(es) with Pin1, PARN and p53 (Figures 12, 16, 19-20), and has been functionally
connected to the 3’ cleavage inhibitor p53 and its isomers (Pehar et al., 2013; Pehar et al., 2010;
Wetzel et al., 2008) I decided to analyzed whether tau plays a role in the regulation of the
mRNA 3’ cleavage reaction under different cellular conditions. The first indication of a potential
cleavage-regulating role of tau was observed in Western blots of NEs of Chinese hamster ovary
(CHO) cells transfected with pAcGFP expression constructs containing WT-Tau sequences
(Figure 21, Chapter III). I also analyzed the expression of phosphomutant-Tau (PH-Tau), which
is a tau variant that possess Ser 199, Thr 212, Thr 231 and Ser 262 changed to glutamic acid to
mimic phosphorylation (Alonso et al., 2010). PH-Tau resembles a pathological human form
found in neurological diseases such as Alzheimer’s disease (AD). Western blot analysis showed
that Pin1 levels were not affected by the overexpression of these tau forms in this cell line.
However, levels of the 3’ cleavage activator RNAP II decreased in CHO cells when WT-Tau,
but not PH-Tau, was overexpressed (Figure 28). These results indicate that tau expression and
nuclear phosphorylation status might affect the expression of an mRNA 3’processing factor,
such as RNAP II, and therefore influence mRNA 3’ cleavage activity. The fact that p53 protein,
an inhibitor of mRNA 3’ cleavage, levels are also affected by tau expression (Figures 21B and
22), further supports this model.
To determine whether tau-mediated regulation of RNAP II expression is also observed in
human, non-neuronal cells, I performed siRNA-mediated depletion of tau in HCT116 cells. NEs
were prepared 48 h after transfection with either control or MAPT siRNAs. As mRNA 3’
cleavage is inhibited under UV-damaging conditions (Kleiman and Manley, 1999, 2001;
Kleiman et al., 2005), HCT116 cells were UV-irradiated (40 Jm-2). Western blotting revealed
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Figure 28. Expression of tau but not of its phospho-derivative PH-Tau
decreases RNAP II expression levels in CHO cells. NEs from CHO cells
transfected with pAc-GFP expression vectors containing WT-Tau or PH-Tau
(Alonso et al. 2010), were analyzed by Western blotting. Panels show expression
levels of indicated protein from NEs tested in Chapter III, Figure 21A.

83

that siRNA-mediated knockdown of tau in HCT116 cells increased RNAP II levels (Figure 29,
right panel); this was consistent with the results obtained in CHO cells (Figure 28). As observed
in Chapter III (Figures 21-22), p53 expression levels decreased with tau depletion. Additionally,
I performed 3’ cleavage assays using these HCT116 NEs and a radiolabeled L3 pre-mRNA
substrate as previously described (Nazeer et al., 2011). The previously described UV-induced
inhibition of mRNA 3’ cleavage (Kleiman and Manley, 1999, 2001; Kleiman et al., 2005) was
observed (Figure 29). Interestingly, tau knockdown increased 3’ cleavage in both non-stress and
DNA damaging conditions in these cells (Figure 29), suggesting that tau, like p53 and Pin1, is an
inhibitor of the reaction. I cannot discard the possibility that tau effect on mRNA 3’ cleavage is
indirect through its interactors.
As shown in Chapter III (Figures 16-17, 19-20), tau can form (a) complex(es) with p53,
an inhibitor of mRNA 3’ cleavage, resulting in the regulation of nuclear PARN deadenylase
activity (Figures 21-24). To further determine whether tau interacts with RNAP II, an activator
of mRNA 3’ cleavage, I performed a co-immunoprecipitation (co-IP) assays using NEs from
non-neuronal cells. I was not able to detect an interaction between tau and RNAP II in NEs of
HCT116 cells by co-IP assays (Figure 30). Consistent with the co-IPs shown in Figures 16-17,
19-20, Pin1 co-IPed with tau in samples from NEs of HCT116 cells. The usage of different
antibodies and conditions might be necessary to further analyze the potential tau-RNAP II
interaction.
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Figure 29. siRNA-mediated knockdown of tau activates mRNA 3’ cleavage in
non-stress and DNA damaging conditions. NEs from HCT116 cells incubated
MAPT or control siRNAs for 48 h and/or treated with UV (40 Jm−2) and allowed
to recover for 2 h, were used in 3’ cleavage assays as described in Figure 25.
RNAs were purified and analyzed by denaturing PAGE. Representative cleavage
reactions from three independent assays are shown. Positions of the AdL3 premRNA and the 5’ cleavage product are indicated. Numbers beneath gel lanes
indicate relative cleavage (RC), calculated as [5’ fragment/(5’ fragment + AdL3)]
×100. The means ± standard deviation of RC values are indicated.
Quantifications were done with ImageJ software (http://rsb.info.nih.gov/ij/).
Panels on the right show expression levels of indicated protein tested by Western
blotting from NEs used in the cleavage reaction.
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Figure 30. While tau interaction with Pin1 is detected by co-IP in NEs of
HCT116 cells, the tau interaction with RNAP II is not detected in these
conditions. Co-IP assays with polyclonal anti-tau (Santa Cruz Biotechnology)
was performed using NEs of HCT116 cells treated with 5 µM Juglone for 2 h,
and/or exposed to UV irradiation (40 Jm−2) and allowed to recover for 2 h. NEs
were treated with RNase A. Equivalent amounts of the pellets (IP) were resolved
by SDS-PAGE, and proteins were detected by Western blotting using antibodies
shown. 10% of the NEs used in the co-IP assays are shown as Input.
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DISCUSSION
The results presented in this chapter provide evidence of novel roles of disease-related
factors Pin1 and tau in the regulation of the mRNA 3’ cleavage step of polyadenylation during
the progression of DDR. First, I showed that either Pin1 inactivation (Figure 25) or Pin1
depletion (Figure 26) decrease mRNA 3’ cleavage in samples from non-stressed cells, and that
addition of recombinant Pin1 can rescue the cleavage activity in those NEs (Figure 27).
Together, these results indicate that Pin1 is an activator of mRNA 3’ processing under non-stress
conditions. On the other hand, either Pin1 inactivation (Figure 25) or Pin1 depletion (Figure 26)
abolish the UV-induced inhibition of 3’ cleavage previously reported (Nazeer et al., 2011),
suggesting that Pin1 is required for the complete inhibition of the reaction during DDR. These
results suggest opposing roles for Pin1 in the regulation of 3’ cleavage in non-stress and stress
conditions. This apparent contradiction may be explained by the fact that Pin1 can bind to and
regulate the phosphorylation and functions of two factors involved in the control of mRNA 3’
cleavage under different conditions, such as p53 (inhibitor) and RNAP II (activator). In fact,
while Pin1 can interact with RNAP II under non-damaging conditions, its interaction with p53,
which expression is low, is weaker in those conditions (Chapter II, Figure 12B). After UV
treatment, Pin1 interacts with p53, as well as with PARN and tau, but does not form a complex
with RNAP II, which gets degraded as part of the DDR (Figure 12B).
Data obtained in Chapter II showed that Pin1 is involved in the regulation of nuclear
deadenylation as well (Figures 11, 13). Pin1 can form (a) nuclear complex(es) with PARN and
p53, and this complex formation is favored during DDR. Based on the results presented in
Chapters II and IV as well as previous work from Dr. Kleiman’s lab, I proposed the following
model for the regulation of mRNA steady state levels by Pin1 and other nuclear factors,
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including PARN, RNAP II and p53 (Figure 31). In non-stress conditions, when p53 expression is
low, Pin1 mainly interacts with cleavage activator RNAP II, keeping basal levels of this reaction
and the steady-state levels of poly(A)+ mRNAs. PARN is bound to cap binding protein 80
(CBP80), which inhibits its activity (Balatsos et al., 2006; Cevher et al., 2010); therefore, mRNA
levels of PARN-regulated genes do not change under non-stress conditions (Figure 31A). After
UV treatment, when p53 levels increase (Nazeer et al., 2011) and RNAP II gets degraded
(Kleiman et al., 2005), p53 works in conjunction with Pin1 as inhibitors of the cleavage reaction
to regulate mRNA 3’ processing. PARN expression is also induced resulting in the inhibition of
3’ cleavage (Cevher et al., 2010). Additionally, Pin1 and p53 interact with PARN deadenylase
and their interaction results in the activation of deadenylation and in the decrease in mRNA
levels of PARN-regulated genes after UV treatment (Figure 31B). As it has been previously
suggested, damage in the DNA might act as a premature termination signal causing release of the
stalled RNAP II (Kleiman et al., 2005; Mirkin et al., 2008; Nudler, 2012; Vermeulen and
Fousteri, 2013), thereby exposing nascent transcripts to possible erroneous polyadenylation.
Inhibition of the polyadenylation machinery prevents inappropriate, and potentially deleterious,
RNA processing that might be disease-related (Danckwardt et al., 2008; Kleiman and Manley,
1999; Ogorodnikov et al., 2016), highlighting the medical relevance of the proper regulation of
these mRNA maturation machineries during stress conditions.
These results add another layer of complexity to the Pin1-mediated roles in the nucleus of
neurons and non-neuronal cells. As Pin1 is overexpressed in most human cancers and its activity
is downregulated in Alzheimer’s disease (Blair et al., 2015; Lee et al., 2011), it has become a
well-recognized target for possible treatment for both diseases (Driver et al., 2014; Lu and
Hunter, 2014). Therefore, efforts should being made to characterize other nuclear roles and
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Figure 31. Model of the regulation of mRNA steady-state levels by PARN,
p53 and Pin1 during DDR. A) In the absence of DNA damage, Pin1 forms a
complex with RNAP II and normal mRNA 3’ cleavage occurs. Low p53 levels
are detected and PARN is bound to/inhibited by cap binding protein 80 (CBP80).
This results in inhibition of mRNA deadenylation and normal expression of
mRNAs regulated by PARN. B) After UV treatment, RNAP II is degraded and
p53 binds to CstF-50/BARD1, inhibiting 3’ cleavage. p53 is phosphorylated and
Pin1 binds/stabilizes phospho-p53. PARN also binds to p53/Pin1 and other
nuclear factors, and is released from inhibition. The outcome is a decrease in
mRNA levels of genes regulated by PARN-mediated deadenylation.
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functional connections of Pin1. For example, Pin1 has been functionally connected to the mRNA
decay of some target genes due to its interactions with well-known AU-rich element binding
proteins (ARE-BPs) that stabilize or destabilize these ARE-containing mRNAs (Krishnan et al.,
2014; Shen and Malter, 2015). On the other hand, Pin1 is needed to activate WT-p53. However,
it is also an essential co-factor of mutant p53, and a combination of high Pin1 levels and
germline mutations of p53 are characteristic in highly susceptible cancers such as breast cancer,
leukemia, brain tumors and adrenal cortical carcinoma (Hu and Wulf, 2011; Mantovani et al.,
2015). Additionally, Pin1 deficiency causes tau hyperphosphorylation, and abnormal tau
hyperphosphorylation causes its aggregation in AD (Kimura et al., 2013; Lee et al., 2011; Lonati
et al., 2011). Clearly, Pin1-mediated roles are diverse, and treatment efforts must take into
account its connections to many cellular pathways and to other medical conditions.
I also presented data on tau-mediated regulation of mRNA 3’ cleavage. My results
indicate that tau is an inhibitor of this reaction in non-stress and stress conditions (Figure 29). It
is possible that this might be an indirect effect on mRNA 3’ cleavage, as tau expression increases
the levels of p53. Besides the data presented here indicate changes in tau interactors in different
cellular conditions. While tau and p53 are part of the same complex(es) that regulates nuclear
PARN-mediated deadenylation (Chapter III, Figure 24), my data indicate that tau and RNAP II
might not interact in the nucleus of HCT116 cells. Additional studies are necessary to identify
the pathways connecting tau expression and its effect on RNAP II and p53 protein levels.
Interestingly, there are indications of tau-mediated regulation of expression of some
target genes, including calcium-binding protein calbindin, chromatin remodeling-associated
protein Baf-57, and several voltage-gated K+ channels (Barreda and Avila, 2011; de Barreda et
al., 2010; Hu et al., 2016; Li et al., 2015). Other studies have shown that non-phosphorylated tau
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binds and protects DNA in heat-stress conditions (Bukar Maina et al., 2016; Qi et al., 2015;
Sultan et al., 2011), suggesting tau-mediated roles during DDR. Nonetheless, the data presented
in this thesis are the first to indicate a direct functional association of tau with mRNA processing
complexes. In Chapter III, I showed that PARN-mediated deadenylation is regulated by tau
expression and phosphorylation at pathological sites during DDR in non-neuronal cells. Further
studies should address the identification of potential tau/PARN gene targets which might include
transcription factors involved in the regulation of the expression of proteins such as RNAP II and
TP53 mRNA. More functional connections between tau and p53 mRNA and protein expression
levels will be further discussed in Chapter VI.
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CHAPTER V

COMMON mRNA TARGETS OF tau, Pin1 and PARN in NON-NEURONAL CELLS,
AND POSSIBLE CONNECTIONS TO CANCER AND ALZHEIMER’S DISEASE

92

INTRODUCTION
Almost all eukaryotic mRNA precursors, with the exception of histones, undergo a cotranscriptional modification at the 3' end, which includes cleavage of an mRNA precursor and
the addition of poly(A) tail (Russell, 2009; Zhang et al., 2010). After UV-induced DNA damage,
cellular levels of these polyadenylated transcripts are transiently decreased and normal recovery
depends on transcription-coupled repair (TCR) (Ljungman et al., 1999). As reviewed before,
deadenylation has an effect on this reported decrease (Zhang et al., 2010). PARN is the main
deadenylase identified in the nucleus of mammalian cells (Chen and Shyu, 1995; Mitchell and
Tollervey, 2000; Wu et al., 2005), and controls the length of poly(A) tails and, consequently,
gene expression under different cellular conditions (Huang and Carmichael, 1996; Preiss et al.,
1998). Dr. Kleiman’s lab has extensively characterized PARN functional regulation by other
polyadenylation factors and tumor suppressors, including CstF-50, BARD1 and p53; as well as
their roles in the UV-induced activation of deadenylation as part of the DNA damage response
(DDR). Furthermore, I showed evidence of tau- and Pin1-mediated regulations of nuclear
deadenylation in Chapters II and III. My studies indicate that Pin1 and tau bind to PARN and
regulate its deadenylase activity under non-stress and UV-damaging conditions. Therefore, I
hypothesize that PARN, Pin1 and tau might regulate the steady-state levels of common mRNA
targets differentially expressed in distinct cellular conditions.
We previously showed that PARN-mediated deadenylation is induced after UV treatment
partly due to its binding to cleavage factor CstF-50 and tumor suppressor BARD1, and its release
from CBP80-induced inhibition (Cevher et al., 2010). An increase in PARN expression levels is
observed after UV-treatment. My contribution to this project included the finding that PARN is
involved in the degradation of different types of transcripts under different cellular conditions
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(Figure 32). We determined how the expression levels of endogenous mRNAs, including
housekeeping genes and short-lived AU-rich element-containing (AREs) mRNAs, change in
cells treated with UV irradiation and/or siRNAs targeting PARN. We analyzed the expression of
two housekeeping genes (GAPDH and actin) under non-stress and UV-induced conditions. Realtime reverse transcriptase PCR (qRT-PCR) analysis showed that the mRNA levels of these genes
decreased under DNA-damaging conditions in cells treated with control siRNA. This UVinduced decrease in mRNA levels is lost after PARN knockdown. These results indicate that
PARN decreases mRNA levels of housekeeping genes under DNA damaging conditions.
Considering that PARN can promote the deadenylation of ARE-containing mRNAs (Moraes et
al., 2006), we also analyzed the expression of short-lived ARE-containing mRNAs, such as c-fos
and c-myc, by qRT-PCR. Both mRNAs are increased transiently under DNA damaging
conditions. However, the UV-induced increase in these mRNA is not affected by PARN
knockdown. Interestingly, PARN depleted cells showed an increase in the mRNA levels of both
genes under non-stress conditions. This finding suggests that PARN has a role in decreasing the
levels of short-lived mRNAs involved in the control of cell growth and differentiation, keeping
their levels low under non-stress conditions. The results presented in Figure 32 were part of my
contribution to the publication in the EMBO Journal (Nuclear deadenylation/polyadenylation
factors regulate 3’ processing in response to DNA damage, Cevher et al. 2010), where I am one
of the authors.
The results presented in Cevher et al. (2010) indicated that PARN is involved in the
regulation of different transcripts under non-stress and UV-induced conditions. Subsequently,
Dr. Kleiman’s lab took a broader and more comprehensive approach to determine which mRNAs
might be under the regulation of PARN-mediated deadenylation (Devany et al., 2013). As shown
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Figure 32. Effect of PARN expression on endogenous gene expression after
UV treatment. RT-PCR analysis of GAPDH, β-actin, c-fos and c-myc expression
after UV-treatment using RNA samples from HeLa cells treated with
control/PARN siRNA. Total nuclear RNA was purified from cells under different
conditions, and gene expression levels were analyzed by real-time reverse
transcriptase PCR (qRT-PCR). Random or oligo-(dT) primers were used for the
reverse transcriptase reaction, and qPCR reactions were performed using
commercially available primers. Since qRT-PCR products of GAPDH (no UV,
control siRNA) were used as endogenous control, the log value corresponding to
this sample was zero. The values shown have been adjusted to avoid the
presentation of negative values. The data shown are mean ± s.e.m from three
independent experiments. Taken from (Cevher et al., 2010).
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in Figure 33, microarray analyses using nuclear RNA samples from HeLa cells treated with
either control or PARN siRNAs revealed the pathways that are most affected by PARN
depletion. Interestingly, the p53 pathway is the most significantly affected pathway by PARN
knockdown in non-stress conditions (Devany et al., 2013). Additionally, they showed evidence
of a feedback loop between PARN and p53. While PARN deadenylase keeps p53 levels low in
non-stress conditions by destabilizing the p53 transcript, an ARE-containing mRNA itself, UVinduced p53 activates PARN deadenylase, regulating gene expression during the DDR in a
transactivation-independent manner. In Chapters II and III, I extended these results by describing
that the tau/Pin1-mediated regulation of PARN deadenylase activity is dependent on p53
expression.
As discussed in Chapters II and IV, Pin1 also regulates mRNA steady state levels of
different genes (Huang et al., 2013a; Nechama et al., 2009; Shen et al., 2008; Takahashi et al.,
2007). Pin1 is involved in the decay of these mRNAs by interacting with ARE-binding proteins,
such as AUF1, KH-type splicing regulatory protein (KSRP), and HuR (Krishnan et al., 2014;
Shen and Malter, 2015). Interestingly, KSRP can also recruit PARN to the nascent target in order
to initiate the deadenylation that precedes degradation (Cevher and Kleiman, 2010). Upon DNAdamaging conditions, ARE-binding protein HuR binds AREs, resulting in the dissociation of
AUF1, TTP, and KSRP from ARE-containing mRNAs and in the up-regulation of genes
involved in DDR, which stabilize or destabilize these ARE-containing mRNAs. Microarray
analyses using RNA nuclear samples from HeLa cells treated with either control or Pin1 siRNAs
showed that the p53 signaling pathway, the most affected pathway after PARN knockdown
(Devany et al., 2013), is also deregulated after Pin1 knockdown (Figure 34) (Krishnan et al.,
2014). Other common pathways affected by PARN and Pin1 expression include the MAPK
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Figure 33. Pathway analysis of genes significantly regulated by PARN.
Nuclear RNA samples isolated from HeLa cells, treated with siRNAs targeting
PARN or control, were analyzed using Human gene 1.0 ST GeneChip
(Affymetrix) array. Analysis of canonical pathways was conducted by using data
from Ingenuity Systems (www.ingenuity.com) and top 5 pathways affected are
shown. Significant genes were selected by t test (P value < 0.05). P values were
calculated using the Fisher’s exact test, and the −log (P value) values are
displayed. Taken from (Devany et al., 2013).
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signaling pathway as well as pathways in cancer. Additionally, I showed evidence of Pin1mediated regulation of mRNA 3’ cleavage and deadenylation (Chapters II and IV), suggesting
that the effect of Pin1 expression on the steady-state levels of some mRNAs might be due to its
effect on mRNA 3’ processing. Together, these results reveal a functional overlapping of Pin1,
PARN and p53 in the regulation of not only mRNA 3’ processing (Chapters II- IV(Cevher et al.,
2010; Devany et al., 2013; Nazeer et al., 2011) but also gene expression under different cellular
conditions.
Recent reports have also linked tau to the expression of different target genes (Bukar
Maina et al., 2016; Multhaup et al., 2015). Tau mRNA targets include calcium-binding protein
calbindin, chromatin remodeling-associated protein Baf-57, and several voltage-gated K+
channels (Barreda and Avila, 2011; de Barreda et al., 2010; Hu et al., 2016; Li et al., 2015).
However, none of these studies identify the mechanism by which tau expression affects the
steady-state levels of target mRNAs. To determine which mRNAs might be regulated by tau,
microarray assays were used with mRNA samples from tau knockout and control mice (Oyama
et al., 2004). The expression of Gem GTPase, a small GTP-binding protein of the ras
superfamily, is significantly increased in the brains of tau-deficient mice at 8 weeks of age, along
with 73 other mRNAs. Additionally, microarray data was obtained on mRNAs differentially
expressed in a mouse line that expresses P301L tau, a relevant form to Frontotemporal dementia
with parkinsonism-17 (FTDP-17) (Matarin et al., 2015). These studies revealed changes mainly
in immune, inflammatory and synaptic gene expression levels in P301L tau mutant mice. It is
important to highlight that in both mice microarray studies the RNA samples used were collected
from mice brain samples only and from mice already showing some signs of disorders. The
genes identified may also be influenced by changes related to plaque and/or tangle pathology.
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Figure 34. Pathway analysis of genes differentially expressed in Pin1 depleted
cells. Functional clustering of genes based upon the major biological pathways
targeted in Pin1 knockdown cells is shown. Pathway-Express software was used
to identify pathways most affected by Pin1 silencing. Numbers in parenthesis
represent a measure of the degree of pathway perturbation. The graph represents
pathways ranked according to impact factor. Taken from (Krishnan et al., 2014).
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In this Chapter I started to explore the possibility that there is an overlapping in the set of
genes regulated by PARN, Pin1 and tau in non-neuronal cells in different cellular conditions.
Here I provided a list of common mRNA targets that are upregulated by the depletion of Pin1
and PARN expression (Table 1). From the PARN/Pin1 mRNA target list I further analyzed
genes with reported connections to cancer and/or Alzheimer’s disease (AD).

RESULTS
Functional assays shown in Chapters II and III indicate that Pin1 and tau bind and
regulate the activity of PARN deadenylase under non-stress and UV-damaging conditions in the
nucleus of non-neuronal cells. Therefore, I hypothesize that PARN, Pin1 and tau might have
some common mRNA targets that are regulated by these three factors under different cellular
conditions. We previously showed that PARN is involved in the degradation of different
transcripts under different cellular conditions using qRT-PCR (Cevher et al., 2010). These
studies were further extended and PARN mRNA targets were profiled using microarray analysis
of nuclear RNA samples isolated from HeLa cells treated with control or PARN siRNAs under
non-stress conditions (Devany et al., 2013). Similar microarray studies were conducted using
samples of nuclear RNA from HeLa cells treated with control or Pin1 siRNAs (Krishnan et al.,
2014). It is important to highlight that only a limited number of upregulated mRNA targets (35)
after Pin1 knock down were listed in that publication. Comparison of these two studies could
allow the identification of possible common PARN and Pin1 mRNA targets. As PARN is a
deadenylase, I expect an increase in the steady-state levels of its targets by knockdown of
PARN-mediated pathway. Therefore, I focused my analysis only in upregulated genes detected
and published in both studies (Table 1). I also limited my study to ARE-containing mRNAs that
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were upregulated in Pin1 siRNA-treated cells (first column, Table 1; Krishnan et al., 2014).
Then, I found the fold change of those ARE-containing mRNAs in PARN siRNA treated cells
(second column, Table 1; Devany et al., 2013). It is important to highlight that PARN is involved
in the decrease of short-lived, ARE-containing transcripts in non-stress conditions (Cevher et al.,
2010). Both published microarray analysis were carried out in non-stress conditions. By
comparing both studies (Devany et al., 2013 vs Krishnan et al., 2014), I identified 8 target
mRNAs that are upregulated after the knockdown of either factor (PARN or Pin1) under nondamaging conditions. These 8 candidates are mRNAs under Pin1/PARN regulation. As tau can
activate PARN-mediated deadenylation (Chapter III), I proposed that these 8 target mRNAs
might also be upregulated after tau depletion.
Five target mRNAs (indicated with an asterisk in Table 1) were selected from the 8
overlapping genes to perform qRT-PCR using nuclear RNA samples from HCT116 cells. These
genes were selected as they have been previously reported being deregulated in cancer and/or
AD models. For example, Annexin A1 (encoded by ANXA1) is a Ca(2+)-regulated phospholipidbinding protein that is overexpressed in many cancers such as breast, pancreatic, and melanoma
(Belvedere et al., 2016; Boudhraa et al., 2014; Shin et al., 2016), having many roles in the
progression of this disease by localizing to different cell compartments (Boudhraa et al., 2016).
Interestingly, Annexin A1 also has roles in anti-inflammatory and apoptosis responses, its
regulation is important for UV-induced damage response, and is fundamental for brain
homeostasis (McArthur et al., 2010; Park et al., 2015). Furthermore, in a genome-wide pathway
analysis, ANXA1 was identified as a potential gene involved in deregulated pathways that may
contribute to AD susceptibility (Lee and Song, 2015).
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Genes upregulated in Pin1 siRNAtreated cells (Krishna et al., 2014)

Fold Change in PARN siRNAtreated cells (Devany et al., 2013)

Candidate

*FOS

1.28

Yes

ILG

-1.59

No

NOV

1.1

Yes

IL11

-1.25

No

SLC30A1

-1.11

No

HIC2

-1.13

No

*ANXA1

1.28

Yes

GLS

-1.17

No

*BIRC3

1.18

Yes

EPHA2

-1.34

No

LEPREL1

-1.51

No

C9ORF3

1.19

Yes

PGM2L1

-1.72

No

*NOTCH1

1.18

Yes

RGL1

-1.25

No

*PLAGL2

1.99

Yes

COL12A1

1.07

Yes

Table 1. Pin1 and PARN common mRNA targets. Genes reported as
upregulated after Pin1 siRNA-mediated knockdown (Krishnan et al., 2014) were
checked for fold changes after PARN knockdown (Devany et al., 2013). The five
genes selected for qRT-PCR analysis in HCT116 cells are indicated with an
asterisk.
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The other four genes have also been linked to these diseases. FOS is a proto-oncogene
encoding a transcription factor overexpressed in a variety of cancers, including thyroid, bladder
and pancreatic (Guo et al., 2015; Kataki et al., 2003; Li et al., 2013). Interestingly, Fos is
significantly decreased in AD mice models and is involved in memory formation (RodriguezOrtiz et al., 2014). BIRC3 is a gene that encodes a regulator of nuclear factor κ-light-chainenhancer of activated B cells (NF-κB) protein, and BIRC3 alterations have been described in Bcell acute lymphocytic leukemia (Alhourani et al., 2016). Notch1, a single trans-membrane
receptor crucial for T cell development (Takahashi et al., 2007), is deregulated in mammary
tumorigenesis. Notch1 induces Pin1 transcription (Rustighi et al., 2009). Interestingly, Pin1-/p53-/- mice have higher amounts of Notch1 than p53-/- or wild-type mice (Takahashi et al.,
2007), suggesting that Pin1 downregulates Notch1 expression. Additionally, Notch1 expression
is altered in sporadic AD (Berezovska et al., 1998). Finally, proto-oncogene pleomorphic
adenoma gene-like 2 (PLAGL2) has been implicated in a variety of cancers, including leukemia,
gastrointestinal, colon, lung, and prostate (Guo et al., 2016; Hanks and Gauss, 2012; Liu et al.,
2014; Yang et al., 2011).
To determine whether the steady-state levels of these five disease-associated mRNAs are
affected by tau expression I use RNA samples from HCT116 cells overexpressing the tau
variants previously used in Chapter III (Figure 21B). Briefly, cells were transfected with
pAcGFP expression constructs containing either WT- or PH-Tau sequences (kindly provided by
Dr. Alonso, College of Staten Island, CUNY). Phosphomutant-Tau (PH-Tau) is a variant that is
mutated at four residues (Ser 199, Thr 212, Thr 231 and Ser 262 changed to glutamic acid) to
mimic phosphorylation, and hence resembles a pathological human form found in neurological
diseases such as AD (Alonso et al., 2010). The mRNA levels of the 5 disease-associated mRNAs
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and tau were checked by qRT-PCR using commercially available primers. Tau primers amplified
both tau variants as well as endogenous tau (Figure 35B). mRNA levels of all five selected genes
were downregulated when WT-Tau was overexpressed in these cells (Figure 35A). Interestingly,
this effect was reduced for all targets when PH-Tau was overexpressed. These results are
consistent with my previous findings describing tau-mediated activation of PARN activity,
which is reduced when tau is phosphorylated at disease associated sites (Figures 21-24), under
non-stress conditions in these non-neuronal cells. These results indicate that the mRNA steadystate levels of common Pin1/PARN mRNA targets are also affected by tau expression and tau
phosphorylation.
To further validate that Pin1/PARN mRNA targets are also regulated by tau expression I
depleted the expression of the MAPT gene using siRNA treatment and analyzed mRNA levels by
qRT-PCR in HCT116 cells (Figure 36). UV-treatment was also analyzed in this study.
Importantly, the mRNA levels of four selected genes (ANXA1, FOS, NOTCH1 and PLAGL2)
increased after siRNA-mediated knockdown of tau in HCT116 cells under non-stress conditions.
This is consistent with my previous findings showing that tau knockdown inhibits nuclear
deadenylation under non-stress in HCT116 cells (Figure 22).
Furthermore, after UV-treatment, my results indicate that mRNA levels of ANXA1,
BIRC3, NOTCH1 and PLAGL2 did not change in samples from cells treated with control siRNA.
In fact, no significant changes have been described in the literature 2 h after UV-treatment in the
levels of ANXA1 (Park et al., 2015), BIRC3 (Chopra et al., 2009) and NOTCH1 (increases 48 h
after UV treatment)(Yugawa et al., 2007). I have not been able to find in the literature material
on the effect of UV-treatment on PLAGL2 expression. Consistent with previous reports (Cevher
et al., 2010), FOS mRNA levels increased after UV-treatment in samples from cells treated with
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control siRNA. We previously showed that ARE-containing transcripts involved in DRR, such as
FOS, JUN and TP53 are under PARN regulation in non-stress conditions, and this PARNmediated downregulation is lost during DDR (Cevher et al., 2010; Devany et al., 2013).
However, my results show both up- and down-regulation of these common Pin1/PARN/tau
transcripts: while ANXA1 and PLAGL2 levels after UV treatment were upregulated in samples
from tau depleted cells; FOS, BIRC3 and NOTCH1 levels after UV treatment were
downregulated in samples from tau depleted cells. These results suggest complex effects of tau
knockdown on the expression of these mRNAs under DNA damaging conditions. After UV
treatment, the changes in the levels of these common Pin1/PARN/tau mRNAs were tauindependent, indicating there is (are) other mechanism(s) involved in the regulation of these
genes expression during DDR.

DISCUSSION

The findings presented in this chapter are consistent with the functional overlapping of
PARN, Pin1 and tau in the nucleus of non-neuronal cells and with tau-mediated regulation of
PARN deadenylation. In Chapter II, I showed data supporting Pin1-mediated activation of
PARN deadenylase (Figure 11). I also showed that Pin1 and PARN are part of the same
complex(es) that include(s) p53 during DDR (Figure 12). Furthermore, in Chapter III, I provided
evidence of tau-mediated activation of PARN activity (Figures 21-24), and this activation is
affected by tau phosphorylation at pathological sites (Alonso et al., 2010). Tau also forms (a)
complex(es) with Pin1/PARN in the nucleus of non-neuronal cells, and p53 is also included in
the complex during DDR (Figures 16-20). Together, these studies suggest that common targets
of the Pin1, PARN and tau pathways might exist.
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Figure 35. Effect of tau expression and phosphorylation at pathological sites
on endogenous gene expression of selected targets. Real-time PCR analysis of
A) ANXA1, FOS, BIRC3, NOTCH1,PLAGL2, and B) MAPT expression using
RNA samples from HCT116 cells transfected with pAc-GFP expression vectors
containing WT-Tau or PH-Tau (as in Figure 21, Alonso et al. 2010). qRT-PCR
products of ubiquitin C (UBC) from cells treated with control vector were used as
endogenous control. Fold changes were calculated using the ΔΔCT method as in
Devany et al. (2013). The data shown are the mean ± s.e.m. from three
independent experiments.
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Figure 36. Effect of tau knockdown and UV treatment on endogenous gene
expression.

Real-time

PCR

analysis

of

A)

ANXA1,

FOS,

BIRC3,

NOTCH1,PLAGL2, and B) MAPT expression using RNA samples from HCT116
cells treated with either MAPT or control siRNAs for 48 h, and/or treated with
UV (40 Jm−2) and allowed to recover for 2 h (as in Figure 22). Fold changes were
calculated using the ΔΔCT method as in Devany et al. (2013). RT products of
ubiquitin C (UBC) from cells treated with control siRNA and non-treated with
UV were used as endogenous control.. The data shown are mean ± s.e.m from
three independent experiments.
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In this Chapter, I provided a list of common Pin1 and PARN targets that might be
downregulated under non-stress conditions by functional complex(es) containing these two
factors (Table 1). To accomplish this I compared microarray data published in Devany et al.
(2013) and in Krishnan et al. (2014). The common targets of the Pin1 and PARN pathways were
further selected based on their reported connections to cancer and/or AD. Then, I extended these
studies and showed evidence that most of Pin1/PARN common targets are also affected by tau
expression in non-stress conditions (Figures 35-36). When tau, an activator of PARN
deadenylase, is overexpressed in non-UV conditions, the levels of these mRNA targets decrease
in non-neuronal cells (Figure 35). This effect is lost when PH-Tau is overexpressed. When tau
expression is knocked down, levels of most of these target transcripts are upregulated (Figure
36). Therefore, the existence of common mRNA targets for the Pin1, tau and PARN pathways
support the functional interaction shown in Chapters II and III.
Based on the results provided in this thesis as well as from previous work from Dr.
Kleiman’s lab (Cevher et al., 2010; Devany et al., 2013) and other labs, I propose the following
model for the regulation of mRNA steady-state levels by the functional overlapping of PARN,
Pin1, p53 and tau during the progression of DDR in non-neuronal cells (Figure 37). In non-stress
conditions, p53 expression is low and nuclear tau forms are in complex(es) with Pin1 and PARN
(Figure 37A), resulting in the activation of PARN-mediated deadenylation and downregulation
of target mRNAs such as FOS, ANXA1, NOTCH1 and PLAGL2. Interestingly, all these targets
are ARE-containing mRNA transcripts. This finding supports previous results showing that
PARN can promote the deadenylation of ARE-containing mRNAs (Moraes et al., 2006), PARN
keeps the levels of short-lived mRNAs low under non-stress conditions (Cevher et al., 2010), and
Pin1 regulates mRNA steady state levels of ARE-containing transcripts (Krishnan et al., 2014).
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After UV-induced DNA damage (Figure 37B), p53 levels increase due to phosphorylation and
Pin1–mediated structural modification followed by inhibition of HDM2-mediated ubiquitination
and degradation (Jentsch and Siepe, 2009; Ryan and Vousden, 2002; Siepe and Jentsch, 2009;
Zacchi et al., 2002). In addition, in UV-stress conditions, TP53 transcript is not a target of
PARN-mediated deadenylation/degradation (Zhang et al., 2015). My data shows that after UVtreatment the Pin1/PARN/tau complex(es) is (are) favored and include(s) p53, and that this
inclusion fully activates PARN-mediated deadenylation. The outcome is the decrease of total
poly(A)+ mRNAs, and hence gene expression, during DDR as depicted in Figure 1 (Cevher and
Kleiman, 2010).
It is important to highlight that tau expression has also been described in non-neuronal
cells (Cross et al., 2000; Thurston et al., 1996). In addition, tau phosphorylation inhibits its
nuclear roles in neurons, including its ability to bind and protect DNA during heat stress (Qi et
al., 2015; Sultan et al., 2011; Violet et al., 2014). In fact, tau is not phosphorylated in the nucleus
but in the cytoplasm before it is transported (Greenwood and Johnson, 1995), and it is
predominantly non-phosphorylated in the nucleus (Brady et al., 1995; Loomis et al., 1990). The
relevance of proper tau phosphorylation is highlighted by the results presented in this thesis,
which describe an effect of tau phosphorylation at pathological sites (Alonso et al., 2010) on
PARN-mediated deadenylation and on the steady-state levels of PARN/Pin1 mRNA targets. In
that scenario, I revised the model presented in Figure 37 to include the role of tau
phosphorylation on mRNA steady-state level regulation by PARN/p53/Pin1/tau (Figure 38). In
healthy, non-neuronal cells, tau forms found in the nucleus are mainly non-phosphorylated and
can associate in (a) complex(es) with PARN/p53/Pin1 during DDR (Figure 38A). The outcome
is that mRNA levels of genes that are regulated by PARN-mediated deadenylation are kept
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Figure 37. Model for the regulation of mRNA steady-state levels by PARN,
p53, Pin1 and tau during DDR. A) In the absence of DNA damage, p53
expression levels are low; and tau binds to PARN and Pin1. The mRNA levels of
genes regulated by PARN deadenylation such as FOS (shown here), ANXA1,
NOTCH1 and PLAGL2, are low. B) After UV treatment, p53 is phosphorylated
and Pin1 is involved in p53 stabilization. Tau can bind to p53/Pin1/PARN,
resulting in the activation of PARN-mediated deadenylation of other target
mRNAs and decrease of their expression as part of the general response to DDR
(Cevher et al., 2010).
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downregulated. However, in cells where tau hyperphosphorylation occurs (Figure 38B), PH-Tau
forms are found in the nucleus and PARN/p53/Pin1 complex(es) do not bind those PH-Tau
forms (see Figures 18 and 20C), resulting in partial activation of PARN deadenylase (see Figures
21B and 24B). In these compromised cells, mRNA levels of genes regulated by PARN-mediated
deadenylation, which should be downregulated during DDR, are highly expressed (Figure 35A).
Great efforts from different labs are aimed to determine how, when and why these abnormally
phosphorylated forms of tau appear, as these are topics of great interest in the AD field.
The findings presented in this Chapter also support the idea of an inverse relationship
between cancer an AD in which factors and pathways involved in both diseases, such as p53,
Pin1, are deregulated in opposite directions (Behrens et al., 2009; Shafi, 2016). Epidemiological
studies have reported an inverse association between cancer and AD (Nudelman et al., 2014;
Realmuto et al., 2012). Cancer survivors have a lower risk of developing AD than individuals of
the same age without a cancer history; and likewise, patients with AD have a lower risk of
developing cancer (Driver, 2014; Driver et al., 2012). Reports investigating this inverse
association have suggested that these two diseases may share common biological pathways
deregulated in opposite directions, such as inappropriate activation and deregulation of the cell
cycle. The list of potential common factors includes Pin1, an isomerase with roles in cell cycle
control and protein folding, and p53, a major regulator of apoptosis (Driver et al., 2012). Indeed,
as reviewed in Chapter II, Pin1 plays opposite roles in the pathogenesis of both diseases, being
overexpressed in many cancers and inhibited in AD, and has become the center of many studies
aimed to explain this inverse association (Driver et al., 2014, 2015). On the other hand, the tumor
suppressor p53, an extensively characterized factor in cancer biology and a key mediator of
DDR, also prevents neurodegeneration in drosophila models of tauopathy by regulating synaptic
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Figure 38. Model for the regulation of mRNA steady-state levels by PARN,
p53, Pin1 and tau during DDR in disease compromised cells with appearance
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gene expression (Khurana et al., 2012; Merlo et al., 2014). In fact, p53 and apoptosis pathways
are upregulated in AD, and tau phosphorylation is indirectly stimulated by p53 (Proctor and
Gray, 2010; Shafi, 2016). p53 and tau functional connections will be further discussed in Chapter
VI.
All together, the results presented in this Chapter indicate that factors involved in cancer
and AD might play a role in regulating gene expression by functional interaction with mRNA 3’
end processing factors, such as PARN, affecting the transcriptome in different cellular
conditions. Some of the target mRNAs analyzed here, such as ANXA1, are overexpressed in
cancer and deregulated in AD (Belvedere et al., 2016; Boudhraa et al., 2014; Lee and Song,
2015; Shin et al., 2016), suggesting potential opposite roles in both diseases. Remarkably,
transcriptomic meta-analyses have revealed that there is a significant overlap between the genes
upregulated in central nervous system (CNS) disorders and downregulated in cancers, as well as
between the genes downregulated in CNS disorders and upregulated in cancers (Ibanez et al.,
2014). These genes, which belong mainly to metabolic and genetic information processing
pathways that are essential for cell survival and apoptotic regulation, might be differentially
expressed because of changes in mRNA 3’ processing during the onset and development of these
diseases.
While further experiments are necessary to test the details of this mechanism, the results
presented here highlight a functional link between mRNA 3’ end processing and diseases such as
cancer and AD. My data also suggest that changes in tau phosphorylation might affect PARN
deadenylase activity in early stages of these diseases, resulting in specific/disease-associated
gene expression patterns. In fact, the functions of phosphorylated-Tau in regulating gene
expression might affect the neuronal transcriptome before the appearance of traditional markers
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of AD, like tangles and plaques. Therefore, these findings are important because they might help
provide possible mechanistic explanations to the association between cancer and AD, offering
new opportunities for treatment and/or prevention of both diseases.
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CHAPTER VI

p53-tau FUNCTIONAL CONNECTIONS IN NON-NEURONAL CELLS
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INTRODUCTION
The data presented and discussed in previous Chapters show that p53 and tau have more
functional connections, other than being targets of Pin1-mediated regulation (Lee et al., 2011)
and support the hypothesis of an inverse association between cancer and AD (discussed in
Chapter V). Other research groups have reported some of these connections. For instance,
regulation of tau phosphorylation has been functionally connected to some p53 isoforms,
including p73 and p44. p73 haploinsufficiency leads to accumulation of phospho-tau (P-tau)positive filaments in mouse neurons, indicating that this p53 family member might be essential
for the prevention of neurodegeneration (Wetzel et al., 2008). In fact, loss of p73 causes an
increase in c-jun N-terminal kinase (JNK) activation and in JNK-mediated tau phosphorylation.
JNK kinases 1, 2 and 3 phosphorylate tau at many serine/threonine-prolines (Yoshida et al.,
2004). These studies were extended to reveal a widespread deregulation of other tau kinases such
as glycogen synthase kinase 3 beta (GSK-3β), c-Abl, and Cdk5 in the brains of aged p73 +/mice (Cancino et al., 2013). On the other hand, mice overexpressing p44, a shorter isoform of
p53 that is preferentially nuclear and overexpressed with age in the brain, show memory decline
and synaptic impairment (Pehar et al., 2010). Further studies showed that p44 promotes the
phosphorylation of tau by activating the transcription of different tau kinases, including Dyrk1A,
GSK-3β, Cdk5, p35 and p39 (Pehar et al., 2013).
Interestingly, GSK-3β, which phosphorylates tau and is regulated by p73 and p44, also
binds to and phosphorylates p53, providing another functional link between tau and p53. GSK3β can regulate the transcriptional activity of p53 by phosphorylating its Ser-33 residue (Turenne
and Price, 2001). Furthermore, the direct binding of GSK-3β and p53 occurs after DNA damage
and the activities of both proteins in neurons are stimulated as a result of this interaction
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(Watcharasit et al., 2003). Considering that GSK-3β has also been implicated in both sporadic
and familial forms of AD, the p53-GSK-3β connection was proposed as a possible significant
cellular event contributing to the disease (Proctor and Gray, 2010). This connection is important
because high activity of GSK-3β partially accounts for tau hyperphosphorylation, a characteristic
feature of AD (Hernandez et al., 2013). Besides suppression of GSK-3 activity by
phosphorylation has also been associated with the progression in some types of cancers, and
therefore GSK-3β might also function as a tumor suppressor (McCubrey et al., 2014), providing
another possible association between cancer and AD.
Research groups have also attempted to characterize p53 roles in AD, and to further
associate this factor to tau functions and phosphorylation in this disease. p53 is upregulated in
AD and it induces tau phosphorylation in human embryonic kidney 293a cells (Hooper et al.,
2007). Some studies showed that p53 prevents neurodegeneration in drosophila models of
tauopathy by regulating synaptic gene expression, suggesting that synaptic function is a central
target in p53-mediated protection from neurodegeneration (Khurana et al., 2012; Merlo et al.,
2014). p53, together with other tumor suppressors such as BRCA1, can protect neurons and
control AD progression facilitating more effective treatments (Nakanishi et al., 2015). These
studies suggest that p53 protects neurons against genomic instability by regulating a number of
genes involved in many signaling pathways (Nakanishi et al., 2015). Considering that deficient
DDR has been connected to aging and to the manifestation of age-related neurodegenerative
disorders such as AD (Madabhushi et al., 2014), a p53 neuroprotective role in neurons appears to
be essential.
However, other groups showed that apoptosis pathways under the control of p53 are
upregulated in AD and that p53 can initiate apoptosis if DNA damage proves to be irreparable
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(Proctor and Gray, 2010; Shafi, 2016). Contradictorily, instead of protecting cells from
neurodegeneration, sustain activation of p53 pathways might contribute to neuronal death, as
seen in AD (Perluigi et al., 2016). Furthermore, p53 is one of the targets that is decreased by
17β-estradiol treatment aimed to protect neurons from β-amyloid peptide induced neurotoxicity
(Micheli et al., 2016). Additional data demonstrated that inhibition of p53 prevents cell death in a
variety of neurodegenerative models (Lanni et al., 2012). Although the roles of p53 in neurons
and in AD are still under consideration, and the factors causing alternations from p53’s
neuroprotective to apoptotic functions in neurons have not been fully characterized, there is
evidence of functional connections of p53 to tau hyperphosphorylation in neurons.
p53 expression and tau phosphorylation are both regulated by miR-125b, a brain-enriched
microRNA implicated in carcinogenesis (Banzhaf-Strathmann and Edbauer, 2014; Huang et al.,
2013b). While overexpression of miR-125b represses endogenous p53 protein level expression,
its knockdown increases p53 expression, proving that miR125b is a negative regulator of this
factor (Le et al., 2009). Additionally, miR-125b induces tau hyperphosphorylation in brain
tissues by increasing the expression of tau kinases p35, cdk5; and by downregulating tau
phosphatases DUSP6 and PPP1CA (Banzhaf-Strathmann et al., 2014). This study also reported
that miR-125b expression is elevated in AD neurons. However, other groups reported that miR125b is downregulated in serum of AD patients compared with that of normal controls, and have
proposed it as a non-invasive biomarker for AD (Galimberti et al., 2014; Tan et al., 2014).
Regardless of this apparent discrepancy in the levels of miR-125b in different samples from AD
patients, p53 and tau are both regulated by this microRNA, offering another functional
connection between these factors.
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Finally, previous studies from Dr. Kleiman’ lab as well as the data presented in Chapters
III and V also associate p53 and tau functions in the nucleus of non-neuronal cells. For example:
both factors are regulated by Pin1 (Lee et al., 2011), form (a) complex(es) with PARN
deadenylase (Figures 16, 19-20), and stimulate its deadenylase activity (Figures 21-22) (Devany
et al., 2013). My data also shows that the tau-mediated activation of PARN is p53 dependent
(Figures 23-24). Furthermore, WT-Tau overexpression increases p53 levels in HCT116 cells
before and after UV exposure (Figure 21B) and p53 expression decreases after MAPT siRNAmediated knockdown in non-stress and DDR conditions (Figure 22). These results further
associate these two disease-related factors, and demonstrate complementary roles of both factors
in the regulation of nuclear PARN-mediated deadenylation. Considering the functional links
between these two disease-related factors in neurons, in this Chapter, I analyzed other potential
p53-tau connections in non-neuronal cells, including the effect of each protein expression on the
mRNA levels of the other factor. My results show that tau expression also increases TP53
mRNA levels. Tau phosphorylation at pathological sites and a mutation found in frontotemporal
dementia with Parkinsonism linked to chromosome 17 (FTDP-17) reduce the increase in TP53
mRNA levels. Interestingly, p53 expression increases tau protein and mRNA levels in nonneuronal cells. Additionally, miR-125b inhibits the expression of both factors and changes tau
patterns in non-neuronal cells. These studies revealed more overlapping functions for these
nuclear factors that might further support the inverse association between cancer and AD
discussed in Chapter V.
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RESULTS
Previous reports have described a functional connection between tau phosphorylation and
some p53 isoforms in neurons (Cancino et al., 2013; Pehar et al., 2013). Additionally, p53
induces tau phosphorylation in human embryonic kidney 293a cells (Hooper et al., 2007).
Similarly, my data from Chapter III demonstrated that the pattern of nuclear tau forms in
HCT116 is affected by p53 expression (Figure 15). To further test the effect of p53 expression
on tau protein levels in this non-neuronal cell model I depleted the expression of p53 using TP53
siRNA and analyzed tau expression levels. Nuclear extracts (NEs) were prepared 48 h after
transfection with either control or TP53 siRNAs. UV treatments were also included and done as
described in Figure 26. In Figure 39, Western blot analysis confirmed the UV-induced increase
in p53 (Devany et al., 2013; Nazeer et al., 2011), and the decrease of p53 expression in cells
treated with TP53 siRNA. Interestingly, siRNA-mediated knockdown of p53 decreases total tau
expression and changes nuclear tau patterns under non-damaging and UV-treated conditions
(Figure 39). If the changes in tau patterns are due to phosphorylation, these results might be
consistent with previous findings connecting the expression of p53 isomers to tau
phosphorylation in neurons (Cancino et al., 2013; Pehar et al., 2013), and with results presented
in Chapters III-V that show the functional association of p53 levels and tau expression in nonneuronal cells.
Interestingly, my previous data also showed that tau expression can regulate p53 protein
levels in HCT116 cells. While WT-Tau overexpression increases p53 levels before and after UV
exposure (Figure 21B), MAPT siRNA-mediated knockdown decreases p53 expression in nonstress and DDR conditions (Figure 22). These results suggest a possible scenario where each

120

HCT116

UV:

-

+

RNAi: CTRL p53 CTRL p53
-PARN
-p53
-actin
72-

-Tau

55-

-Pin1
1

2

3

4

Figure 39. p53 knockdown decreases nuclear tau expression and changes
nuclear tau patterns under non-stress and UV-induced conditions in HCT116
cells. NEs from HCT116 cells treated with p53/control siRNAs for 48 h, and/or
treated with UV (40 Jm−2) and allowed to recover for 2 h, were monitored by
Western blotting. Equivalent amounts of total protein content from each sample
were analyzed by SDS-PAGE, and tau forms were detected using monoclonal
Tau-13 antibody provided by Dr. Alonso (College of Staten Island). Antibody
against actin was used as loading control.
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factor regulates the protein expression levels of the other. I further investigated this hypothesis
by determining the effect of each protein on the mRNA steady-state levels of the other factor. To
accomplish this I depleted the expression of tau using MAPT siRNA and analyzed mRNA levels
of TP53 and MAPT using designed primers in different cellular conditions. UV treatment was
included in these studies as well. Nuclear RNA samples from cells under different treatment
were purified following manufacturer’s protocol (Quiagen), and real-time reverse transcriptase
PCR (qRT-PCR) analysis was performed as in Chapter V. The depletion of MAPT mRNA levels
was tested by qRT-PCR (Figure 40B). TP53 mRNA levels decrease after siRNA-mediated
knockdown of MAPT in HCT116 cells under non-damaging and UV-treated conditions (Figure
40A), suggesting that the effect of tau on p53 expression occurs at the mRNA level.
To further analyze the effect of tau on the mRNA steady-state levels of TP53 I
overexpressed WT-tau and different tau variants in HCT116 cells and analyzed the TP53 mRNA
levels in different cellular conditions. Overexpression of tau was done using pAcGFP constructs
kindly provided by Dr. Alonso (College of Staten Island, CUNY). The tau variants included
phosphomutant-Tau (PH-Tau), which is a variant that is mutated at four residues (Ser 199, Thr
212, Thr 231 and Ser 262 changed to glutamic acid) to mimic phosphorylation, and hence
resembles a pathological human form found in neurological diseases such as AD (Alonso et al.,
2010). Another variant is FT-Tau, which is a variant containing Arg 406 replaced by Trp
(R406W mutation) that is found in FTDP-17 (Alonso et al., 2010; Kimura et al., 2013). These
disorders are part of a family of diseases known as tauopathies (Kovacs, 2015). I also included a
tau variant combining both modifications (PH/FT-Tau) in the overexpression studies. These
constructs were previously used to analyze the effect of tau on PARN-mediated deadenylation
(Figure 21B), and to verify some possible tau/Pin1/PARN common mRNA targets using qRT-
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Figure 40. siRNA-mediated knockdown of tau decreases TP53 mRNA levels
under non-stress and UV-induced conditions in HCT116 cells. qRT-PCR
analysis of A) TP53 and B) MAPT using nuclear RNA samples from HCT116
cells treated with MAPT/control siRNAs for 48 h, and/or treated with UV (40
Jm−2) and allowed to recover for 2 h (as in Figure 22). qRT-PCR products of
ubiquitin C (UBC) from cells treated with control vector were used as endogenous
control. Fold changes were calculated using the ΔΔCT method as in Devany et al.
(2013). The data shown are mean ± s.e.m from three independent experiments.
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PCR (Figure 35). Total MAPT mRNA levels were checked by qRT-PCR using primers designed
to amplify all tau variants as well as endogenous (Figure 41B and D). qRT-PCR results show
that only overexpression of WT-Tau, but not of the other variants, increases TP53 mRNA levels
in HCT116 cells (Figure 41A), suggesting that tau phosphorylation at pathological sites and FTmutations affect tau nuclear activity in non-neuronal cells. These results are consistent with my
previous findings (Figure 35). Additionally, this WT-Tau-mediated increment in TP53 mRNA
levels was detected only in non-stress conditions (Figure 41C), as cells overexpressing WT-tau
that were UV-treated did not show this increase. These results suggest that the effect of tau on
p53 expression might occur at the mRNA level and that DNA damaging conditions might alter
these regulations. Besides as tau is an activator of PARN-mediated deadenylation (Figures 21,
22, and 24) and PARN decreases TP53 mRNA levels in non-stress conditions (Devany et al.,
2013), the increase in TP53 mRNA levels observed with tau overexpression suggest that this
regulation is PARN independent.
As seen in Figure 39, p53 knockdown also resulted in a decrease in tau expression. To
determine whether p53 expression also has any effect on MAPT mRNA levels I isolated nuclear
RNA samples from HCT116 and isogenic HCT116 p53 -/- cells and analyzed the MAPT mRNA
levels in different cellular conditions (Figure 42). UV treatments were also included in these
studies. TP53 mRNA levels in both cells lines were analyzed by qRT-PCR using the designed
primers as before (Figure 42A). Importantly, MAPT mRNA levels were higher in HCT116 than
in isogenic HCT116 p53 -/- cells, independently of UV treatment (Figure 42B). Together, the
results in this chapter suggest an interesting scenario where mRNA and protein levels of p53 and
tau might be mutually regulated. Further studies will be necessary to identify pathways and
factors involved in this mutual p53-tau regulation in non-neuronal cells.
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Figure 41. WT-Tau overexpression increases TP53 mRNA levels in nondamaging conditions. qRT-PCR analysis of A) TP53 and B) MAPT using
nuclear RNA samples from HCT116 cells transfected with pAc-GFP expression
vectors containing WT-Tau, PH-Tau, FT-Tau and PH/FT-Tau (as in Figure 21;
Alonso et al., 2010). qRT-PCR analysis of C) TP53 and D) MAPT using mRNA
samples from HCT116 cells transfected with pAc-GFP vectors containing WTTau and/or treated with UV (40 Jm−2) and allowed to recover for 2 h. qRT-PCR
products of ubiquitin C (UBC) from non-stressed cells treated with control vector
were used as endogenous control. Fold changes were calculated using the ΔΔCT
method as in Devany et al. (2013). The data shown are mean ± s.e.m from three
independent experiments.
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Figure 42. MAPT mRNA levels are higher in HCT116 than in isogenic HCT116 p53 -/- cells independently of stress conditions. qRT-PCR analysis of A)
TP53 and B) MAPT mRNA using nuclear RNA samples from HCT116 and
HCT116 p53 -/- cells non-treated or treated with UV (40 Jm−2) and allowed to
recover for 2 h. Fold changes were calculated using the ΔΔCT method as in
Devany et al. (2013). qRT-PCR products of ubiquitin C (UBC) from non-stressed
cells were used as endogenous control. The data shown are mean ± s.e.m from
three independent experiments.
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Studies have functionally connected the regulation of tau phosphorylation to the
expression of some microRNAs in neurons (Santa-Maria et al., 2015). miR-125b, a microRNA
deregulated in many human cancers, induces tau hyperphosphorylation by decreasing the
expression of tau phosphatases, such as DUSP6, in neurons of AD patients (Banzhaf-Strathmann
et al., 2014). miR-125b has also been described as a negative regulator of p53 expression during
stress responses (Le et al., 2009). To test whether miR-125b might play a role in regulating p53
and tau expression in non-neuronal cells I transfected HCT116 cells with miR-125b inhibitor
expression plasmid, which blocks endogenous miR-125b, or control plasmid and analyzed
mRNA steady state levels (Figure 43). As miRNA inhibitors work as a ‘miRNA-sponges’ to
form an entrapping structure and bind to their target miRNA, they prevent the binding of
endogenous miRNA to target mRNA and inhibit the effect of miRNA on target gene expression.
The functional knockdown of miR-125b was verified by an increase in p53 protein levels (Zhang
et al., 2015). The expected UV-induced increase in p53 levels was also observed (Devany et al.,
2013; Nazeer et al., 2011). Upon miR-125b depletion, total tau expression increased both in nonstress and stress conditions in HCT116 cells (Figure 43). Interestingly, different tau patterns
were observed in both conditions. There were no noticeable changes in PARN and Pin1
expression levels as a consequence of miR-125b inhibition. Although more studies are necessary
to test miR-125b functions on tau and p53 expression, these findings further support a scenario
where the levels of p53 and tau are mutually regulated, this time by a common microRNA
pathway. However, this regulation might be tissue- or cell-type specific, and should be further
characterize in both neurons and non-neuronal cells.
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monitored by Western blotting. . Equivalent amounts of total protein content from
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Antibody against actin was used as loading control.
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DISCUSSION
The results presented in this thesis are consistent with potential roles of tau and p53 in the
regulation of the protein and mRNA expression levels of each other, supporting the previously
published functional connections between these two disease-related factors. Some of these
connections include GSK-3β, a kinase that phosphorylates both factors resulting in the regulation
of their activities (Hernandez et al., 2013; Watcharasit et al., 2003). Additionally, p53 isomers
control tau phosphorylation in neurons (Cancino et al., 2013; Pehar et al., 2013). My previous
data using a non-neuronal cell line showed that both factors not only are targets of Pin1
regulation (Lee et al., 2011) but also form (a) complex(es) with PARN deadenylase (Figures 16,
19-20) and stimulate its deadenylase activity (Figures 21-22) (Devany et al., 2013). Finally, taumediated activation of PARN is p53 dependent (Figures 23-24), further linking both diseaserelated factors in the regulation of this nuclear deadenylase.
My preliminary data shows that tau expression increases p53 protein levels in HCT116
cells and this effect is lost when tau is phosphorylated at disease associated sites (Figures 21-22).
In this Chapter, I extended these studies by showing that tau expression also increases TP53
mRNA levels (Figures 40-41), and this is abolished by tau phosphorylation at pathological sites
and R406W mutation, as in FTDP-17. Interestingly, p53 expression also has an effect on tau; a
rise in p53 expression increases tau protein and mRNA levels in non-neuronal cells (Figures 39
and 42). Additionally, miR-125b inhibits the expression of both factors in non-neuronal cells
(Figure 43). Therefore, my data add a new layer of complexity to the functional connections
between these two factors in a non-neuronal cell model, suggesting that they work in conjunction
by regulating each other’s mRNA and, hence, protein levels.
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Since these factors are involved in many cellular events other than mRNA 3’ end
processing, the effects on each other’s expression levels might not be direct. For instance, the
p53-mediated effect on MAPT mRNA levels and the tau-mediated effect on TP53 mRNA levels
might be the result of different regulatory pathways. Even though both factors can activate
PARN deadenylase, only TP53 mRNA is a target of PARN deadenylase activity in nondamaging conditions (Devany et al., 2013). The steady-state levels of MAPT mRNA did not
change when we performed microarray assays of nuclear RNA samples from HeLa cells treated
with control or PARN siRNAs under non-stress conditions (Devany et al., 2013), indicating that
MAPT mRNA is not a target of PARN deadenylase activity in non-damaging conditions. In fact,
a feedback loop exists between p53 and PARN, where TP53 mRNA levels are kept low in nonstress conditions and PARN deadenylase is activated by p53 during DDR. Such a loop has not
been detected between tau and PARN. In addition, while tau can activate PARN deadenylase,
my results indicate that the tau-mediated effect on TP53 mRNA levels does not involve PARN
(Figures 21-22 and 24). On the other hand, p53 might have transactivating roles on the MAPT
gene affecting transcription and increasing MAPT mRNA levels. While more studies are
necessary to reveal the pathways and factors that regulate the steady-state levels of both mRNA
transcripts under diverse cellular conditions, my studies further support the tau-p53 functional
connections previously described and discussed in this Chapter.
p53 functions in neurons and AD development are still being elucidated. While some
studies have described a p53 neuro-protective role (Nakanishi et al., 2015), others have reported
that sustain activation of p53 pathways might contribute to the neuronal death seen in AD
(Perluigi et al., 2016). Nonetheless, most studies have reported higher p53 expression levels in
AD neurons (Hooper et al., 2007; Merlo et al., 2014; Perluigi et al., 2016). Consistent with this,
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the data presented here shows that p53 expression increases tau protein and mRNA levels.
Although these data have been collected using non-neuronal cell models, and similar studies
should be performed in neurons, these preliminary findings are of great valuable. Considering
that tau hyperphosphorylation is one of the hallmarks of AD, my results suggest that
deregulations in neurons that cause an increase in p53 expression might indirectly favor
tauopathies such as AD. However, as more studies suggest that DNA damage and repair
responses are not limited to pathological conditions but are also important for neuronal activity
and gene expression regulation under different physiological conditions (Madabhushi et al.,
2015; Su et al., 2015), p53 expression in neurons might also be important before the onset of the
disease. Therefore, characterization of more potential roles of p53 in these neuronal responses is
essential and far from complete.
The implications of the p53-tau functional connections described in this Chapter might
also prove important and should be considered when studying cancer pathways. In some breast
cancers, tau expression levels have been associated to low sensitivity to anti-cancer chemical
treatments (Ikeda et al., 2010; Souter and Lee, 2010; Zhou et al., 2015). In fact, MAPT
downregulation increases the sensitivity to taxane treatment in MCF7 breast cancer cells (Ikeda
et al., 2010). Furthermore, tau expression levels correlate to estrogen receptor (ER) status (Zhou
et al., 2015), which are key drivers of cell proliferation in most breast cancers (Rajbhandari et al.,
2011). On the other hand, p53 and estrogen receptor activities are mutually regulated (Berger et
al., 2013). Additional reports have suggested that tau might act as a transcriptional activator due
to its ability to induce the separation of double-stranded DNA into single-stranded (Krylova et
al., 2005), which could be one way in which tau regulates TP53 mRNA levels. However, none of
these studies have shown a direct involvement of tau in the transcription of these genes, or a
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direct association of tau with mRNA processing complexes. The preliminary results presented in
this Chapter show that tau regulates p53 mRNA levels, suggesting that the functional
interconnection among these factors in different cell types are more intricate than previously
thought. Therefore, additional studies in cancer cell lines such as MCF7 are indispensible to fully
understand the implications of tau-p53 functional connections on the onset and development of
the disease. These studies will reveal insights of alternative mechanisms for the progression of
the disease, which may help in the development of drugs and treatment strategies.

132

CHAPTER VII

FUTURE DIRECTIONS
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Introduction
mRNA 3’ end processing regulates the steady-state levels of different mRNAs and
contributes to the cells rapid response to stress. Studies have described possible contributions of
mRNA 3’ end processing and regulation of mRNA stability to numerous human diseases such as
cancer, Alzheimer’s (AD), amyotrophic lateral sclerosis, -thalassemia, among others
(Danckwardt et al., 2008; Ogorodnikov et al., 2016). Therefore, the main purpose of this
dissertation has been to further elucidate some of the roles of different disease-related factors
such as Pin1, p53 and tau, in the regulation of mRNA 3’ end processing in non-neuronal cells. In
mammalian cells, PARN is the major nuclear deadenylase that regulates the length of mRNAs 3’
end poly(A) tail and, consequently, mRNA stability and gene expression. Additionally, tumor
suppressor p53 has roles in the regulation of the mRNA 3’ cleavage step of the polyadenylation
reaction, and of nuclear PARN-mediated deadenylation. Taking this into account, I determined
new functional connections among Pin1, tau and these two nuclear factors during the DNA
damage response (DDR), which can be important to further understand the onset/development of
cancer and AD.
This dissertation evaluates how Pin1 activity and tau phosphorylation/localization might
play key roles in controlling nuclear functions. Both factors increase nuclear PARN deadenylase
activity during DDR, and this effect is dependent on p53 expression (Chapters II and III). They
also inhibit the mRNA 3’ cleavage step of the polyadenylation reaction during DDR (Chapter
IV). Levels of some genes implicated/deregulated in cancer and/or AD are common targets of
PARN, Pin1 and tau in non-neuronal cells (Chapter V). p53 and tau also regulate the mRNA and
protein expression levels of each other in non-neuronal cells (Chapter VI). Together these data
support the idea of an inverse association between cancer and AD in which factors and pathways
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involved in both diseases are deregulated in opposite directions (Behrens et al., 2009; Shafi,
2016). The further characterization of these connections in different cellular models will be
significant in the development of innovative approaches preventing or treating these diseases.
The studies presented in this dissertation are innovative because they show evidence of
the possible connections between these disease-related factors, DDR, and mRNA 3’ end
processing. Now, it is important that we further elucidate the functional connections between
these factors and PARN-mediated regulation of gene expression in different cellular responses.
The following proposed studies might help us understand some aspects of the working models
shown in this dissertation (Chapter V).

Further characterization of Pin1/tau-mediated regulation of PARN deadenylase activity
and consequences at the genomic scale
The results presented in Chapters II and III suggests that Pin1 and tau are activators of
nuclear deadenylase activity, mainly during DDR. I also showed evidence that tau activates
PARN, and that phosphorylation at certain residues, as in neurological disorders such as AD
(Alonso et al., 2010), abolishes this activation (Chapter III). My results suggest that the
formation of nuclear complex(es) containing tau, Pin1, p53 and PARN is (are) necessary for the
control of nuclear deadenylation, as part of the rapid and efficient response to UV-induced DNA
damage in non-neuronal cells. However, more analyses are needed to prove that Pin1 and tau
regulate PARN-mediated deadenylation only, and not the activity of other nuclear deadenylases
such as CCR4 and PAN2 (Zhang et al., 2010). These studies are important to further elucidate
the roles of these disease-related factors in the regulation of gene expression during DDR in nonneuronal cells.
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In Chapter V, I showed that some genes deregulated in cancer and/or AD are common
targets under the control of PARN, Pin1 and tau in non-neuronal cells. However, a more
comprehensive approach at a larger scale could be used to identify all the genes that are under
the regulation of complex(es) containing these factors. The effect of tau expression on the
transcriptome will be analyzed in RNA samples isolated from HCT116 or HeLa cells treated
with MAPT siRNAs to knockdown tau expression using qPCR arrays. The role of tau will be
assessed by using TaqMan array mouse Alzheimer's panel (4378714, ThermoFisher Scientific).
Biological triplicates data will be presented as n-fold differences in gene-expression in the tau
knockdown cells with respect to that of control siRNA-treated cells. The array includes 92 genes
related to AD and implicated in multiple secondary steps of β-amyloid aggregation, tau
hyperphosphorylation, excitotoxicity, inflammation, oxidation microglial activation; and a
variety of controls (four housekeeping genes). We will isolate total RNAs (RNeasy kit) and
synthesize first-strand cDNA (RT² First Strand Kit). We will use QuantStudio 7 Flex RealTime PCR System (Applied Biosystems) located at Hunter College to amplify, detect and
analyze mRNA with SYBR Green master mixes (Qiagen). Relative mRNA expression will be
normalized with housekeeping gene expression, and data analysis will be performed using web
portal: http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php. Previous microarray
analyses have used RNAs from mice brain samples only, and from animals already showing
some signs of disorders (Matarin et al., 2015; Oyama et al., 2004). The tau-target genes
identified by these previous analyses may have been influenced by changes related to plaque
and/or tangle pathology. The study proposed here would look at tau-target genes before any
signs of disease in non-neuronal cells. As in Chapter V, tau targets could be identified and then
compared to the targets listed in PARN (Devany et al., 2013) and Pin1 databases (Devany et al.,
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2013; Krishnan et al., 2014). These analyses will be important to identify the pathways that are
the most significantly affected by the formation of nuclear complex(es) containing these diseaserelated factors, which may inform us on potential drug target candidates. Identification of
common PARN/Pin1/tau mRNA targets will also reveal more overlapping functions for these
nuclear factors, for example potential roles of tau in the onset and development of cancer.
Besides I propose to determine the effect of tau and PH-Tau expression on the
transcriptome by analyzing RNA samples isolated from brains of tau or PH-Tau expressing and
tau-knockout mice using the qPCR arrays described above. Although the analysis of these
samples will allow us to identify different targets for tau and PH-Tau, it will not address their
potential role in deadenylation. To further understand the functional overlapping of tau and
PARN deadenylase, I propose to analyze RNA samples from neuroblastoma cells depleted in
either PARN or tau expression by siRNA treatment. We will also include neuroblastoma cells
overexpressing either FLAG-Tau or FLAG-PH-Tau proteins. We will assess role of tau, tau
phosphorylation and PARN by using TaqMan array human Alzheimer's panel (4414070,
ThermoFisher Scientific) as described above. Selective sub-set of genes will be validated in
qRT-PCR and subsequent Western analyses. Features of the potential target mRNAs will be
examined to find underling mechanisms. Changes in gene expression will be compared to the
changes reported for AD patients.

Determination of the mechanisms in p53-tau mutual regulation of mRNA expression levels
My preliminary results confirmed potential roles of tau and p53 in the regulation of
protein and mRNA levels of each other, adding another layer of functional connections between
these two disease-related factors in non-neuronal cells (Chapter VI). These connections suggest
that both factors work in conjunction to regulate each other’s expressions in these cells.
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However, more studies are necessary to reveal the RNA-binding proteins and microRNAs
involved in the regulation of the steady-state levels of both mRNA transcripts under diverse
cellular conditions. For instance, the presence of each factor at the 3’ end of the mRNA transcript
of the other will be verified by using biotin-labeled 3’UTRs of TP53 or MAPT mRNAs, and
nuclear extracts from non-neuronal cells under different cellular conditions. Previous results
have shown that PARN is recruited to the 3’UTR of TP53 mRNA and is involved in ARE- and
miRNA-mediated pathways that regulate the steady-state levels of this transcript (Zhang et al.,
2015). Interestingly, a knockdown of PARN expression does not have any effect on MAPT
mRNA levels (Devany et al., 2013). I propose that similar studies to those performed with TP53
should be extended to the 3’UTR of MAPT. Those studies have the potential to reveal RNA
binding proteins and/or microRNAs regulating the expression of the MAPT gene.
Additionally, in Chapter VI, I showed evidence of functional connections between p53
and tau involving the regulation of both mRNAs by miR-125b, a brain-enriched microRNA
implicated in carcinogenesis (Banzhaf-Strathmann and Edbauer, 2014; Huang et al., 2013b). As
miR-125b is deregulated in AD and has been proposed as a potential non-invasive marker in the
serum of patients (Galimberti et al., 2014; Tan et al., 2014), further understanding of the possible
regulation of tau in non-neuronal cells by this microRNA is important. miR-125b is also
deregulated in many human cancers (Le et al., 2009), adding another layer of overlapping
between these two diseases. I propose to characterize the mechanistic connections between miR125b and MAPT mRNA levels. As my studies indicate that tau expression levels increase after
the functional knockdown of miR-125b, I hypothesize that the 3’UTR of MAPT mRNA might
encompass miR-125b binding sites. If found, luciferase reporter constructs carrying MAPT
3’UTR will be prepared, and the effect of mutations in miR-125b binding sites on luciferase
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mRNA levels and activity will be characterized. These results will reveal more functional
connections between miR-125b and MAPT and TP53 expressions, which might contribute to the
characterization of the inverse association between cancer and AD.
Characterization of the role of tau in the regulation of gene expression in different models,
including breast cancer cells and neurons
Tau nuclear functions, such as its effect on p53 expression and regulation of PARN
deadenylase activity in different cellular conditions and disease-related backgrounds, should be
further explored in other cellular models. For example, the role of nuclear tau in breast cancer is
one idea. MCF7 breast cancer cell line represents a model for the characterization of the role of
tau in the regulation of mRNA 3’ processing, and for the study of how changes in this regulation
might influence the development of cancer. MCF7 cells will be incubated with estrogen to
increase the expression of tau, as demonstrated in other studies (Ikeda et al., 2010). In fact, tau
expression has been shown to correlate to estrogen receptor (ER) status (Zhou et al., 2015). This
treatment will be of more biological relevance than UV exposure, as estrogen receptors are key
drivers of cell proliferation in most breast cancers (Rajbhandari et al., 2012).
Additionally, neuroblastoma cell lines, such as SK-N-SH, would be a good model to
extend these studies to analyze the role of nuclear tau in a neuronal background. This cellular
background will help us understand the role of tau and PH-Tau in controlling gene expression
during the progression into AD. In both cells lines, the role of tau in the regulation of PARNmediated deadenylation under non-stress and DDR conditions can be validated. Also, both cell
lines can be manipulated to knockdown or overexpress WT- and PH-Tau. Microarrays will be
prepared as described above to further analyze genes that are differentially expressed and that
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might have consequences on the origination and/or development of these diseases. These
proposed studies will extend the results I obtained in non-neuronal cells and confirm whether
these tau-mediated roles are cell specific or occur in cancer and/or neuronal cellular
backgrounds, further proving evidence of the association of AD and cancer.
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CHAPTER VIII

EXPERIMENTAL PROCEDURES
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Tissue culture methods - HeLa, HCT116 and HCT116 p53 null cells were cultured in
Dulbecco’s modified Eagles medium (DMEM)-10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin antibiotic. RKO cells were cultured in Eagle’s minimal essential medium
(EMEM)-10% FBS and 1% penicillin/streptomycin antibiotic supplemented with 2 mM
glutamine.
DNA damaging agents - 90% confluent cultures were exposed to UV and harvested after 2 h.
UV doses (40 Jm-2) were delivered in two pulses using a stratlinker (Stratagene). Prior to
pulsing, medium was removed and replaced immediately after treatment.
Juglone treatment, CHO cells transfections, and cellular fractionation - All juglone-treated
cultures were incubated with 5 µM juglone (Sigma) for 2 h as in Siepe and Jentsch (2009). CHO
cells were cultured, transfected with PAC-GFP vectors containing WT-Tau or PH-Tau, and
collected in Dr. Alonso’s lab (College of Staten Island) as previously described (Alonso et al.,
2010). Cellular fractionation was done in HCT116 cells (90% confluent) using a “Subcellular
fractionation kit” from Thermo Scientific. Manufacturer’s instructions were followed.
Knockdown expression of Pin1, tau, and p53 by siRNA - siRNAs specific for human Pin1,
p53, and the control siRNA duplex were obtained from Dharmacon RNA technologies. siRNAs
specific for human tau were obtained from Ambion-Life Technologies. HCT116 cells were
grown in a 10-cm cell culture plate in complete medium. At 50-60 % confluence, the cells were
transfected with 100 nM of Pin1, tau, p53 or control siRNA and 35 µl of Lipofectamine
RNAiMax (Invitrogen) according to manufacturer’s protocol. After culturing the cells for 24 h,
the transfection protocol was repeated and the cells were harvested for analysis 48 h after the
initial transfection. A fraction of the cells was exposed to UV treatment and harvested after 2 h
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recovery time. NEs were prepared and analyzed by Western blot to confirm knockdowns and
protein levels.
miRNA inhibitor expression plasmid transfection - Either miR-125b inhibitor expression
plasmid (HmiR-AN0096-AM03, GeneCopoeia) or control plasmid (AM03, GeneCopoeia) were
transfected into HCT116 cells. Cells were grown a 10-cm plate in complete DMEM. At 50-60%
confluence, the cells were transfected with 24 µg of the plasmid of interest and 60 µl of
Lipofectamine TM 2000 (Invitrogen) according to the manufacturer’s protocol. After culturing
the cells in antibiotic/FBS free medium for 8 h, medium was changed to complete medium. After
16 h (24 h after the initial transfection), cells were harvested for analysis.
Overexpression of tau derivatives - pAcGFP expression plasmids containing WT-Tau, PHTau, FT-Tau or PH/FT-Tau sequences (kindly provided by Dr. Alonso, College of Staten Island,
and described in Alonso et al., 2010) were transfected into HCT116 cells. Cells were grown in a
10-cm plate in complete DMEM. At 50-60 % confluence, the cells were transfected with 8 µg of
the plasmid of interest and 60 µl and 25 µl of Lipofectamine TM 2000 (Invitrogen) according to
the manufacturer’s protocol. Cells were cultured in antibiotic/FBS free medium for 24 h, and
cells were harvested for analysis.
Nuclear extracts (NE) and whole cell extract preparation, calf intestinal phosphatase (CIP)
treatment - After different treatments, NEs were prepared from harvested RKO, CHO, HeLa,
HCT116, and HCT116 p53-/- cells as described (Cevher et al., 2010; Devany et al., 2013; Lee et
al., 1988). Cells were lysed by douncing in 4 ml of 10 mM Tris pH 7.9, 1.5 mM MgCl 2, 10 mM
KCl, 0.5 mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Lysates
were centrifuged for 10 min at 13000 rpm, and pellets were resuspended in 20 mM Tris pH 7.9,
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1.5 mM MgCl2, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 0.3 M NaCl.
Preparations were rocked for 30 min at 4°C and centrifuged for 15 min at 13000rpm.
Supernatants were quick frozen and stored at -80°C. Whole cell extracts were prepared by
harvesting cells as previously described (Lee et al., 1988). Cells were resuspended in 0.4 ml of
RIPA buffer: 50 mM Tris pH 7.9, 150 mM NaCl, 1% NP-40, 0.5 % sodium deoxycholate, 0.1%
SDS, and 0.5 mM PMSF. These extracts were sonicated twice for 10 sec (30 second-rest period
in between) at 40 Watts, and centrifuged for 10 min at 10000 rpm. Supernatants were quickly
frozen and stored at -80°C. NEs were treated with CIP from New England BioLabs, as suggested
by the manufacturer. Briefly, NE samples were incubated for 1 h at 37°C. CIP treatment was
stopped with 2 mM EDTA and samples were further incubated for 20 min at 30°C.
Construction of GST-tagged tau variants - GST-tagged recombinant WT-Tau, PH-Tau, FTTau and PH/FT-Tau proteins were generated by subcloning the full-length coding sequence of
each variant into pGEX-2TK bacterial expression vectors using DNA recombinant techniques.
These sequences were amplified by PCR from pAcGFP expression plasmids provided by Dr.
Alonso (described in Alonso et al., 2010). The primer sequences for tau variants were as follows:
forward primer 5’-ATTTGGATCCATGGCTGAGCCCCG-3’; reverse primer: 5’-GGCGAATTCGTCACAAACCCTGCTT-3’. The PCRs were performed using high-fidelity F-530 Phusion
DNA polymerase (FINNZYMES) following the manufacturer instructions and products were
later confirmed by sequencing (GENEWIZ). The PCR products were digested by BamHI and
EcoRI and the resulting DNA fragments were inserted into the pGEX-2TK vector.
Purification of recombinant proteins - Plasmid encoding wild-type His-p53 was provided by
Dr. Prives (Columbia University), plasmid encoding His-PARN was provided by Dr. Virtanen
(Uppsala University), and plasmid encoding GST-Pin1 plasmid was provided by Dr. Graves
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(University of North Carolina at Chapel Hill). GST-tagged tau variants were prepared as
explained above, using pAcGFP expression plasmids provided by Dr. Alonso (College of Staten
Island). All proteins were purified as previously described (Cevher et al., 2010; Devany et al.,
2013). Briefly, His-fusion proteins were transformed into BL21 cells and purified by binding to
and eluting from Ni-agarose columns (Millipore) as described (Nilsson and Virtanen, 2006).
GST-tagged proteins were transformed into Rosetta cells and purified using glutathione-agarose
columns (GE Healthcare) as described (Kleiman et al., 2005).
Immunoprecipitation assays – 100 μg of total protein from NEs prepared from different cell
lines

and

conditions

were

pre-cleared

with

50

µl

of

Protein-A-Sepharose

and

immunoprecipitated with antibodies against Pin1 (H-123, Santa Cruz Biotechnology), tau
polyclonal (H-150, Santa Cruz Biotechnology), PARN (H-105, Santa Cruz Biotechnology), p53
monoclonal (SC-126, Santa Cruz Biotechnology), and p53 polyclonal (FL-393, Santa Cruz
Biotechnology). For tau detection in Western blot analysis, Tau-13 mouse monoclonal antibody
provided by Dr. Alonso (College of Staten Island) was used. The antibodies were coupled to the
protein A-magnetic beads (PureProteome, Millipore) for 30 min at RT in phosphate-buffered
saline (PBS): 137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.04% Albumin,
0.5mM PMSF, 0.001% NP-40). Immunoprecipitations were carried out for 4 h at 4°C in 200 μl
of buffer C (20 mM Tris pH 7.9, 1.5 mM MgCl2, 25% glycerol, 0.2 mM EDTA, 0. 5mM DTT,
0.5 mM PMSF, and 0.3 M NaCl). NEs were treated with 50 µg of RNase A (Promega) while
incubation. Washing was with PBS-T buffer. The beads were recovered and incubated at 100ºC
with loading buffer for 10 min. 10 % of the original sample was loaded as input along with the
immunoprecipitated samples and analyzed by SDS-PAGE and immunoblotting.
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Protein-protein interaction assays – The pull-down assays with GST-Pin1, GST-tagged tau
derivatives, His-p53 and His-PARN were performed as described (Cevher et al., 2010; Devany et
al., 2013; Kleiman and Manley, 2001). Briefly, 2 μg of His-tagged proteins were incubated with
Ni-Magnetic beads for 2 h at 4°C in 300 μl final volume of binding buffer (20 mM HEPES pH
7.9, 0.5 M KCl, 0.5% NP-40, 10% glycerol, 2 mM mercaptoethanol and 2.5 mM imidazole).
Beads were treated extensively with washing buffer (binding buffer plus different concentrations
of NaCl). Then 2 μg of the GST-tagged proteins were added and incubated for 3 h at 4ºC.
Samples were washed as described above. Alternatively, 2 μg of GST-tagged proteins were
incubated Glutathione Sepharose beads in binding Buffer (1 ✕ PBS) for 2 h, rinsed six times
with washing buffer (binding buffer plus different concentrations of NaCl) and incubated with 2
μg of His-tagged proteins for another 2 h. Washing conditions were as described before.
Additionally, 200 μg of NEs from HCT116 treated under different conditions were incubated
with 2 μg of the indicated GST- or His-fusion proteins-bound beads, the binding and washing
conditions were as described before. NEs were treated at 4°C with 50 μg of RNase A while
incubation. Equivalent amounts of pull-downs and 5% of the original samples were analyzed by
immunoblotting as described before.
3’ cleavage assays-

32

P-labeled L3 pre-mRNA substrates were prepared as described (Kleiman

and Manley, 1999). Protein concentrations of the extracts were equalized by Bradford assays
(BioRad) before use in processing reactions. Cleavage assays with equivalent amounts of total
protein were carried out as described (Kleiman and Manley, 2001). HeLa and HCT166 cells
under different cellular conditions were used. Increasing amounts of recombinant GST-Pin1
were also used.
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Deadenylation assays - Conditions for in vitro deadenylation assays were previously described
(Martinez et al., 2001). Deadenylation assays with His-PARN, His-p53, GST-WT-Tau, or GSTPH-Tau were carried out in reaction mixtures containing 25 mM Hepes pH 7, 100 mM NaCl, 0.1
mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 2.5% polyvinyl alcohol, 10% glycerol, 0.25 U
RNasin, and 10 nM 7MeGpppG capped in vitro transcribed L3(A30) RNA substrate,
radioactively labeled by the inclusion of

32

P-α-UTP during transcription. Incubations were

performed at 30°C for 30 min; the reactions were terminated and analyzed by electrophoresis in
10% polyacrylamide/7 M urea gels. Results from independent samples were quantified by using
image J program.
Deadenylation assays using NEs-

32

P-labeled L3(A30) substrates were prepared as described

(Astrom et al., 1991; Martinez et al., 2000). Conditions for NEs deadenylation assays using
RKO, CHO, HCT116 and HCT116 p53-/- cells were described (Cevher et al., 2010; Devany et
al., 2013). Assays using equivalent amounts of total proteins from NEs from different cell lines
and treatments were carried out in reaction mixtures containing 25 mM Hepes pH 7, 100 mM
NaCl, 0.1 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 2.5% polyvinyl alcohol, 10% glycerol,
0.25 U RNasin, and 10 nM 7MeGpppG capped radiolabeled L3(A30). Protein concentrations of
the NEs were equalized by Bradford assays (Bio-Rad) before used in deadenylation reactions.
Incubations were performed at 30°C for 2 h; the reactions were terminated and analyzed by
electrophoresis in 10% polyacrylamide/7 M urea gels. Results from independent samples were
quantified by using image J program.
Analysis of endogenous mRNAs by real-time reverse transcription polymerase chain
reaction (qRT-PCR) - Total nuclear RNA was purified from HCT116 cells using the RNeasy
kit (Qiagen) according to the manufacturer’s directions. RNA concentrations of samples obtained
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under different conditions were equalized. Equivalent amounts (2 μg) of purified RNA were used
as a template to synthesize cDNA using qScript cDNA SuperMix (Quanta Bioscience) according
to the manufacturer’s protocol. Commercially available primers for ANXA1 (NM_000700), FOS
(NM_005252), BIRC3 (NM_001165), NOTCH1 (NM_017617) and PLAGL2 (NM_002657)
were used in the qRT–PCR reactions (Integrated DNA Technologies). UBC: forward primer 5’TGGCACAGCTAGTTCCGTCGCA-3’, reverse 5’-CGAGGGTGATGGTCTTACCAGTC-3’.
MAPT:

forward

primer

5’-GGCAACATCCATCATAAACCAGGA-3’,

GGTCAGCTTGTGGGTTTCAATCTT-3’.

TP53:

forward

reverse

primer

5’5’-

GCCTGAGGTTGGCTCTGACTGTA-3’, reverse 5’-CCTCAAAGCTGTTCCGTCCCAGTA3’. Relative levels were calculated using the ΔΔCT method as before (Devany et al., 2013), with
RT products of UBC from RNA samples from non-transfected cells used as endogenous control.
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